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Abstract
Globally, 5 billion people lack access to safe, timely, and affordable surgical, obstetric, and
anaesthetic care. Increasing access to surgery saves lives, promotes economic growth, and
drives equitable global development. Essential surgery includes caesarean section,
laparotomy, and open fracture treatment, otherwise known as the Bellwether procedures.
Thesis objectives included conducting a systematic review examining cost-effectiveness of
undergoing or increasing access to Bellwether procedures in resource restricted settings and
performing an economic evaluation of increasing access to caesarean section for obstructed
labour compared to existing care in the South African Development Community region. Our
systematic review found that Bellwether procedures were likely to be highly cost-effective.
Our economic evaluation demonstrated that increasing access to caesarean section to 80%
costs $52.97 per disability-adjusted life year averted from a health systems perspective,
relative to existing care (30% access). Future research should focus on improved estimates of
cost, effectiveness, and unmet need related to essential surgery.

Keywords
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Summary for Lay Audience
Globally, 5 billion people lack access to safe, timely, and affordable surgical care. Lack of
surgical access is inequitably distributed in low-and middle-income countries and is largely
responsible for the number of deaths and time spent in disability from conditions that can be
treated. The three procedures that account for most of this burden are caesarean section,
laparotomy, and treatment of open fracture, otherwise known as the Bellwether procedures.
Research has found that increasing access to essential surgery, defined as the Bellwether
procedures, is likely to be cost-effective. However, limitations such as lack of high-quality
synthesized evidence and funding impede health policy decision-making. Therefore, it is
important to examine best available evidence on health and economic impacts of increasing
access to essential surgery in resource restricted settings to address this gap in knowledge and
better inform policymakers and stakeholders. The objectives of this thesis were to first,
systematically review all existing cost-effectiveness analyses on increasing access or
undergoing the Bellwether procedures in low-and middle-income countries; and second, to
inform a subsequent de novo economic model that evaluates the costs and health impacts of
increasing access to caesarean section to 80% for obstructed labour compared to existing care
(30% access) in the South African Development Community region. From the review of
existing studies, we found that undergoing a Bellwether procedure was likely to be highly
cost effective. However, the identified studies varied in quality, context, and methodology,
while excluding neonates and unmet need from their analyses. Consequently, an economic
model was constructed to assess the costs and health impacts of increasing access to
caesarean section for treatment of obstructed labour to 80% compared to the 30% level of
access in existing care. Results from our analyses suggested that increasing access is likely
cost-effective at $52.97 and $19.77 per disability-adjusted life year averted compared to
existing care for mothers and babies, respectively. A combined estimate for mothers and
babies cost $32.00 per disability-adjusted life year averted, assuming additivity. Future
economic evaluations would greatly benefit from improved evidence in essential surgery
related to costs, effectiveness, and the number of individuals in need of care that cannot
access it.
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Chapter 1

1

Introduction

Lack of access to essential surgical care in low-and middle-income countries (LMICs)
contributes greatly to premature death and disability from surgically treatable
conditions.1,2 Findings from the Lancet Commission on Global Surgery (LCoGS) 2030
advocate for the prioritization of increasing access to essential surgical procedures to
improve health outcomes in impoverished populations.2 Access to caesarean section,
laparotomy, and open fracture reduction (also known as the Bellwether procedures) has
been proposed as a proxy for broader access to essential surgery.2 However, several
limitations such as scarcity of funding, lack of high-quality synthesized evidence, and
various sociodemographic factors prevent the proposed expansion. The aim of this thesis
is to examine best available evidence on health and economic impacts of improving
access to essential surgery in LMICs and to use the results of the former to inform a de
novo economic evaluation of the most common unmet need in the field of global surgery:
increased access to caesarean section for obstructed labour in low-middle income settings
(applied specifically to the South African Development Community (SADC) region).

1.1 Thesis Organization
The overall thesis is in integrated article format, structured around two manuscripts
prepared for journal publication. The first chapter is an introduction to essential surgery
and the Bellwether procedures, global health priorities, and an overview on issues
surrounding unmet surgical need in impoverished countries. The second chapter is a
systematic review appraising economic evaluations of increasing access to the Bellwether
procedures in LMICs. The third chapter is an economic evaluation using decisionanalytic modelling to assess cost-effectiveness of increasing access to caesarean section
for obstructed labour in the SADC region. The fourth chapter discusses the results of both
studies in the context of current evidence and global health policy considerations, while
incorporating directions for future research and implementation of the model.
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1.2 Essential Surgery and the Bellwether Procedures
Five billion people around the world are unable to access safe, timely, affordable surgical
care.2 Lack of access to essential surgery is also disproportionately distributed in low-and
middle-income countries, where only 6% of the 313 million surgical procedures
performed annually are occurring.2 An estimated 1.4 million lives are lost to surgically
avertable conditions per year, and this loss could be mitigated by increasing access to
safe surgical and anaesthetic care for those in need.3 The Bellwether procedures, defined
as caesarean section, laparotomy, and treatment of open fracture, account for a large
proportion of this disparity in global access to surgery.2,4 Targeting these procedures is
ideal due to their high-value, acute nature that allows for significant reductions in death
and disability.1,2 Their consistent provision is also considered to indicate a functional
surgical system and effective service delivery.2

1.3 Lancet Commission on Global Surgery
In 2015, the 68th World Health Assembly declared surgery and anesthesia care to be an
essential component of universal health coverage (UHC) as part of resolution 68.15.5,6
The WHO targets for UHC align with the Lancet Commission of Global Surgery 2015
core indicators that were proposed to assess strength and capacity of surgical systems to
provide timely, safe, affordable care to the Bellwether procedures (Table 1).2
Table 1 Lancet Commission on Global Surgery Core Indicators for Monitoring
Universal Access to Safe, Affordable Surgical and Anaesthesia Care When Needed
Indicator
Access to timely essential
surgery

Definition
Proportion of the population who can
access, within 2 h, a facility that can
provide Bellwether procedures (i.e.,
laparotomy, caesarean section, or openfracture treatment)
Number of specialist surgical, anaesthetic,
and obstetric physicians who are working
per 100,000 population

Goal
A minimum of 80% coverage of essential
surgical and anaesthesia services per country by
2030

Surgical volume

Volume of surgical procedures, per 100,000
population per year

Perioperative mortality

All-cause death rate in patients who have
undergone a surgical procedure, divided by
total number of procedures (%)

80% of countries by 2020 and 100% of countries
by 2030 tracking volume; a minimum of 5000
procedures per 100 000 population by 2030
80% of countries by 2020 and 100% of countries
by 2030 tracking postoperative mortality; in
2020, evaluate global data and set national
targets for 2030

Specialist surgical
workforce density

100% of countries with at least 20 surgical,
anaesthesia, and obstetric physicians per 100 000
population by 2030
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Protection against
impoverishing expenditure

Proportion of households protected against
impoverishment from direct out-of-pocket
payments for surgical and anesthesia care

100% protection against impoverishment from
out-of-pocket payments for surgical and
anaesthesia care by 2030

Protection against
catastrophic expenditure

Proportion of households protected against
catastrophic expenditure from direct out-ofpocket payments for surgical and anesthesia
care

100% protection against catastrophic expenditure
from out-of-pocket payments for surgical and
anaesthesia care by 2030

The purpose behind the development of these six core metrics is monitoring universal
access to safe surgery in the context of current global health priorities (Table 1). The
metrics are grouped by preparedness, delivery, and effect of surgical and anesthesia care. 2
The decision analytic model developed in Chapter 3 of this thesis engages with the
indicators pertaining to access to essential surgery, perioperative mortality, and protection
against impoverishing or catastrophic expenditure by assessing impacts of increasing
access to timely caesarean section for obstructed labour with regards to reducing
premature death and disability at increased costs. Overall, the studies included in this
thesis project seek to identify priorities for implementation and address gaps in current
knowledge on health and economic impacts of increasing access to essential surgery.

1.4 Obstetric Care and Inequities in Maternal and Neonatal
Health
1.4.1

Inequitable Maternal Death in LMICs and the South African
Development Community (SADC) region

In 2019 alone, 2.08 million mothers and babies across the world died following
complications during pregnancy and childbirth.7 Ninety-four percent of all maternal
deaths occur in developing countries such as those in Sub-Saharan Africa, representing
the single largest health disparity between high-income countries and LMICs.7,8 Within
Sub-Saharan Africa, a regional economic community comprised of 16 countries called
the South African Development Community (SADC) was established in 1992, consisting
of Angola, Botswana, Comoros, the Democratic Republic of Congo, Eswatini, Lesotho,
Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa,
Tanzania, Zambia, and Zimbabwe.9 These countries are the focus of the economic
evaluation in Chapter 3 due to their connectedness through a shared agenda and mission
towards eradication of poverty and achieving increased quality of life.9
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In parallel, a disproportionately high maternal mortality ratio reflects inequities in access
to safe obstetric care.8,10 The maternal mortality ratio in the SADC region countries range
from 61 per 100,000 live births in Mauritius to 487 per 100,000 live births in Lesotho,
with an average maternal mortality rate of 353 per 100,000 live births across the SADC
region.11 When compared to the maternal mortality rate of 15.68 per 100,000 live births
in high-income countries, the gap in access to obstetric care results in a death toll directly
related to increased risk of death following complications such as obstructed labour and
secondary sequelae like hemorrhage, sepsis, and uterine rupture.7,11,12 In recent years,
improvements in bolstering surgical capacity at hospitals in LMICs have continued to be
pursued.13,14 Strengthening surgical systems by monitoring and targeting the six LCoGS
indicators will lead to substantial reductions in avertable deaths and disability due to
decreased health over a lifetime.2 However, the persisting problem that needs to be
addressed is lack of access and availability of surgical procedures for obstetric
emergencies and life-threatening conditions that require timely treatment.2

1.4.2

Neglected Obstructed Labour

Neglected obstructed labour is a severe obstetric condition that frequently leads to
maternal death or lifelong disability due to secondary conditions.12 Obstructed labour is
defined by the World Health Organization (WHO) as “labour with no advance of the
presenting part of the fetus despite strong uterine contractions, left untreated or
neglected.”12 If labour does not advance, caesarean section is needed, otherwise the
mother may experience severe sequelae such as sepsis, hemorrhage, uterine rupture, and
death.12 Associated complications for the neonate include high rates of stillbirth, birth
asphyxia and trauma, sepsis, and long-term cognitive or motor impairments for the rest of
their lifetime.12,15,16 Inability to provide treatment for obstructed labour is an urgent
health problem that exists across LMICs due to inability to access safe, timely caesarean
section for an acute health condition that severely harms health outcomes of mothers and
babies. Obstructed labour and secondary uterine rupture were responsible for 5,647
deaths in SSA in 2019 alone, with a corresponding number of 317,565 years of life lost
due to premature death and an additional 189,470 years lived with disability.7 These
figures are likely to underestimate the true burden of neglected obstructed labour because
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death due to obstructed labour may be misclassified as death due to sequelae such as
maternal sepsis and haemorrhage.12 In 2019, maternal haemorrhage and sepsis were
responsible for 16,922 and 11,593 deaths in SSA, respectively.7

1.4.3

Perinatal Mortality in LMICs

Investing in increased access to caesarean section for women in obstructed labour will
significantly reduce perinatal mortality and morbidity.17–19 Perinatal mortality due to
neglected obstructed labour ranges from 25% to 52%, with much uncertainty around the
true estimates of this death toll.20 Neglected obstructed labour also leads to an estimated
25% of babies experiencing birth asphyxia and trauma-related outcomes, which is
associated with 30% of babies developing hypoxic-ischemic encephalopathy in those
who survive birth20–22 Death from neonatal disorders led to 761,684 deaths in SSA in
2019, with 281,278 being attributed to neonatal encephalopathy due to birth asphyxia and
trauma.7 If neonates survive birth, the likelihood of remaining with a life-long debilitating
condition greatly increases their years of life lived in disability and reduces their quality
of life.7 In SSA, neonatal disorders led to 2.81 million years lived with disability in 2019,
with 852,797 directly attributed to neonatal encephalopathy due to birth asphyxia and
trauma.7

1.4.4

Barriers to Surgical Care

A large proportion of maternal deaths and maternal injury-related disability are
preventable with the provision of timely access to safe caesarean section for obstructed
labour.2,23 Women in the SADC region experience barriers to care such as risk of
catastrophic impoverishment, inability to access facilities, and inadequate or poor-quality
services.2,11,24 These delays in care result in disproportionate death and disability related
to obstructed labour for both mothers and babies.2,25,26
Reaching the recommended provision levels set by the LCoGS, including 80% coverage
of essential surgery, tracking perioperative mortality, and 100% protection against
catastrophic impoverishment will complement the United Nations General Assembly’s
Sustainable Development Goals (SDGs) 2030.10,27 SDG3 aims to reduce maternal
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mortality ratio to under “70 per 100,000 live births with no country having a maternal
mortality rate of more than twice the global average.”10 Achieving these goals is integral
to all health systems in the SADC region and will lead to tremendously improved health
outcomes for those in need.10

1.5 Health Economic Evaluation in the Context of Global
Surgery
To support the Lancet Commission on Global Surgery goals, economic evaluations of
increasing access to the Bellwether procedures are necessary to inform policymakers and
stakeholders in health funding decision-making and prioritization.28 Results of these
economic analyses are reported in the WHO-recommended outcome of cost per
disability-adjusted life years (DALYs) to measure cost-effectiveness against a defined
willingness-to-pay threshold or benchmark intervention.29,30 The Global Burden of
Disease study uses disability-adjusted life years (DALYs) to represent the loss of one
year of healthy life.31,32 This universal metric allows comparison across varying
countries, age groups, and years, which is beneficial to policymakers when making
funding decisions.33 Outdated perceptions around surgical and anesthetic care being too
expensive have been replaced by several economic evaluations that suggest investing in
essential surgery in LMICs is cost-effective, comparing well to public health or infectious
disease interventions that were previously thought to be more cost-effective.27,34,35 Such
examples include $54 for cost per DALY averted for providing repair surgery for
obstetric fistula in Uganda, $87 per DALY averted for trauma surgery in Cambodia, and
$36 per DALY averted for cataracts surgery in Sub-Saharan Africa.36–38 Previous
research has also been conducted on projected losses in economic productivity that were
an estimated $12.3 trillion (2010 $USD), with greatest losses being in LMICs.27
However, there is a lack of formal economic evaluations of scaling-up access to the
Bellwether procedures in LMICs. To better inform national healthcare resource allocation
decisions, further work on quantifying long-term health and economic impacts related to
scaling-up surgical access as an investment needs to be done.
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1.6 Gaps in Knowledge
1.6.1

Maternal and Neonatal Outcomes

There are known issues with uncertainty around the true number of maternal deaths,
obstetric fistula cases, and deaths due to neglected obstructed labour in the SADC region,
and in Sub-Saharan Africa as a whole.12,15,39 Deaths due to neglected obstructed labour
are often misclassified as deaths due to various sequelae stemming from obstructed
labour such as sepsis, hemorrhage, and uterine rupture.12 Furthermore, estimating the
number of women who are unable to reach a facility for treatment is an additional
challenge faced by health systems and researchers.12,25 Of those estimates, there is a high
likelihood that the number is far greater than that reported due to unrecorded stillbirths
and maternal deaths.12,40 Accurate data on the length of delays in care for obstructed
labour are often scarce, and detailed information on outcomes following neglected
obstructed labour is sparse.12,15,21,40 The quality of maternal health data available is
oftentimes limited to retrospective hospital record reviews, cross-sectional surveys,
physician recollection, or short-term observational studies specific to a local hospital.

1.6.2

Economic Evaluations of Essential Surgery in LMICs

Generally, economic evaluations conducted on cost-effectiveness of Bellwether
procedures in LMICs are limited by lack of formal decision-analytic modelling, reported
outcome measures, short time horizons, and choice of perspective. Most of the existing
cost-effectiveness analyses are not realistic in terms of reflecting true access to care. The
patient populations in these studies are often those who can reach a facility for treatment,
which is highly unrepresentative of the current standard of care available to most
individuals in the SADC region.
To date, no economic evaluation exists that evaluates the impact of increasing access to
caesarean sections for obstructed labour for both mothers and babies using a decisionanalytic model for a life-time time horizon, incorporating long-term disabilities. The
model constructed in Chapter 3 of the thesis is the first to address this gap in knowledge.
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1.6.3

Relevance and Applicability

Insight into costs and health outcomes related to provision of the Bellwether procedures
is crucial yet severely lacking for LMICs, particularly in Sub-Saharan Africa and the
SADC sub-region.41 The results of economic evaluations can be used to inform
policymakers and decision-makers to improve resource allocation and healthcare delivery
for impoverished populations.
The goals of this thesis are to fill knowledge gaps regarding lack of evidence on
feasibility of increasing access to the Bellwether procedures in LMICs. Synthesized
results for all relevant economic evaluations assessing health and economic impacts of
increasing access to the Bellwether procedures are presented and critically appraised in
Chapter 2. Subsequently, the decision-analytic model presented in Chapter 3 addresses
the long-term, inequitable disease burden due to obstructed labour by increasing
provision of caesarean section to meet the goals of the LCoGS targets for increased
access in the SADC region.

1.7 Objectives
The objectives of this thesis are as follows:
1. To conduct a systematic review and critically appraise all existing economic
evaluations that examine costs, effects, and feasibility of increasing access to the
Bellwether procedures in LMICs.
2. To construct a Markov cycle tree using decision-analytic modelling that compares
current standard of care to increased access to caesarean section for women in obstructed
labour in the SADC region across a lifetime time horizon. This model accounts for the
estimated two-thirds of women in obstructed labour who are unable to receive treatment
at a healthcare facility and the long-term disability or premature death that they face due
to sequelae such as sepsis, haemorrhage, uterine rupture, and obstetric fistula. 25
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3. To construct an accompanying Markov cycle tree that compares neonatal outcomes
from standard care to increased access to caesarean section, accounting for birth asphyxia
and trauma-related disability across a life-time time horizon.
4. To provide policymakers and healthcare decision-makers an estimate of the cost per
DALY averted for mothers and babies if they were to invest in scaling-up access to safe,
timely caesarean section to treat obstructed labour in the SADC region.
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Chapter 2

2

Health and Economic Impacts of Improving Access to
Essential Surgery in Resource Restricted Settings: A
Systematic Review

The following is an unpublished manuscript formatted for journal submission. The
planned submission date is September 2021.
Authors: Anne Zhao, Joo-Hyun Jeong, Shehzad Ali*, and Janet Martin
*Janet Martin and Shehzad Ali are senior authors and contributed equally to this work.

2.1 Introduction
Five billion people across the world lack safe, timely, and affordable access to surgical,
obstetric, and anaesthetic care.2 Furthermore, the Lancet Commission on Global Surgery
determined that very little information is available on the quality of the 313 million
surgical procedures performed annually.2 A recent analysis by Nepogodiev et al. 2019
indicated that the 30-day death toll following surgery was at least 4.2 million, half of
which occurred in low and middle-income countries (LMICs).4,35 The perioperative
surgical death toll surpasses the combined death toll from HIV/AIDS, malaria and
tuberculosis.4 The burden of illness, due to lack of access and poor quality of surgical
care, is disproportionately distributed in low-income households. Closing this gap in
access, particularly in LMICs, could lead to a reduction of 1.5 million deaths per year, or
6.7% of all avertable deaths in LMICs.42
Globally, the highest impact of poor access to surgeries is due to low rates of caesarean
section, laparotomy, and treatment of open fracture, i.e. the Bellwether procedures.4
Targeting the Bellwether procedures is especially important for LMICs as they are acute,
high-value procedures that can significantly reduce mortality from treatable conditions. 4
Recent reports on the burden of non-communicable diseases and injuries highlight the
need for increase in availability of surgical care.43,44 Failure to address this lack of access
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to surgical procedures results in considerable economic loss as well as reduced quality of
life.2,35,42
In 2015, the World Health Assembly declared essential surgical and anaesthesia care to
be a component of universal health coverage (UHC). 2,5 The WHO target for UHC is 80%
essential health services coverage and 100% financial protection from out-of-pocket
health services payments by 2030.2 Reaching these goals will also complement the
Sustainable Development Goals set by the United Nations General Assembly. 10
To identify priority surgical procedures for implementation in LMICs, cost-effectiveness
has been established as an important criterion.1,35 To date, there remains a gap in
knowledge about the cost-effectiveness of Bellwether procedures in LMICs. While a
number of economic analyses have been published, they vary in quality, study context,
reported outcomes and costs, time horizon and perspective. There is urgent need to
synthesize this evidence to inform resource allocation decisions and set priorities for
implementation as well as future research. To address this gap, the objective of this study
was to conduct a systematic review of economic evaluation studies that examine the
costs, effects, and feasibility of increasing access to the Bellwether procedures in LMICs.

2.2 Methods
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines were used for this systematic review (see Appendix D for completed
checklist).45

2.2.1

Search Strategy

A comprehensive literature search following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted.45
MEDLINE and EMBASE on the OVID platform, PubMed, CINAHL, EconLit, NHS
Economic Evaluation Database, Health Technology Assessment Database, the WHO
Global Index Medicus, and the Cochrane Library were searched for the controlled
vocabulary and keywords: “cost-utility” AND “Bellwether procedures” AND “low
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middle-income countries” (see Appendix A for search strategy). Additional articles were
retrieved using citation tracing of identified studies from the search. The last search was
performed on June 20, 2021.

2.2.2

Selection Criteria

Inclusion criteria included economic evaluations of patients undergoing or in need of an
essential procedure (defined as the Bellwether procedures: caesarean section, laparotomy,
or treatment of open fracture) in low and middle-income countries as defined by the
World Bank.46 Outcomes measured in cost per quality-adjusted life year (QALY), cost
per disability-adjusted life year (DALY), incremental cost-effectiveness ratios (ICERs),
DALYs averted, unmet surgical need, or years of life lost.
Clinical trials and observational studies were excluded from the review. There were no
language restrictions placed on the search.
All inclusion and exclusion criteria were finalized a priori.

2.2.3

Study Selection

Two reviewers (AZ and JHJ) independently reviewed abstracts and full text articles for
inclusion and exclusion criteria. AZ and JHJ extracted data from finalized articles and
independently conducted risk of bias assessments using the ECOBIAS checklist. 47
Discrepancies at any stage were resolved by discussion with JM and SA. The PRISMA
diagram (Figure 1) describes the detailed search and screening process, with reasons for
exclusion.

2.2.4

Data Extraction and Quality Assessment

Data was extracted using a piloted form agreed upon by all authors. Thirteen
measurements were classified as economic evaluations of undergoing or increasing
access to one or more Bellwether procedures. Twenty-five measurements of cost-utility
and cost-effectiveness were included. Due to potential risk of high heterogeneity from
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differing countries, baseline disease conditions, and delivery methods, quantitative
summary measures were not calculated across articles.
All articles classified as economic evaluations were assessed for quality and bias related
to structure, data, and consistency using the ECOBIAS Checklist, a tool developed to
assess model-based economic evaluations.47 Although this tool was developed for modelbased economic evaluations, most elements of the tool were effectively applicable to
non-model-based studies and broad economic evaluations.
Results from all studies that reported cost-utility were converted to international dollars
($I) using purchasing power parities (PPP) before inflation. Costs were then inflated to
PPP-adjusted 2020 United States Dollars ($USD) using GDP Implicit Price Deflators to
allow for comparability across studies.48 If not otherwise stated, market exchange rate
was used to convert costs into original local currency before calculating PPP-adjusted
2020 $USD. Outcome measures for different procedures were reported as separate
occurrences despite originating from a single study.

2.2.5

Statistical Analysis and Software

Data was entered and compiled into Microsoft Excel 2021 (Version 16.44; Microsoft
Corporation, Redmond, WA, USA). Results were grouped by Bellwether procedure and
presented in table format.

2.3 Results
2.3.1

Overall results

A total of 6054 articles were identified through database searching, of which 5,952 were
excluded for not meeting inclusion criteria. One hundred and two articles were identified
for full-text review and 13 articles published between 1998 and 2020 from 49 countries
met the pre-specified inclusion criteria to be included for data extraction, quality
assessment, and subsequent qualitative analyses (Tables 2 and 3). Of these 13 articles, 6
were identified through citation tracing of systematic reviews captured in the initial
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search.37,49–53 Table 4 and Appendix B summarize the ECOBIAS checklist results for
quality assessment.
We identified and included 13 cost-effectiveness analyses. Five articles exclusively
looked at caesarean section,19,54–57 three articles examined only laparotomy,51,53,58 one
article examined only open fracture treatment,52 two articles looked at laparotomy and
treatment of open fracture,37,50 and one article looked at all three Bellwether procedures.59
Surgery type included both elective and emergency procedures.
Across the Bellwether procedures, the most cost-effective procedures included $7.93 per
DALY averted for exploratory laparotomy in Uganda,58 $10.18 per DALY averted for
emergency hernia repair in a Zambian hospital calculated using global life expectancy,59
$15.55 per DALY averted for emergency hernia repair in Zambia,59 and $16.90 per
DALY averted for emergency caesarean section in a Zambian hospital calculated using
global life expectancy.59 The least cost-effective procedures included $491.81 per DALY
averted for emergency caesarean section for obstructed labour across 49 low-middle
income countries55 and $786.13 per DALY averted for fracture dislocation fixation in
Zambia.59
Ten studies used no surgery as a comparator,37,49–55,58,59 2 used vaginal birth,56,57and 1
used care as usual.19 5 studies evaluated cost per DALY averted,51,53,55,58,59 3 studies
evaluated ICERs,54,56,57 2 evaluated cost per maternal death avoided,56,57 1 evaluated total
number of deaths averted,19 1 evaluated cost per life year saved,49 and 1 evaluated costbenefit ratio.55 Five studies were population-based economic analyses assessing
increasing access to surgery19,49,55–57 and the remaining eight studies were cohort-based
economic analyses examining costs and outcomes of those undergoing surgery in a
specific setting.
Key study characteristics are presented in Tables 2 and 3.
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2.3.2

Risk of Bias

Risk of bias was assessed using the ECOBIAS Tool developed by Adarkwah et al. and
presented in Table 4 and Appendix B.47 The ECOBIAS Tool assesses overall bias in
economic evaluation, and specifically bias related to structure and data as well. Overall,
there was a considerable amount of bias and uncertainty across a number of domains.
Regarding overall bias in economic evaluation (Table 4), bias related to narrow
perspective, inefficient comparator, and reporting and dissemination bias was present
across most of the studies included. There were few studies with cost measurement
omission bias, intermittent data collection bias, and invalid valuation bias. Ordinal ICER
bias was not identifiable in most studies due to lack of formal modelling but was present
in both Brazilian studies by Entringer and colleagues.56,57 It was unclear whether doublecounting bias and sponsor bias was present across multiple studies. However, sponsor
bias was partly present in two studies.19,53 Inappropriate discounting bias was present in 5
studies19,37,50,52,59 and partly present in 4 others.51,53–55 Limited sensitivity analysis bias
was present in 4 studies37,49,50,59 and partly present in 5 others.19,52,54,55,58
In particular, bias related to structure (see Appendix B) was largely unavailable and not
reported in 11 out of 13 studies. Bias related to data regarding baseline data and qualityof-life weights was also unavailable in 11 out of 13 studies. Bias related to limited scope
was present in 4 studies37,49,50,59 and partly present in 5 others.19,37,54,55,58 There was littleto-no bias found related to treatment effects, non-transparent incorporation of data, and
internal consistency. There was bias related to data identification partly present in 3
studies.19,56,57

2.3.1 Caesarean Section
Across 7 studies that evaluated cost-effectiveness of caesarean section, there were 13
varying outcome measures in total: 5 reported cost per DALY averted, 2 reported cost per
maternal mortality avoided, 3 reported ICERs, 1 reported cost per LY saved, 1 provided
cost per newborn death avoided per 1000 procedures, 1 provided cost-benefit ratio, and 1
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reported deaths averted per $100,000. Of these, 4 studies evaluated emergency caesarean
sections, 2 evaluated elective caesarean section, and 1 study included both (Table 5).
The costs per procedure ranged from $98.92 in the Republic of Guinea49 to $1,723 in
Brazil.56 Two studies did not report costs per procedure.55,59 Effect measures ranged from
106 DALYs averted for elective caesarean in a Zambian hospital to 7956 DALYs averted
globally for emergency caesarean section.59 Elective caesarean sections accounted for the
lower end of effect measures.56,57 Cost per DALY varied from $16.90 per DALY averted
in a Zambian hospital calculated using global life expectancy59 to $491.81 per DALY
averted across 49 countries (Table 5).55
Hounton and colleagues reported a range of $230.79 to $247.23 per caesarean section by
training clinical officers and doctors respectively.54 The resulting ICER was $238.86 per
newborn death avoided per 1000 caesarean sections when training doctors instead of
clinical officers.54 Verguet and colleagues reported that a $486,383 investment for a 10%
increase in provision of caesarean section would avert 590 deaths in one year, resulting in
122 deaths averted per $100,000 spent (Table 5).19

2.3.2

Laparotomy

Across 7 studies that evaluated cost-effectiveness of laparotomy, there were 11 measures
of average cost per outcome in total: 9 of these were cost per DALY averted and 2 were
cost per LY saved. The mean costs per surgery ranged from $123.45 to $1049.46.50,53
Two studies did not report mean costs per surgery.37,50 Effect measures ranged from 6.4
DALYs to 18.51 DALYs averted per person,53,58 and from 98 DALYs to 1424 DALYs in
total per individual hospital.37,59 Life years saved per person ranged from 0.71 to 1.86.49
Cost per DALY varied from $7.93 per DALY averted58 to $164.31 per DALY averted,53
where hernia repair53,59 was more costly per DALY averted than exploratory and
emergency laparotomy.58,59 Cost per LY saved ranged from $83.46 to $171.70, where
hernia repair represented the higher end of costs.49 Two studies did not report
intervention-specific cost-utility (Table 6).37,50
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2.3.3

Open Fracture

Across 4 studies that evaluated cost-effectiveness of open fracture reduction, there were 4
measures of average cost per outcome in total, all being cost per DALY averted. The
mean costs per surgery were not reported. Effect measures ranged from 35 to 2,780 total
DALYs averted at a local hospital.37,59 Cost per DALY varied from $161.13 per DALY
averted to $786.13 per DALY averted, where fracture dislocation fixation in Zambia
occupied the high end of costs and fracture dislocation reduction in a Zambian hospital
calculated using global life expectancy made up the lower end.59 Three studies did not
report intervention-specific cost-utility (Table 7).37,50,52

2.4 Discussion
2.4.1

Applicability Compared to WTP Thresholds

Our findings highlight the importance of published cost-effectiveness data on global
surgery for understanding the unmet surgical need in low-middle income countries
worldwide. Under the World Health Organization’s Choosing Interventions that are CostEffective (WHO-CHOICE) project, previous suggestions stated that an intervention
whose cost per DALY averted is less than three times the national annual GDP per capita
of the country is considered cost-effective.60 A cost per DALY averted that is less than
the national annual GDP per capita is considered highly cost-effective.60 In lieu of these
recommendations, more conservative willingness-to-pay (WTP) thresholds estimated by
Woods and colleagues that reflect opportunity costs of health care spending are used for
comparison.61 Woods and colleagues’ predicted thresholds are markedly lower than the
WHO-CHOICE recommendations after accounting for the relationship between marginal
productivity, healthcare spending, and income elasticity.61
In Tables 5 through 7, the PPP-adjusted WTP thresholds of each country is reported,
which allows for direct comparison with the associated cost per DALY averted. Using
this comparison threshold, we found that all procedures included in our review except
elective caesarean section in Brazil are considered cost-effective, being within the
proposed range for WTP.56,57 Most procedures have economic measures less than the
lower end of the estimated WTP and are considered highly cost-effective. Predominantly,
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the range of cost-effectiveness across multiple studies shows a noticeable variation
depending on country, procedure, and whether the surgery was elective or emergency in
nature. For example, cost-effectiveness of caesarean sections varied from $16.90 per
DALY averted in a Zambian hospital calculated using global life expectancy59 to $491.81
per DALY averted across 49 countries.55

2.4.2

Benchmark Interventions and Current Evidence

Another commonly used approach is by using benchmark interventions from comparable
countries as a threshold.60 Several widely accepted health intervention strategies in lowmiddle income countries include general surgery and hospital care, including emergency
obstetric care in Bangladesh ($17.04 per DALY averted),62 cleft lip and cleft palate repair
in Nepal ($45.45 per DALY),63 management of obstructed labour in Sub-Saharan Africa
($93.17 per DALY averted),64 intrapartum care in Mexico ($349.96 per DALY
averted),13 and non-emergency orthopedic surgery in Nicaragua ($407.91 - $613.58 per
DALY averted).14,65
When comparing the cost utilities reported in our review to those widely accepted in
literature, several estimates reported for laparotomy were comparable to general surgery
and hospital care in Bangladesh.62 Cost- effectiveness of open fracture reduction in
Zambia compares favourably to that for intrapartum care in Mexico.13 Treatment for
obstructed labour across 49 countries also compares favourably to non-emergency
orthopedic surgery in Nicaragua, being less costly.14,65 A notable exception is elective
caesarean section in Brazil, ranging from $1,358.14 to 1,727.92 per maternal mortality
avoided).56,57 Elective caesarean rates have been steadily increasing globally beyond rates
considered medically necessary, particularly in Latin America and North America, which
is associated with excess risk, increased maternal mortality, unnecessary cost, and
reduced cost-effectiveness.66–68 Efforts to reduce harm and minimize the overuse of
caesarean sections have been introduced but further work is required to address these
issues to optimize resource allocation for better return on investment in other
underfunded aspects of public health.68–70
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2.4.3

Limitations of Existing Economic Evaluations

Given our inclusive search strategy, we were able to capture economic evaluations across
multiple countries and regions. However, since there is no global standard for costeffectiveness analyses, the outcomes and methodology used in each study varied heavily.
Results from the review were qualitatively summarized due to the high heterogeneity
across outcomes, patient population, procedure, and costing methods. For example,
laparotomy varied from general emergency laparotomy37,59 to more specific procedures
such as elective and emergency inguinal hernia,49–51,53,59 and emergency appendectomy.49
Issues arose with many of the studies and their use of comparator. 7 out of 9 studies using
no surgery as a comparator did not explicitly state as such, meaning that it had to be
inferred.37,49,50,52,55,58,59 In addition to being unclear, issues with using comparators of no
cost and no effect are evident. The true cost of not receiving surgical treatment could vary
from incurring costs from seeking alternate care, or even monetary damages related to not
being able to work. Additionally, costs saved from avoiding complications were not
captured either.
Only 2 of the 13 studies performed a formal cost-effectiveness analysis using a decisionanalytic tree model.56,57 One other study quantitatively calculated ICERs without using
formal health economic modelling techniques.54 Time horizon was stated in only 2 out of
13 studies56,57 but was clearly limited in all studies to only immediate, acute outcomes
associated with surgery without consideration of long-term costs and effects. In
evaluating costs, several articles used WHO-CHOICE guidelines,54 others used a
differing regional guideline, and several did not report use of a standard costing
procedure.
Only five of the 13 studies reported economic outcomes as cost per DALY
averted.51,53,55,58,59 The differing use of various health effect metrics had an impact on the
results of the review. While the generic outcome of DALYs are the accepted metric used
by the WHO and Institute for Health Metrics and Evaluation,71,72 several included studies
reported specific outcomes such as life years or cost per maternal death avoided, which
mitigates comparisons across studies.49,54 It is recommended to only compare higher
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quality economic evaluations with cost per DALY estimates against each other, as lower
quality studies evaluating cost per natural outcome (i.e. cost per death avoided) cannot be
compared to cost-utility studies. Results elucidate a basic overview of the immediate
deaths and disability prevented in the short term but there remains a large gap regarding
long term complications and sequelae. Solely evaluating short term costs without
capturing long term cost and effect of lives saved and disability averted may skew the
effect measures toward lower estimates of effect.

2.4.4

Generalizability and Future Directions

An issue regarding unmet need in global surgery, and specifically the Bellwether
procedures, is that a large component of individuals who require care are unable to reach
the operating room or the hospital due to barriers related to geographic distance and/or
affordability.2,68,70 These patients are by default not included in economic evaluations
since most economic evaluations draw from those who are able to arrive at hospital for
treatment. This inequity should be addressed in future economic evaluations to better
reflect the issue of disproportionate access to essential surgery in LMICs.
From the appraisal of existing economic evaluations on increasing access to the
Bellwether procedures, it is recommended that future economic evaluations be conducted
using standardized metrics such as cost per DALY averted across longer time horizons
for a population-based analysis when possible. Analyses assessing cost per natural
outcome (i.e. maternal death avoided) should be presented as additional analyses to
supplement the reference case but are not adequate replacements for cost-utility
estimates. Model-based analyses should also be distinguished from cohort-specific cost
and DALY estimates, with careful consideration for choice of comparator.
Despite evidence supporting the cost-effectiveness of increasing access to essential
surgery in developing countries, barriers such as financial, political, workforce, and
sociodemographic factors continue to limit patient access to life-saving care.73–75 Recent
efforts to address these limitations have been broadly successful. Several health service
providers, hospitals, and organizations have created local or international programs to
train mid-level health workers such as medical officers or nurses in surgery for improved
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patient health outcomes.54,76–78 Task-shifting has not only been successful in saving lives
but is also cost-effective for reducing the healthcare worker shortage, directly
contributing to both the WHO targets and UN Sustainable Development Goals for
2030.54,76–78 Other examples of successful interventions include providing altered fee
scheduling and vouchers for caesarean section.79–81 Future economic evaluations should
continue to assess the feasibility of implementing these programs and policy
interventions in addition to analyses of providing surgical procedures. Continued focus
on increasing access to high-value, low-cost interventions such as the Bellwether
procedures is a priority that needs to be further supported by policymakers and
stakeholders to reach global targets.

2.4.5

Conclusion

The results of our systematic review indicate that many essential surgeries are highly
cost-effective in low-middle income countries and represent good value for money
compared to alternate use of resources. The importance and feasibility of the LCoGS
target for 80% coverage of essential surgical and anaesthesia services per country by
2030 are supported by the findings from this review and the growing evidence base of
essential surgery. It is recommended that future economic evaluations follow
standardized guidelines, such as those proposed by the WHO, to ensure comparability
across cost-effectiveness studies in LMICs.
Despite challenges in improving access to the Bellwether procedures in developing
countries, the corresponding health gains from reducing substantial amounts of death and
disability emphasize the urgent need to reduce these inequities in access. Considerable
efforts are still necessary to reach the WHO 2015 and UN SDG global targets for scalingup surgical access and reducing perioperative mortality by 2030.5,6,10 Effective
investment by policymakers, health systems, and organizations into improving access to
essential surgery will lead to expansive growth and advancement in health systems and
human welfare in LMICs.
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2.5 Tables and Figures for Chapter 2

Figure 1. PRISMA Diagram
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Table 2 Study Characteristics
Study
Jha et al.
199849

Country
Republic
of Guinea

Sample Sizea
5600 procedures

Baseline status
NR

Sex
NR

Length of Study
NR

Gosselin et
al. 200650

Sierra
Leone

177 cases

Patients needing general care, orthopedic
surgical care, pediatric out- patient and
inpatient care

NR

July to Sept 2004

Gosselin et
al. 200837
Hounton et
al. 200954

Cambodia

395 cases

78% Male

Oct to Dec 2006

Burkina
Faso

2305 caesarean
deliveries

Patients in the emergency room, intensive
care unit (ICU), and operating theaters
Patients with obstructed labour, ruptured
uterus, eclampsia, or haemorrhage

All female

2004 to 2005

Shilcutt et al.
201051
Gosselin et
al. 201052

Ghana

113 referred
patients
788 cases

Male 95%

Nov 2007 (5 days)

NR

Aug to Oct 2008

Shillcutt et
al. 201353
Alkire et al.
201555

Ecuador

102 patients

Male 82%

47
countries

July 2010 (2 weeks), Nov
to Dec 2010 (2 weeks)
NR

Roberts et al.
201559

Zambia

811,629
caesarean
deliveries
405 patients

Referred or presenting patients from rural
areas with inguinal hernias of various sizes
Patients from the outpatient department
(OPD), the operating theaters (OT), and all
wards
Patients with inguinal hernias of various
size from rural areas.
Patients in obstructed labour

NR

Verguet et
al. 201519

Ethiopia

NR

NR

Laparotomy male 48%, CS
all female, hernia repair all
male, open fracture male
71%
NR

Entringer et
al. 2018a56

Brazil

NR

Normal risk pregnant women

All female

Entringer et
al. 2018b57

Brazil

NR

Nigeria,
Haiti

All female

Sept to Dec 2012

Time period in which 10%
increase in access is
achievable (i.e. 1 year)
NR

Intervention
Caesarean section for
obstructed delivery,
surgery for hernia,
surgery for appendicitis
Acute abdomen surgery,
hernia surgery, fractures

Comparator
No surgeryb

Outcome
Cost per LY saved

No surgeryb

Cost per DALY averted

Laparotomy and open
fractures
Caesarean section

No surgeryb

Cost per DALY averted

Varying caesarean
section providers
(CO, D, O)
No surgery

ICER, case fatality rate

No surgeryb

Cost per DALY averted

No surgery

Cost per DALY averted

No surgeryb

Cost per DALY averted, costbenefit ratio

Caesarean section,
laparotomy, inguinal
hernia repair, fracture
reduction
Caesarean section

No surgeryb

Cost per DALY averted

Usual coverage of
intervention

Total number of deaths
averted

Cesarean section

Vaginal delivery

ICER for cost per averted
maternal mortality, cost per
averted maternal mortality
ICER for cost per averted
maternal mortality, cost per
averted neonatal death
Cost per DALY averted

Lichtenstein method of
inguinal hernia repair
External fixation of
significantly open
fractures of long bones
Lichtenstein method of
inguinal hernia repair
Caesarean section

Cost per DALY averted

Normal risk pregnant women undergoing
All female
NR
Cesarean section
Vaginal delivery
spontaneous vaginal delivery or elective
cesarean (with no clinical indication)
Bellamkonda Uganda
103 patients
Patients presenting with bowel obstruction,
Male 46%
Feb to April 2017, June to
Emergency laparotomy
No surgeryb
58
et al. 2020
gut perforation, intussusception, penetrating
Dec 2018
trauma, and abdominal mass/tumor, or blunt
trauma
NR = Not reported, LY = life year, DALY = disability-adjusted life year, ICER = incremental cost-effectiveness ratio, CO = clinical officer, D = doctor, O = obstetrician, CS = caesarean section OOP = out of pocket, GBD = Global Burden of
Disease
a Distinction

was made between number of procedures and patients, since it is possible that double-counting could have occurred for studies that count total procedures
was inferred and not explicitly stated

b Comparator
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Table 3 Economic Model
Parameter Sources
Study

Analysi
s Typea

Population

Costs

Intervention Effect

Jha et al.
199849

PB

Labour costs from monthly salaries; drug,
supplies, and equipment from Central
Pharmacy, direct health centre purchases or
independent distributors; overhead costs
from national non-recurrent salary budget

Published literature
and expert opinion

Gosselin et al.
200650

CB

Local data from
health centres,
first referral
hospitals, and
national
programs
Local data from
NGO hospital

Fixed costs (land purchase, construction,
equipment) and local operating costs
(salaries, drugs, utilities, fuel, etc.)

Gosselin et al.
200837

CB

Local data from
emergency
hospital

Hounton et al.
200954

CB

Shilcutt et al.
201051

CB

Hospital records
and patient case
notes
Referred or
presenting
patients

Gosselin et al.
201052

CB

Local data from
MSF surgical
trauma centers

Fixed costs (construction, medical equipment
and other equipment), and local operating
costs (salaries, medical material, drugs,
cargo, utilities, etc.)
Costs incurred by the hospital, salaries,
pension, training, time spent on surgical
tasks
Variable costs (drug unit costs taken from
International Drug Price Indicator Guide,
Ghana Pharmaceutical Pricing Study, WHOCHOICE project, out-of-pocket costs by
survey) and fixed costs (WHO-CHOICE
study, building and refurbishment costs,
equipment costs and utilities)
Fixed costs (medical and other equipment,
cars, etc). Operating costs from MSF internal
accountancy, costs for drugs and medical
material from pharmacy management
software.

Shillcutt et al.
201353

CB

Private rural
local hospital

Perspective

Time
Horizon

Discounting

Costing
Year
(Currency)
1994 (USD)

Sensitivity
Analyses

Health
system

NR

3% on cost
and DALYs

Hospital admission
logs and patient
charts and published
literature
Published literature

Hospital

NR

None

2004 (USD)

NR

Hospital

NR

Life
expectancy

2006 (USD)

NR

Facility records

Health
system

NR

3% on
training cost

2006 (CFA)

Major cost categories

Expert opinion for
counterfactual,
WHO burden of
disease equations for
health outcomes,
and published
literature
Published literature
using discounted,
age-weighted life
expectancy tables
and disability
weights
Published literature;
inguinal hernia
disability weight and
mortality for
untreated case based
on expert opinion

Health
Provider

NR

3% on
DALYs

2008 (USD)

PSA
DALY assumptions,
patient perspective
(including OOP costs)

Hospital

NR

NR

2008 (USD)

DALY calculation
(severity of condition,
probabilities for success
of treatment)

Health
provider

NR

3% on
DALYs

2011 (USD)

Monte-Carlo simulation
for uncertainty in
patient-level data;
variation in disability
weight; scenario
analysis for life tables,
costing perspective, and
mortality

b

Local supply companies or literature for
component costs of program. Patient out-ofpocket costs (patient survey). Unit costs from
pharmacies, WHO-CHOICE project, and
catalog prices from medical suppliers.

NR
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Alkire et al.
201555

PB

Published
literature (crosssectional and
cohort studies)

Published literature and WHO estimates

Published literature

Health
system

NR

NR

2010 (USD)

Roberts et al.
201559

CB

Single-district
local hospital

Published literature

Health
system

NR

PB

Published literature

Health
system

NR

2011 (USD)

Evaluated sensitivity to
change in coverage
increments

Entringer et al.
2018a56

PB

Ethiopia Central
Statistical
Agency, ICF
International
Hospital
Information
System of the
Unified Health
System (SIHSUS) and
DATASUS

NR (but 3%
inflation rate
for
equipment)
NR

2012 (USD)

Verguet et al.
201519

Hospital cost records, government-funded
distribution network for drugs and
consumables (WHO African essential price
indicator), and online wholesalers
Secondary data and published literature

Brazilian Hierarchial Classification of
Medical Procedures 2016 (CBHPM),
National health plan operators’ pricing
tables, expert opinion, Simpro Hospitalar
Magazine, and the Brasindice
Pharmaceutical Guide

Published literature

Health
subsystem
financing
(private
care)

Between
admission
for
delivery to
maternity
hospital
discharge

None due to
short time
horizon

2016
(Reais)

DSA and PSA for costs
and probabilities,
effectiveness
parameters were varied

Entringer et al.
2018b57

PB

Brazilian
Unified
National Health
System

2014
(Reais)

DSA and PSA (MonteCarlo simulation)

Soroti regional
referral hospital

Between
hospitaliz
ation for
delivery
until
delivery
NR

None due to
short time
horizon

CB

SUS Hospital
Information System,
(SIH-SUS)
DATASUS, hospital
records, consultation
with specialists
Expert opinion

Health
system

Bellamkonda
et al. 202058

Expert opinion, cost analyses, and public
databases (Health Price Bank, Federal
Government Purchasing Portal
(Comprasnet), Support System for the
Development of Health Investment Projects
(SomaSus)
Hospital records

3% on
DALYs

2014 (USD)

Hospital

PSA using Monte-Carlo
simulation (incidence of
cases, incidence of
maternal mortality, cost
proportions of vaginal
delivery to caesarean
delivery)
Range of caesarean
section disability
weights accounted for

Scenario-analysis
(conservative
assumption on survival
benefit, DALYs
averted, salaries).
NR = Not reported, PB = population-based economic analysis, CB = cohort-based economic analysis, DA = decision analytic, OOP = out of pocket costs, MSF = medecins sans frontieres, GBD study =
Global Burden of Disease Study, PSA = probabilistic sensitivity analysis, DSA = deterministic sensitivity analysis
a = Analysis type was inferred when not directly reported by authors. Bolded analysis type meant that the model used was a decision-analytic model. If not a decision-analytic model (model-based), the
analysis was based on an observational cohort study
b = Perspectives were inferred when not directly reported by authors. Perspectives that were inferred were italicized.
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Table 4 Summary of Risk of Bias Assessment using ECOBIAS Tool
Part A: Overall checklist for bias in economic evaluation
Study
Narrow
Inefficient
Cost
perspective comparator measurement
bias
bias
omission bias

Jha et al.
199849
Gosselin et
al. 200650
Gosselin et
al. 200837
Hounton et
al. 200954
Shilcutt et al.
201051
Gosselin et
al. 201052
Shillcutt et
al. 201353
Alkire et al.
201555
Roberts et al.
201559
Verguet et
al. 201519
Entringer et
al. 2018a56
Entringer et
al. 2018b57
Bellamkonda
et al. 202058

Intermittent
data
collection
bias

Invalid
valuation
bias

Ordinal
ICER
bias

Doublecounting
bias

Inappropriate
discounting
bias

Limited
sensitivity
analysis
bias

Sponsor
bias

Reporting
and
dissemination
bias

Yes

Yes

No

No

No

N/A

Unclear

No

Yes

Unclear Yes

Yes

Yes

No

No

Partly

N/A

Unclear

Yes

Yes

Unclear Yes

Yes

Yes

No

No

Partly

N/A

Unclear

Yes

Yes

Unclear Yes

Yes

Yes

No

No

No

No

Unclear

Partly

Partly

No

Yes

Yes

Yes

No

No

No

No

Unclear

Partly

No

No

Yes

Yes

Yes

No

No

Partly

N/A

Unclear

Yes

Partly

Unclear Yes

No

Yes

No

Unclear

Yes

No

Unclear

Partly

No

Partly

Yes

Yes

No

No

No

N/A

Unclear

Partly

Partly

Unclear Yes

Yes

Yes

No

No

No

N/A

Unclear

Yes

Yes

No

Yes

No

Yes

Unclear

No

No

N/A

Unclear

Yes

Partly

Partly

Yes

Yes

No

No

Unclear

No

Yes

Unclear

No

No

No

No

Yes

No

No

Unclear

No

Partly

Unclear

No

No

No

No

Yes

Yes

No

No

No

N/A

Unclear

No

Partly

No

Yes

Yes
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Table 5 Summary of Findings for Caesarean Section
Study

Procedure
Type

Non-model-based studies
Jha et al.
Emergency
199849
Alkire et
Emergency
al. 201555
Roberts et
Emergency
al. 201559
(Global)
Roberts et
Emergency
al. 201559
(Zambia)
Roberts et
Elective
al. 201559
(Global)
Roberts et
Elective
al. 201559
(Zambia)
Verguet et
Emergency
al. 201519
Hounton et
Emergency
al. 200954

Hounton et
al. 200954

Emergency

Model-based Studies
Entringer
Elective
et al.
2018a56

Entringer
et al.
2018b57

Elective

GDP per
capitaa (in
PPPadjusted
2020 $USD)

Costs (in PPP-adjusted 2020
$USD)
Mean costs
Currency

Effect

Measure

Economic Outcome (in original
reported currency)b

Economic Outcome (in PPPadjusted 2020 $USD)b

$25 - $720

$98 per surgery

USD

2.309

Life years saved

$18 USD per LY saved

$98.92 per LY saved

$18 - $600

NR

USD

NR

DALYs averted

$491.81 per DALY averted

$127 - $1,826

NR

USD

DALYs averted

$127 - $1,826

NR

USD

DALYs averted

$11.07 USD per DALY averted

$25.84 per DALY averted

$127 - $1,826

NR

USD

7956
(6376-9098)
5329
(4264-6106)
158

$416 USD per DALY averted
4:1c
$7.24 USD per DALY averted

DALYs averted

$15.26 USD per DALY averted

$47.85 per DALY averted

$127 - $1,826

NR

USD

106

DALYs averted

$24.03 USD per DALY averted

$62.88 per DALY averted

$29 - $777

$486,383(for 10%
increase)
$229.79 per
caesarean by
training clinical
officer (CO)
$247.23 per
caesarean by doctor
(D)

USD

590

Deaths averted

USD

198

Newborn Lives per 1000 csections

141 deaths averted per $100,000
USD
$36,260 CFA per newborn death
avoided per 1000 procedures (from
CO to D)*

122 deaths averted per
$100,000
$238.86 per newborn death
avoided per 1000 procedures
(from CO to D)*

USD

125

Newborn Lives per 1000 csections

NR

NR

$1727.92
(primiparous) per
procedure

USDd

1 (-0.02%)

Probability of maternal
death (compared to vaginal
birth)

$3,429.27 Brazilian Reais per
maternal mortality avoided (from
vaginal birth to caesarean section)*

$1,727.92 per maternal
mortality avoided (from
vaginal birth to caesarean
section)*

$42 - $938

$42 - $938

$3,584 $11,303)

$3,584 $11,303)

$1358.14
(primiparous) per
procedure

USDd

1 (-0.02%)

Avoided maternal
mortality
(probability/”effectiveness”
compared to vaginal birth)

LY = Life year, DALY = disability-adjusted life year, CO = clinical officer, D = doctor, NR = not reported
a = Willingness-to-pay thresholds estimated by Woods and colleagues 2016 in PPP-adjusted 2020 USD$
b = Reported as either average cost per outcome (ACO), incremental cost-effectiveness ratio (ICER)*, or benefit cost ratio (BCR)
c = Benefit-cost ratio calculated by dividing gross economic benefit by total cost
d = Study originally reported local currency, results are converted to PPP-adjusted USD of corresponding costing year

C-section dominated in all outcomes,
natural childbirth more cost-effective
for normal risk pregnant women
$2,245.86 Brazilian Reais per
maternal mortality avoided
$2,659,339 Brazilian Reais per
maternal mortality avoided (from
vaginal birth to caesarean section)*

$16.90 per DALY averted

$1,358.14 per maternal
mortality avoided
$1,608,216.17 per maternal
mortality avoided (from
vaginal birth to caesarean
section)*
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Table 6 Summary of Findings for Laparotomy
Study

Type of
Laparotomy

GDP per capitaa
(in 2020 $USD)

Jha et al.
199849
Jha et al.
199849
Gosselin et
al. 200650
Gosselin et
al. 200650
Gosselin et
al. 200837
Shilcutt et al.
201051

Emergency
Appendectomy
Hernia repair

$25 - $720

Acute abdomen
surgery
Inguinal hernia
Emergency
laparotomy
Tension-free
inguinal hernia
repair
Tension-free
inguinal hernia
repair
Emergency
laparotomy
(Global)
Emergency
laparotomy
(Zambia)
Emergency hernia
repair (Global)
Emergency hernia
repair (Zambia)
Elective hernia
repair (Global)
Elective hernia
repair (Zambia)
Exploratory
laparotomy

Shillcutt et
al. 201353
Roberts et al.
201559
Roberts et al.
201559
Roberts et al.
201559
Roberts et al.
201559
Roberts et al.
201559
Roberts et al.
201559
Bellamkonda
et al. 202058

Costs (2020 $USD)

Effect

Measure

Economic Outcome (in
original reported currency)b

Economic Outcome (in 2020
$USD)b

Life years saved per
person
Life years saved per
person
Total DALYs
averted
Total DALYs
averted
Total DALYs
averted
DALYs averted per
person

$36 USD per LY saved

$83.46 per LY saved

$74 USD per LY saved

$171.70 per LY saved

NR

NR

NR

NR

NR

NR

$12.9 USD per DALY
averted

$33.52 per DALY averted

Mean costs

Currency

USD

1.86

USD

0.71

$59 - $1,106

$156.96 per
surgery
$123.45 per
surgery
NR

USD

1019

$59 - $1,106

NR

USD

450

$146 - $1,746

NR

USD

1424

$250 - $2,281

$312.33 per
surgery

USD

9.3

$1,739 - $6,463

$1049.46 per
surgery

USD

6.4

DALYs averted per
person

$78.2 USD per DALY
averted

$164.31 per DALY averted

$127 - $1,826

NR

USD

2080

Total DALYs
averted

$8.62 USD per DALY
averted

$20.12 per DALY averted

$127 - $1,826

NR

USD

1418

Total DALYs
averted

$12.64 USD per DALY
averted

$29.51 per DALY averted

$127 - $1,826

NR

USD

328

NR

USD

215

$127 - $1,826

NR

USD

154

$127 - $1,826

NR

USD

98

$31 - $810

$146.68 per
surgery

USD

18.51

$4.36 USD per DALY
averted
$6.66 USD per DALY
averted
$15.26 USD per DALY
averted
$24.03 USD per DALY
averted
$4.08 USD per DALY
averted

$10.18 per DALY averted

$127 - $1,826

Total DALYs
averted
Total DALYs
averted
Total DALYs
averted
Total DALYs
averted
DALYs averted per
person

$25 - $720

LY = Life year, DALY = disability-adjusted life year, CO = clinical officer, D = doctor, NR = not reported
a = Willingness-to-pay thresholds estimated by Woods and colleagues 2016 in PPP-adjusted 2020 USD$
b = Reported as average cost per outcome (ACO), either cost per DALY averted or cost per LY saved

$15.55 per DALY averted
$35.62 per DALY averted
$56.09 per DALY averted
$7.93 per DALY averted
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Table 7 Summary of Findings for Open Fracture
Study

Type of Laparotomy

GDP per capitaa
(in 2020 $USD)

Costs (2019 USD$)
Mean costs

Effect

Measure

Cost Utility (in
original reported
currency)

Cost Utility (in
2020 $USD)

Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted
Total
DALYs
averted

NR

NR

NR

NR

NR

NR

NR

NR

$69.03 USD
per DALY
averted
$98.73 USD
per DALY
averted
$225.9 USD
per DALY
averted
$336.8 USD
per DALY
averted

$161.13 per
DALY
averted
$230.46 per
DALY
averted
$527.29 per
DALY
averted
$786.13 per
DALY
averted

Currency

Gosselin
et al.
200650
Gosselin
et al.
200837
Gosselin
et al.
201052
Gosselin
et al.
201052
Roberts et
al. 201559

Fractures (conservative
treatment, reduction, and
fixation)
Fractures

$59 - $1,105

NR

USD

531

$146 - $1,746

NR

USD

2,780

External fixation of long
bone open fractures
(Teme Hospital)
External fixation of long
bone open fractures
(La Trinité Hospital)
Fracture dislocation
reduction (Global)

$498-$3,216b
$46 - $977c

NR

USD

1,676

$498-$3,216b
$46 - $977c

NR

USD

976

$127 - $1,826

NR

USD

238

Roberts et
al. 201559

Fracture dislocation
reduction (Zambia)

$127 - $1,826

NR

USD

166

Roberts et
al. 201559

Fracture dislocation fixation
(Global)

$127 - $1,826

NR

USD

52

Roberts et
al. 201559

Fracture dislocation fixation
(Zambia)

$127 - $1,826

NR

USD

35

NR = not reported
a = Willingness-to-pay thresholds estimated by Woods and colleagues 2016 in PPP-adjusted 2020 USD$
b = Willingness-to-pay threshold for Nigeria
c = Willingness-to-pay threshold for Haiti
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Chapter 3

3

Cost-Effectiveness of Increasing Access to Caesarean
Section for Obstructed Labour in the South African
Development Community (SADC) Region

The following is an unpublished manuscript formatted for journal submission. The
planned submission date is September 2021.
Authors: Anne Zhao, Shehzad Ali*, and Janet Martin
*Janet Martin and Shehzad Ali are senior authors and contributed equally to this work.

3.1 Introduction
3.1.1

Neglected Obstructed Labour and Associated Sequelae

Globally, there were an estimated 196,000 maternal deaths related to obstetric
complications that occurred in 2019.7 Of these deaths, an estimated 94% occurred in lowand middle-income countries (LMICs), resulting from global inequities in accessing
emergency obstetric care, including safe and timely access to caesarean section for
obstructed labour (WHO).2,24,82 One of the most common causes of death due to lack of
emergency obstetric care is neglected obstructed labour, defined by the World Health
Organization (WHO) as “labour with no advance of the presenting part of the fetus
despite strong uterine contractions, left untreated or neglected.”12,83 The global incidence
of obstructed labour is approximately 5% of all pregnancies, with markedly higher
estimates in LMICs compared to high-income countries.84 Incidence estimates for
obstructed labour range from 12% to 20% in LMICs like Ethiopia but are essentially
negligible in developed countries where individuals can readily access timely care.20,83,85
Obstructed labour is also one of the largest contributors to years lived with disability of
all maternal conditions because it affects young women of childbearing age.7,12,15 The
highest disability-adjusted life year (DALY) burdens due to obstructed labour and
associated sequelae occur in Sub-Saharan Africa.7,12,17 Obstructed labour and uterine
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rupture combined were directly responsible for 507,034 DALYs and 5,646 deaths in SubSaharan Africa in 2019 alone.7
Obstructed labour is typically managed through caesarean section or instrumental
delivery.12,15 Appropriate use of caesarean section or instrumental delivery reduces the
risk of life-threatening sequelae such as sepsis, hemorrhage, surgical site infections,
uterine rupture, and death.12,15,39 Obstetric fistula, a severe but preventable condition, is a
chronic condition caused by neglected obstructed labour that may lead to life-long
disability and adverse psychosocial outcomes such as being shunned from their homes
due to stress incontinence.86,87 Obstetric fistula occurs after ischemic damage and
necrosis of vaginal tissue due to prolonged obstructed labour, resulting in a hole between
the bladder and vagina (vesicovaginal) or vagina and rectum (rectovaginal).88 There are
an estimated 33,000 cases of obstetric fistula occurring each year in Sub-Saharan Africa
that lead to severe life-long disability for this population of women due to unmet need for
repair surgery.89
Obstructed labour is also directly associated with high rates of perinatal mortality and
morbidity.90 For babies born to mothers in prolonged obstructed labour, an estimated
26% are affected by perinatal asphyxia following neglected obstructed labour, which may
lead to stillbirths, encephalopathy, or motor and cognitive impairments.21,22 Stillbirth
rates for babies born from prolonged obstructed labour range from 25% to 52%,
depending on the setting and source of data.20 Despite an estimated 2.60 million
stillbirths occurring yearly worldwide, focus on the targets set for reducing national
stillbirth rates to 12 per 1,000 livebirths by 2030 has been limited in global surgery
research to date.91,92

3.1.2

Treatment and Scaling Up Access to Timely Caesarean
Section for Obstructed Labour in the SADC Region

Within Sub-Saharan Africa, a regional economic community of 16 member countries
called the South African Development Community (SADC) was formed with goals for
achieving economic development, enhanced quality of life, growth, and security.9 The
SADC region includes sixteen Sub-Saharan African countries: Angola, Botswana,
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Comoros, the Democratic Republic of Congo, Eswatini, Lesotho, Madagascar, Malawi,
Mauritius, Mozambique, Namibia, Seychelles, South Africa, Tanzania, Zambia, and
Zimbabwe.9 There have been significant efforts in improving health outcomes in the
SADC region because it represents the highest burden of disease globally.7,9 In 2019, the
maternal mortality ratio in the SADC region ranged from 61 per 100,000 live births in
Mauritius to 525 per 100,000 live births in Zimbabwe.11 Of the 16 member countries,
only Mauritius and Seychelles are on track to reaching the Sustainable Development
Goals (SDGs) proposed by the United Nations to reduce maternal mortality ratio to under
70 per 100,000 live births.11 Major direct causes of maternal mortality in the SADC
region include obstetric hemorrhage, obstructed labour, pregnancy-induced hypertension,
sepsis, and abortion complications.11
Prolonged obstructed labour and the associated excess maternal death are preventable if
timely access to surgical and anaesthetic care is made available in developing countries.11
Despite promising evidence, insufficient funding towards maternal and child health is a
significant barrier to reducing health inequities, maternal death, and neonatal death in
SADC countries.11

3.1.3

Statement of Inquiry

The proposed study evaluates the costs and effects associated with scaling-up access to
timely caesarean section compared to existing care for women of childbearing age
experiencing obstructed labour in the SADC region. Using previously published
literature, a decision analytic model was built to evaluate the incremental cost per
disability-adjusted life year averted for mothers and babies from a health systems
perspective. To our knowledge, this is the first study to use decision analytic modelling
using a lifetime time horizon to quantify the health and economic impacts associated with
increasing access to caesarean section compared to maintaining existing level of
coverage.
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3.2 Methods
This economic evaluation is reported in accordance with the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) guidelines, and in alignment with
WHO guidelines for economic evaluation (see Appendix M for the completed
checklist).93

3.2.1

Type of Economic Evaluation

A cost-utility analysis was conducted to examine the health and economic impacts of
increasing the use of caesarean section for treatment of obstructed labour to support
decision-makers with broad health system budgets. This cost-utility analysis examined
incremental costs per disability-adjusted life years averted for mothers and babies
following obstructed labour.

3.2.2

Target Population

The base case population of the analysis was women requiring caesarean section for
treatment of obstructed labour and their neonates. The economic evaluation is specific to
women in the SADC region between the ages of 15 and 49. Obstructed labour is defined
as labour with no advance of the presenting part of the fetus despite strong uterine
contractions, left untreated or neglected.12

3.2.3

Perspective

This analysis was conducted from a health systems perspective.

3.2.4

Treatment Comparators

In the existing care strategy, 30% of women in obstructed labour received caesarean
section, 3.33% received instrumental delivery, and 66.67% had no intervention for
obstructed labour. In the increased access strategy, 80% of women in obstructed labour
received caesarean section, 6.7% received instrumental delivery, and 13.3% had no
intervention for obstructed labour. Estimates of existing care are derived from
Demographic Health Surveys data for health facility deliveries in SSA and WHO
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descriptive analyses estimating the incidence of neglected obstructed labour.12,25 Within
those who can access a health facility, the proportion of those receiving caesarean section
and instrumental delivery are based on WHO assumptions of 90% caesarean section and
10% instrumental delivery.12 The estimates for the increased access strategy are based on
the 68th WHA resolutions on universal health coverage and the Lancet Commission of
Global Surgery (LCoGS) 2030 goals for global surgery provision (see Appendix G1 for
details).2,6

3.2.5

Discounting and Time Horizon

Costs and effects were discounted at 3% to reflect WHO recommendations for
conducting cost-effectiveness analysis.94 Sensitivity analyses were conducted varying the
discount rate to 0% for health effects and 6% for costs as per recommendations by the
WHO guidelines for cost-effectiveness analysis.94 Costs and health impacts were
examined over a lifetime time horizon to incorporate the long-term effects of potential
sequelae caused by obstructed labour.

3.2.6

Modelling

3.2.6.1
3.2.6.1.1

Maternal Outcomes
Decision Tree Model

The decision analytic model is comprised of a decision tree to represent in-hospital or incommunity outcomes and costs in the short-run, followed by a Markov model that
projects long-term survival, health outcomes, and costs of increasing access to caesarean
section for obstructed labour (Figures 2-4). Two alternative strategies were modeled: (a)
continuing current level of coverage of access to caesarean section (existing care: 30% of
all obstructed labor); and (b) increased access to caesarean section (expanded access:
80% of all obstructed labor). For each management strategy in the decision tree
(caesarean section, instrumental delivery, and being unable to reach the hospital),
branches were constructed to represent the seven short-term sequelae that a woman in
obstructed labour may experience: (1) sepsis, (2) hemorrhage, (3) surgical site infections,
(4) uterine rupture, (5) uterine prolapse, (6a) maternal hospital discharge without
sequelae or (6b) survival without sequelae, and (7) death.12,21,90 For women unable to
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reach a hospital for treatment, the corresponding branch for (6a) maternal hospital
discharge without sequelae in the caesarean section and instrumental delivery subtrees
was (6b) survival without sequelae in the prolonged obstructed labour subtree. Uterine
prolapse was assumed to be applicable only to women unable to reach the hospital, since
it is attributed to prolonged obstructed labour and difficult vaginal delivery.95,96 Disability
weights were applied based on the sequelae branch. In the event of uterine rupture
occurring after caesarean section or instrumental delivery, additional nodes were
constructed for women requiring hysterectomy to control severe cases of haemorrhage.97
If premature maternal death occurred, years of life lost were calculated relative to each
woman’s remainder of life based on the total healthy life expectancy in the SADC region
of 61 years.11

3.2.6.1.2

Markov Model

Women surviving obstructed labour from the decision tree entered the Markov model
(with an annual cycle) to reflect long-term survival, effects of sepsis (assumed to last up
to 2 years), and long-term disability due to obstetric fistula for the remainder of their
lifetime.86,90 The Markov nodes for long-term survival without fistula were comprised of
two states: i) survival and ii) death. If women developed sepsis, additional costs for
treatment and disability associated with the sequela were applied for two years in the
survive state.98,99 In following cycles, women surviving without obstetric fistula either
remained in the survival state or transitioned to death due to external causes.
In the model, women with obstetric fistula either underwent repair surgery or remained
untreated, and then transitioned to (i) alive without disability, (ii) alive with vesicovaginal
fistula, (iii) alive with rectovaginal fistula, (iv) alive with stress incontinence), or (v)
death, depending on surgical success or failure.100–102 In following cycles, women then
remained in the same state for the remainder of their lifetime or transitioned to death due
to external causes, which applies a simplifying assumption that women only attempt
repair surgery once in their lifetime. We assumed that women could have developed
obstetric fistula only if they survived prolonged obstructed labour without treatment.12
The Markov nodes for obstetric fistula were partially based on a published model by Epiu
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and colleagues evaluating the cost-effectiveness of repairing obstetric fistula compared to
no repair in Uganda.36 Our analyses also included the probability of developing obstetric
fistula in the decision tree model with the two alternative strategies (existing care and
increased access to caesarean section), SADC-specific parameters (where possible), and
long-term costs related to healthcare expenditure to reflect a health systems
perspective.12,103 To estimate the long-term costs related to healthcare expenditure for
women who survive, an average cost for healthcare expenditure per capita representative
of the SADC region was incorporated into each Markov node (see Appendix F).103

3.2.6.2

Neonatal Outcomes

3.2.6.2.1

Decision Tree Model

For the neonates, a separate decision tree was constructed to represent an outcome of i)
stillbirth or ii) survival, based on the management strategies (caesarean section,
instrumental delivery, and unable to reach hospital) used in the maternal model (Figures 5
and 6). For neonates born in-hospital from caesarean section or instrumental delivery, an
additional branch for iii) admission to the neonatal intensive care unit was included.104
The number of neonates correlated to the number of mothers in the maternal model to
account for cases of obstructed labour where maternal mortality occurred, but the neonate
survived. We assumed that all mothers had singleton pregnancies to simplify the model
structure. Years of life lost from untimely death were calculated in the event of stillbirth
or death in the neonatal intensive care unit based on the healthy life expectancy in the
SADC region of 61 years.11,31 As neonates experience certain health states, the associated
costs for treatment and DALYs are accumulated to estimate a cost per DALY averted
comparing the two alternative strategies: (a) continuing current level of coverage of
emergency obstetric care; and (b) increasing access to caesarean section for obstructed
labour to 80%.

3.2.6.2.2

Markov Model

Following survival or neonatal hospital discharge, neonates entered a Markov model
(with an annual cycle) to reflect the long-term effects of birth asphyxia and hypoxicischemic encephalopathy from obstructed labour depending on if they received hospital
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treatment (either caesarean section or instrumental delivery) or did not arrive at the
hospital in a timely fashion (prolonged obstructed labour).21,22 The Markov nodes for
long-term survival following caesarean section or instrumental delivery were comprised
of two states: i) survival without sequelae and ii) death from external causes. In following
cycles, neonates either remained in the survive state for the remainder of their lifetime or
transitioned to death due to external causes. The Markov nodes for long-term survival
after prolonged obstructed labour were comprised of three states: i) survival without
sequelae, ii) survival with intrapartum hypoxia with a probability of experiencing
hypoxic-ischemic encephalopathy, or iii) death from external causes. In following cycles,
neonates either remained the survival without sequelae state or the survival with
intrapartum hypoxia-related complications state for the remainder of their lifetime, or
transitioned to death due to external causes.

3.2.7

Event Probabilities

A literature review was conducted to parameterize the decision analytic model
probabilities using information from published systematic reviews and meta-analyses,
cohort studies, or cross-sectional studies. Due to lack of high-quality data from the SADC
region, parameters were evaluated and selected in the following order of preference: (1)
SADC region, (2) Sub-Saharan Africa, (3) Country-specific in the SADC region, (4)
Country-specific in Sub-Saharan Africa, (5) Low-and middle-income countries, (6) Highincome countries and (7) Based on expert opinion or assumptions (see Appendix G2 for
details and assumptions surrounding each source). Sensitivity analyses accounting for
how results differ based on uncertainty in event probabilities are presented in the results
(see Section 3.3) and Appendix (see Appendices I and J).

3.2.7.1

Maternal Sequelae Related to Obstructed Labour

The probability of developing sequelae following obstructed labour differed based on
whether the woman received caesarean section, had an instrumental delivery, or was
unable to receive treatment and experienced prolonged obstructed labour.105,106
Probabilities specific to each treatment option were sourced for each sequela where
possible: (1) sepsis, (2) hemorrhage, (3) surgical site infections, (4) uterine rupture, (5)
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uterine prolapse, and (6) maternal hospital discharge or survival without sequelae (Table
8). Probabilities were sourced from various registries, observational studies, and
systematic reviews and meta-analyses due to lack of SADC-specific estimates for
procedure-specific outcomes (see Appendix G2 for detailed information on all parameter
sources, study type, and assumptions). For women experiencing prolonged obstructed
labour, probabilities of developing obstetric fistula, repair rate, surgical success, and
subsequent outcomes (alive without disability, alive with vesicovaginal fistula, alive with
rectovaginal fistula, and alive with stress incontinence) were sourced from observational
studies from Zambia, Ethiopia, and Sub-Saharan Africa (Table 9).100–102

3.2.7.2

Maternal Mortality Related to Obstructed Labour

Mortality due to sequelae experienced by women receiving in-hospital treatment for
obstructed labour were assumed to be the same across delivery methods (Table 11).107–109
Probabilities of death following sepsis, hemorrhage, and uterine rupture were sourced
from a population-based survey of West African women experiencing obstructed
labour.107 Probability of death following surgical site infection and hysterectomy were
also included from SSA estimates from MSF and LMIC estimates from the WOMAN
trial, respectively.108,109
Estimates of mortality due to sequelae (hemorrhage, surgical site infection, and uterine
rupture) following prolonged obstructed labour were primarily taken from the
MANDATE analysis, a mathematical model aiming to estimate reductions of maternal
mortality from obstructed labour following treatment in Sub-Saharan Africa conducted
by Harrison and colleagues.106 Probability of death following sepsis after prolonged
obstructed labour was estimated based on severity of uterine rupture between hospital and
no-hospital due to lack of available evidence.107 The age-specific annual probability of
mortality was sourced from the GBD 2019 study for the Sub-Saharan African region.7
See Table 11 and Appendix G2 for detailed information on all parameter sources, study
type, calculations, and settings.
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3.2.7.3

Neonatal Sequelae Related to Obstructed Labour

Probabilities of events related to neonatal outcomes such as stillbirth, mortality in
neonatal intensive care units, perinatal asphyxia, and hypoxic-ischemic encephalopathy
were sourced from observational studies from LMICs, SSA, Ghana, and South Africa
(Table 10).21,104,105,110 Probabilities of stillbirth following caesarean section or
instrumental delivery were derived from an analysis done by Harrison and colleagues
using data from a prospective community-based registry called the Maternal and
Newborn Health Registry established by the Eunice Kennedy Shriver National Institute
of Child Health and Human Development.105 The registry collected information on births
occurring from January 1, 2010 through December 31, 2013 in six LMICs (Guatemala,
India, Pakistan, Argentina, and Zambia).105 Stillbirth probabilities were derived from
these six LMICs because SADC-specific stillbirth probabilities based on delivery method
were unavailable in literature (see Appendix G2).105 Evidence of NICU admission rates
and neonatal mortality following NICU admission specific to instrumental delivery and
caesarean section was also not available in literature. Therefore, it was assumed that
NICU admission rate and neonatal mortality following NICU was the same for both
delivery methods, due to neonates receiving hospital treatment in both cases (see
Appendix G2). These estimates were sourced from observational studies in South Africa
and Ghana.104,110 Probabilities of neonates experiencing intrapartum hypoxia and
hypoxic-ischemic encephalopathy were also included for those born following prolonged
obstructed labour without treatment.20–22 The age-specific annual probability of mortality
was sourced from the GBD 2019 study for the Sub-Saharan African region.7 Details,
assumptions, and information on sources is available in Appendix G2.

3.2.8

Health Impacts of Increasing Access to Caesarean Section

Disability-adjusted life years (DALYs) were used to measure health impact of increasing
access to caesarean section in the management of obstructed labour for mothers and
babies (Table 12). DALYs were calculated as the sum of years of life lost to premature
death and time lived with disability.31,33 Years of life lost were calculated as the
difference between each woman’s age at time of death and the healthy life expectancy in
the SADC region of 61 years for each premature death.11,31 Years lived in disability were
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calculated using disability weights for a given health state multiplied against the length of
time spent in the health state for a life-time horizon.31,32 Disability weights were sourced
from The Institute of Health Metrics and Evaluation Global Burden of Disease Study
(GBD) 2019, as it is the most comprehensive and consistent estimate for mortality and
morbidity at a regional or global level.7 The GBD 2019 gives updated estimates for
disability weights that reflect severity of disease, where 0 represents perfect health and 1
represents death.31,33,72 Sources were selected in the same order of priority as probabilities
(see Section 3.2.7). Detailed information disability weight sources and calculations are
available in Appendix H.

3.2.8.1

Maternal Outcomes Related to Obstructed Labour

Disability weights for caesarean section, instrumental delivery, and short-term and longterm sequelae following obstructed labour were incorporated in the model (Table 12).
Disability weights for in-hospital and in-community conditions were applied up to the
duration of hospital stay. For long-term sequelae, disability weights specific to each
health states were incurred for each year spent in the health state. Disability weights
While GBD 2019 disability weights were used for health conditions or states when
available, the disability weights for caesarean section and stress incontinence were taken
from the GBD 1990 due to lack of updated information.111 The disability weight for
uterine prolapse was adapted from the Korean Burden of Disease Study (KBD) 2015 due
to regional information in literature being unavailable.112 Disability weights for
instrumental delivery, acute sepsis, and hysterectomy were estimated as well using GBD
2019 and KBD 2015 data, expert opinion, and published literature (details on all
assumptions and calculations in Appendix H).7,111–114 It was assumed that women who
survive obstructed labour and do not develop obstetric fistula or sepsis return to full
health, meaning that a disability weight of 0.01 was associated with survival following
recovery (see rationale in Appendix H). Sensitivity analyses were conducted to assess
how assumptions affected the results of our analysis, presented in Section 3.3 and
Appendices I and J.
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3.2.8.2

Neonatal Outcomes Related to Obstructed Labour

Disability weights for hypoxic-ischemic encephalopathy were incorporated for a
proportion of neonates experiencing birth asphyxia after prolonged obstructed labour.21,22
These estimates were taken from GBD 2019 data (see Table 12 and Appendix H).7
Neonates were assumed to return to full health after surviving the neonatal intensive care
unit and did not experience disability due to lack of available published estimates (see
Appendix H for assumptions). Similarly, neonates surviving prolonged obstructed labour
without experiencing birth asphyxia were also assumed to return to full health for the
remainder of their lifetime. Sensitivity analyses were conducted to assess the impact of
these assumptions on the base case analyses, presented in Section 3.3 and Appendices I
and J.

3.2.9

Resources and Costs Estimation

A health systems perspective was taken in determining costs (see Table 13). Costs across
different treatment paths and adverse events were sourced primarily from published
literature and evaluated for quality in the same order as probabilities and effectiveness
(see Section 3.2.7). Costs included variable and fixed costs such as cost of procedure,
associated devices and drugs, operative facility time, personnel, and facility maintenance.
Further details on calculations and assumptions for each cost can be found in Appendix
F. Cost of caesarean section was estimated to be $303.48 USD from nine SADC
countries included in a cost-benefit analysis by Alkire and colleagues.55 Cost of
instrumental delivery was $177.36 USD, calculated by taking the ratio between costs of
caesarean section and instrumental delivery from Adamu and colleagues and applying it
to cost of caesarean section derived from Alkire and colleagues.55,115 It was assumed that
no short-term costs were associated with remaining in prolonged obstructed labour and
not receiving timely treatment, which has been widely used in other economic
evaluations for receiving essential surgery in LMICs.36,53,55 However, our analyses
include an average yearly health expenditure per capita of $53.03 USD for essential
health services utilization, applicable to all women who survive obstructed labour.103 This
annual cost per capita is the minimum investment recommended by the Taskforce on
Innovative International Financing for Health Systems and is likely not achieved in the
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SADC region.103 Treatment costs for each sequela related to obstructed labour
(hemorrhage, sepsis, surgical site infection, uterine rupture, hysterectomy, and fistula
repair) and neonatal intensive care for the neonates can be found in Table 13 with
assumptions and rationale in Appendix F.
Purchasing power parity (PPP) from the source country was used to convert values to
international dollars ($I) before inflation. Values were then inflated to PPP-adjusted 2020
United States Dollars ($USD) for analysis using GDP Implicit Price Deflators to ensure
comparability across costs from varying countries (see Appendix F). If PPP-adjustment
was not specified in the published source, market exchange rate was used to first convert
costs into original local currency before conversion to PPP-adjusted $USD for 2020
estimates to ensure consistency in methodology (see Appendix F).48

3.2.10

Analytic Methods

3.2.10.1 Base Case Analysis
In the decision tree, costs and associated DALYs were estimated based on probabilities of
experiencing specific health conditions. Years of life lost due to premature death were
calculated based on healthy life expectancy of 61 years for the SADC region, whether
that is in-hospital for those able to access caesarean section or instrumental delivery or no
treatment for women in prolonged obstructed labour.11,31 For those who survive hospital
discharge or prolonged obstructed labour, costs and DALY burdens were estimated
depending on the probability of experiencing health states and length of time spent in
them.31 Since provision of caesarean section for treatment of obstructed labour is
intended for the combined benefit of mother and baby, a combined cost per DALY
averted when considering the health and economic impacts of mother and baby together
was also estimated. In this estimate, we are assuming that the costs and effects are
additive (Table 20, see Appendix K for calculation).
A Monte Carlo microsimulation with 10,000 trials was conducted to estimate the
incremental cost-effectiveness ratios (cost per DALY averted) comparing increased
access to caesarean section to 80% and existing care for a life-time time horizon using a
health systems perspective. Cost per DALY averted was calculated for (a) maternal
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health outcomes and costs; (b) neonatal health outcomes and costs; and (c) a combined
estimate for both mothers and babies. The cycle length for the Markov model was one
year and the termination condition for the microsimulation was when individual reached
or surpassed the age of 100 years old. Costs and effects were discounted at 3% to reflect
WHO guidelines for conducting cost-effectiveness analyses.94 To correct for the
traditional Markov model assumption that transitioning between health states occurs only
at the end of a cycle, a half-cycle correction was included to assume that events occurred
in the middle of each cycle.116 Model construction and analyses were conducted using
TreeAge Healthcare Pro 2021 (Treeage Software. Inc., Williamstown, MA, USA).
The willingness-to-pay (WTP) threshold for the SADC region ranges from $574 to
$2,763 per DALY averted in 2020 PPP-adjusted USD, which was calculated as a
population-weighted average of SADC country-specific WTP thresholds estimated by
Woods and colleagues (see Appendix E).61 Woods and colleagues provide more
conservative estimates for WTP that reflect opportunity cost and PPP-adjusted GDP per
capita in comparison to those previously suggested by the WHO-CHOICE project.60,61
The Report of the WHO Commission on Macro-Economics and Health suggested that
interventions costing less than three times the national annual GDP per capita per DALY
averted is considered cost-effective and should be supported by the international
community if a country cannot undertake the implementation of the intervention on its
own.60

3.2.10.2 Variability and Uncertainty
Assumptions surrounding model inputs were tested through one-way sensitivity analyses
to identify parameters that contributed the most to uncertainty surrounding ICERs using
published 95% confidence intervals or an estimated range of ±10% (see Appendix J for
assumptions and rationale). A probabilistic sensitivity analysis (PSA) was performed
using a Monte Carlo simulation with 10,000 iterations to examine stability of the results.
Probabilities were defined using beta or Dirichlet distributions, utilities were defined
using beta distributions, and costs were defined using gamma distributions. Details on the
range of values used in one-way sensitivity analyses and distributions for the PSA were
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included in Appendix I and J. A cost-effectiveness acceptability curve was generated to
assess the probability of the increased access to caesarean section strategy being costeffective across a range of willingness-to-pay thresholds. Sensitivity of the results to a
0% discount rate for health effects and 6% for costs were examined as a scenario analysis
as per recommendations by the WHO guidelines.94

3.3 Results
Increasing access to caesarean section has impacts on health outcomes and costs for both
the mother and the neonate. Results are reported using three approaches: (a) using
maternal health outcomes and costs; (b) using newborn health outcomes and costs; and
(c) aggregating maternal and newborn health outcomes and costs.

3.3.1
3.3.1.1

Maternal Outcomes
Base Case Analysis

The cost of increasing access to caesarean section from 30% to 80% was $1,191 with
2.85 DALYs accumulated over a lifetime. For the existing level of coverage, the cost was
$843 with 9.42 DALYs accumulated over a lifetime. Compared to the existing level of
coverage, increasing access to caesarean section is expected to avert 6.57 DALYs for an
additional $348 per woman experiencing obstructed labour between the ages of 15 and 50
(Table 14). Over a lifetime time horizon, increasing access to caesarean section from
30% to 80% cost the health system $52.97 per DALY averted. Results of the maternal
model were assessed for sensitivity to a 0% discount rate for DALYs and 6% for costs,
resulting in an estimate of $44.57 cost per DALY averted (Table 15).

3.3.1.2

Deterministic Sensitivity Analysis

Results from our one-way sensitivity analyses are presented in a tornado diagram
including parameters that affected the model outputs most substantially (Figure 7).
Additional tornado diagrams for all variables and by parameter-type are available in
Appendix J. Results indicate that the model varies the most with changes in average cost
per capita spent on healthcare expenditure, cost of caesarean section, and probability of
surgical site infection following caesarean section. Increasing these parameter values

46

resulted in increased ICERs relative to the base case for the increased access strategy
compared to existing care. ICERs decreased when mortality rate from hemorrhage after
obstructed labour increased and when the disability weight for experiencing obstructed
labour increased. Across all variables tested in the one-way sensitivity analyses, the ICER
ranged from $51.69 to $57.35 per DALY averted. ICERs slightly increased when cost of
treating surgical site infection increased, when probability of developing sepsis after
caesarean section increased, and when the disability weight for undergoing caesarean
section increased. Adjusting other model parameters resulted in very slight adjustments to
ICER values, with results presented in Appendix J.

3.3.1.3

Probabilistic Sensitivity Analysis

Probabilistic sensitivity analyses suggested that the mean ICER was $50.16 per DALY
averted (Table 16). The probability of increasing access to caesarean section being costeffective approaches 100% at a willingness-to-pay threshold of $172 per DALY averted,
which is significantly lower than the SADC-specific lower-end threshold of $574 per
DALY averted (Figure 8; see Appendix I for additional information). Results from the
ICER scatterplot show that incremental costs and effectiveness are found in the top-right
quadrant, indicating that outputs from the model consistently result in additional cost for
additional DALYs averted. Cost of increasing access to caesarean section was within the
range of $280 to $380 higher than existing care and resulted in a range of 2 and 10
DALYs averted per woman in obstructed labour (Figure 9).

3.3.2
3.3.2.1

Neonatal Outcomes
Base Case Analysis

The cost of the increased access to caesarean section strategy was $1,053 with an
accumulated 6.37 DALYs. In the existing care strategy, cost was $830 with 17.64
DALYs accumulated. Compared to existing coverage, increasing access to caesarean
section led to a reduction of 11.27 DALYs for an additional $223 per neonate born from
a mother experiencing obstructed labour (Table 17). Over a lifetime time horizon,
providing increased access to caesarean section cost the health system $19.77 per DALY
averted. Results of the neonatal model were assessed for sensitivity to a 0% discount rate
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for DALYs averted and 6% for costs, resulting in an estimate of $12.93 cost per DALY
averted (Table 18).

3.3.2.2

Deterministic Sensitivity Analysis

Results from our one-way sensitivity analyses (Figure 10; see Appendix J for additional
information) indicate that the model varies the most with changes to the average cost per
capita spent on healthcare expenditure, probability of stillbirth from prolonged obstructed
labour, and disability weight of hypoxic-ischemic encephalopathy. Increasing the average
cost per capita spent on healthcare expenditure led to a higher ICER for increased access
to caesarean section relative to base case results. ICERs decreased when probability of
stillbirth after prolonged obstructed labour and disability weight of hypoxic-ischemic
encephalopathy increased. ICERs slightly increased when the probability of admission
into the neonatal intensive care unit following caesarean section and the cost of treatment
in the neonatal intensive care unit increased. Adjusting other model parameters resulted
in very slight changes in ICER values (Appendix J). Across all variables tested in the
one-way sensitivity analyses, the ICER ranged from $18.04 to $21.51.

3.3.2.3

Probabilistic Sensitivity Analysis

Probabilistic sensitivity analyses suggested that the mean ICER was $24.16 per DALY
averted (Table 19). The probability of increasing access to caesarean section being costeffective approaches 100% at a willingness-to-pay threshold of $32.50 per DALY
averted, which is significantly lower than the SADC-specific lower-end threshold of $574
per DALY averted (Figure 12; see Appendix I for additional information). Results from
the ICER scatterplot show that incremental costs and effectiveness are also found in the
top-right quadrant, meaning that outputs from the model consistently result in additional
cost for additional DALYs averted. Cost of increasing access to caesarean section was
within the range of $130 to $320 higher than existing care and resulted in a range
between 6 to 13 DALYs averted per neonate (Figure 12).

48

3.3.3

Combined Estimates for Mother and Baby

The combined cost of the increased access to caesarean strategy was $2,244 with an
accumulated 9.22 DALYs. In the existing care strategy, combined cost was $1,673 with
an accumulated 27.06 DALYs. Compared to existing coverage, increasing access to
caesarean section led to a reduction of 17.84 total DALYs for an additional $571 per
mother and baby treated (Table 20). Over a lifetime time horizon, providing increased
access to caesarean section cost the health system $32.00 per DALY averted, assuming
the health and economic impacts for mother and baby are additive.

3.4 Discussion
3.4.1

Summary of Findings and Applicability

The results from our model suggest that increasing access to caesarean section to ensure
80% of all women presenting with obstructed labor receive treatment reduces DALYs
due to years of life lost and years lived in disability at a cost of $52.97 per DALY averted
over a lifetime time horizon for childbearing women. Accompanying the maternal
estimate is an ICER of $19.77 per DALY averted for neonates born from mothers in
obstructed labour. Sensitivity analyses showed that above a threshold of $172 and
$32.50, increasing access to caesarean section is likely to be more cost-effective than
existing care for mothers and babies, respectively. Combining the health and economic
impacts for mother and baby cost $32.00 per DALY averted, assuming they can be
additive. Importantly, our model estimates cost per DALY averted for mothers and babies
both separately and combined while accounting for long-term health and economic
impacts, which strengthens and adds to the current evidence base. These estimates
support that scaling up access to caesarean section to reduce DALY burdens in mothers
and newborns is likely cost-effective and should be considered a high-value intervention
worthy of investment for health systems in the SADC region.
When comparing the cost per DALY averted for increased access to caesarean section to
benchmark interventions reported in the Disease Control Priorities 3 Volume 1, our
estimates are comparable or lower than cleft lip and cleft palate repair in Nepal ($45.45
per DALY), intrapartum care in Mexico ($349.96 per DALY averted), and non-
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emergency orthopedic surgery in Nicaragua ($407.91 - $613.58 per DALY
averted).3,13,14,65,116 Furthermore, the estimates for both maternal and neonatal outcomes
are markedly lower than the willingness-to-pay threshold calculated for the SADC
region.
Previous recommendations by the WHO-CHOICE project suggested three times the
national annual GDP per capita of the country to be cost-effective and one times GDP to
be very cost-effective.60 However, these willingness-to-pay thresholds have been found to
bias towards higher estimates than what patients are reporting.117,118 The WHO-CHOICE
thresholds are based on previous research that require more rigorous estimation to avoid
misallocation of limited resources in LMICs after further exploration of costeffectiveness, budget feasibility, and broader consideration of opportunity costs.117 In
comparing model estimates to more conservative willingness-to-pay thresholds derived
by Woods and colleagues that reflect opportunity costs of health care spending, the
weighted threshold range calculated for the SADC region is between $574 and $2,763
PPP-adjusted USD 2020 per DALY averted (see Appendix E).61 Even by these more
precise standards, increasing access to caesarean section remains highly cost-effective in
the SADC region.

3.4.2

Comparison to Existing Economic Evaluations and Modelling
Studies

Our model improves upon previously conducted cost-effectiveness analyses of caesarean
section for obstructed labour that are restricted to cohort-based estimates of those
receiving treatment for a short time horizon (generally up until hospital discharge) by
including long-term health and economic impacts and unmet need for caesarean
section.49,56,59
The findings from our model also support previous mathematical and epidemiological
modelling studies. Verguet and colleagues performed an extended cost-effectiveness
analysis to assess health gains and financial risk protection afforded if caesarean section
were made universally available.19 Their findings demonstrated that government
investment in scaling up access to caesarean section led to 122 deaths averted per
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$100,000 spent and 85 cases of poverty averted per $100,000 spent.19 To examine health
impacts, Higashi and colleagues quantified the burden of maternal and neonatal
conditions in LMICs that could be averted by full access to first-level obstetric surgical
procedures through epidemiological modelling and GBD 2010 data.17 They found that
21.1 million DALYs of a total estimated 56.6 million DALYs related to obstructed
labour, maternal haemorrhage, obstetric fistula, abortion, and neonatal encephalopathy
are avertable by full coverage of obstetric surgery in LMICs.17 In parallel, Molina and
colleagues estimated a potential reduction of up to 163,513 maternal and 803,129
neonatal deaths averted annually if countries with low rates of caesarean section
increased their rates and those with high rates decreased their rates of caesarean section to
meet ideal thresholds.18 Furthermore, Alkire and colleagues performed a cost-benefit
analysis of caesarean delivery for obstructed labour in 47 LMICs, estimating the number
of caesarean deliveries required to prevent 80% of obstructed labour cases, as well as cost
per DALY averted per country.55 The estimated cost per DALY averted was $492, which
is markedly higher than our model estimates due to their exclusion of neonates and lack
of comparison to the null (e.g. existing care).55 Alkire and colleagues’ estimates remain
the most comprehensive and relevant in published literature that address research
objectives related to our model. While these modelling studies seek to address the issues
of unmet need, inequitable DALY burdens, and catastrophic expenditure in global
surgery, ours is the first to use formal decision analytic modelling in an economic
evaluation assessing the health and economic impacts of scaling-up access to caesarean
section while addressing key limitations in Alkire and colleagues’ estimates. Overall, our
findings align with epidemiological modelling and support that increasing access to
caesarean section for obstructed labour results in substantial health gains while
addressing unmet need in caesarean section in resource-restricted settings.

3.4.3

Strengths

To our knowledge, this is the first decision-analytic model that estimates DALYs averted
for scaling-up caesarean section compared to existing care for a lifetime time horizon for
both mothers and babies. Notably, the model incorporates multiple interventions that
reflect the burden of obstructed labour and estimated proportion of those who receive
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treatment into each overall strategy (existing care versus increased access). It also
includes obstetric complications related to instrumental delivery, caesarean section, and
prolonged obstructed labour to best represent existing standard of care and clinical
pathways following obstructed labour. The model incorporates years of life lost due to
premature death from obstructed labour or resulting sequelae while also incorporating
years lived in disability for those who develop obstetric fistula or severe sepsis for the
remainder of their lives. The decision-analytic model constructed for treatment of
obstructed labour also makes novel contributions to existing literature by incorporating
perinatal outcomes for neonates, including long-term disability related to birth asphyxia
and hypoxic-ischemic encephalopathy. Reductions in neonatal mortality are incorporated
into years of life lost in neonates who are stillborn or die in the NICU. To date, estimates
have largely excluded neonates, despite neonatal mortality due to obstructed labour
accounting for 29% to 44% of stillbirths.21,119
An important aspect of unmet need in global surgery is the number of individuals in need
of care who are unable to reach the hospital due to barriers related to affordability or
distance.2 These patients are generally excluded from economic evaluations as most
patient populations are drawn from hospitals which, by definition, includes only those,
and therefore represent data from populations who have actually reached care, but fails to
account for those who did not reach care.53,56,58,59 Our model attempts to address this
disparity in access by modelling health gains associated with reducing the proportion of
women who remain in prolonged obstructed labour without access to caesarean section.

3.4.4
3.4.4.1

Limitations
Limitations in Estimating Probabilities

Primarily, our analysis was dependent on data from publicly available sources. The
parameter estimates in our model reflect best available evidence but remain limited by
the quality of data available from the SADC region, or next closest alternative source. In
particular, there are constraints with estimating the incidence of prolonged or neglected
obstructed labour, which are done through proxy measures using proportion of pregnant
women able to reach a health facility and number of live facility births.12,25 Due to
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scarcity of data specific to the SADC region, several estimates were taken from SubSaharan African or country-specific data which may reduce applicability of our results to
the SADC region. Our model also applies the simplifying assumption that women
experience one short-term sequela at a time, which is assumed to be the primary cause of
morbidity or mortality. In reality, short-term sequelae following obstructed labour are
likely not mutually exclusive and a woman may experience more than one sequela at the
same time.15,120 We also assumed that women only developed obstetric fistula when
remaining in neglected obstructed labour following delays in care, but a small proportion
of women treated late with caesarean section or instrumental delivery may also develop
obstetric fistula.121,122 This exclusion was largely due to our treatment strategies being
defined by proportions of women able to receive safe, timely, affordable treatment as per
WHA resolutions and LCoGs 2030 targets for global surgery.2,6

3.4.4.2

Limitations in Estimating Disability Weights

Another limitation of the model is lack of information on expanded contributors to longterm disability due to prolonged obstructed labour. While this was largely accounted for
by the inclusion of obstetric fistula in our analysis, current literature does not provide
estimates for other potential contributors to disability associated with neglected
obstructed labour which may also be mitigated by access to caesarean section. This could
result in underestimation of the disability experienced by these women across a life-time
horizon, and potentially underestimation of the number of DALYs avertable through
increased access to caesarean section. Consequently, our estimates may be an
underestimation of benefit, and estimates incorporating more accurate estimates of longterm disability are likely to remain cost-effective at the threshold range of $574 to $2,763
per DALY averted in the SADC region.

3.4.4.3

Limitations in Estimating Costs

Due to lack of costing information for the SADC region, certain model parameters were
limited by the calculation method of applying costing ratios from other countries (see
Appendix F for details on calculations). This approach was used in the estimation of costs
of instrumental delivery, hysterectomy, long-term sepsis, and uterine rupture, and could
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have resulted in underestimated or overestimated cost per DALY estimates. In particular,
costs are known to vary based on the setting and there is a lack of SADC-specific cost
estimates for the parameters included in our model.123 Future efforts should focus on
country-specific estimates and costing information applicable to specific settings. Our
analyses also assumed that provision of surgery was the primary cause for reductions in
DALY burdens. The costs of caesarean section used in our model were primarily focused
on cost per procedure and facility maintenance at present levels. Health system costs of
scale-up related to healthcare professional training to expand access to obstetricians,
surgeons, anaesthesiologists, and related infrastructure and supplies have not been
incorporated, but current estimates of cost per capita for surgery system scale-up from the
SADC countries indicate that the ICER will remain highly cost-effective even after
incorporation into the model.124

3.4.4.4

Limitations in Analyses

While the results of the sensitivity analyses produced estimates that are relatively precise,
sourcing probabilities from a mixture of published evidence and de novo sources did not
always allow for the full range of potential heterogeneity to be incorporated. The
methodology used for conducting sensitivity analyses follows WHO cost-effectiveness
guidelines, but the true population-level uncertainty is likely to be much larger than the
95% confidence limits reported in literature, and the assumption of 10% variation in
costs.
Regarding perspective, a societal perspective would be more comprehensive since
observational studies find that neglected obstructed labour and related sequelae are
associated with reduced workforce capability and economic losses to society.21,125
However, a health systems perspective was taken due to lack of data as well as
methodological uncertainty surrounding the valuation and incorporation of productivity
and societal costs. A societal perspective would likely result in higher incremental benefit
and lower incremental cost related to improved social productivity across the maternal
and neonatal lifespan, suggesting even higher value to society of increasing access to
caesarean section in the SADC region.
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3.4.5

Conclusion & Implications

The cost of increasing access to caesarean section (80% of all obstructed labour) is
relatively low, while the health gains are relatively high. Therefore, increasing access to
caesarean section to treat 80% of women in obstructed labour is likely cost-effective.
When considering the associated health gains for neonates born to these women, the costutility estimates appear to be even more cost-effective. Validated health system costing
data will need to be estimated and used for future cost-effectiveness research in the area
before we can definitively conclude cost-effectiveness.
Overall, our model supports previous research that suggests investing in caesarean
section is both cost-effective and of high value for health systems in the SADC
region.19,55,64 Further work is encouraged to develop improved, country-specific estimates
for SADC countries that address the uncertainty in our model parameters due to lack of
evidence. Our results support the United Nations Sustainable Development Goals 2030 of
reducing maternal mortality rates and the Lancet Commission on Global Surgery 2030
targets for increased access to safe, timely surgical care.2,6,10 Investment in continued
strategies to strengthen existing health systems and increase access to caesarean section
for treatment of obstructed labour in developing countries is necessary to achieve health
gains for impoverished populations that inequitably cannot access essential care.
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3.5 Tables and Figures for Chapter 3

Figure 2 Maternal Decision Analytic Model (Caesarean Section Subtree)
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Figure 3 Maternal Decision Analytic Model (Instrumental Delivery Subtree)
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Figure 4a Maternal Decision Analytic Model (Prolonged Obstructed Labour
Subtree: Collapsed Markov Model). Collapsed Markov model to show individual
pathways following each sequela.
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Figure 4b Maternal Decision Analytic Model (Prolonged Obstructed Labour
Subtree: Expanded Markov Model). Prolonged obstructed labour subtree: expanded
sample branch to show all possible events occurring after sepsis and health states in the
Markov model. The same model structure applies to other sequelae shown in Figure 4a.
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Figure 5 Neonatal Decision Analytic Model (Increased Access Subtree)
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Figure 6 Neonatal Decision Analytic Model (Existing Care Subtree)
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Table 8 Probabilities of Short-Term Maternal Outcomes Following Obstructed Labour
Parameter
Mean
Distribution Source
Increased
Access to
Caesarean
Section
Strategy

Existing
Care
Strategy

Caesarean
Section

Instrumental
Delivery

Prolonged
Obstructed
Labour

Caesarean Section

0.800

—

Meara et al. 20152

Instrumental Delivery

0.067

—

Dolea et al. 200012

Prolonged Obstructed Labour

0.133

—

Dolea et al. 200012

Caesarean Section

0.300

—

Doctor et al. 2018,25
Dolea et al. 200012

Instrumental Delivery

0.033

—

Dolea et al. 200012

Prolonged Obstructed Labour

0.667

—

Sepsis
Hemorrhage
Surgical site infection

0.0173
0.0104
0.0729

Beta
Beta
Beta

Doctor et al. 2018,25
Dolea et al. 200012
Dare et al. 1998126
Harrison et al. 2015105
Chu et al. 2015108

Uterine rupture
Hysterectomy
Maternal Death
Sepsis
Hemorrhage
Surgical site infection
Uterine rupture
Hysterectomy
Maternal Death
Sepsis
Hemorrhage
Surgical site infection
Uterine rupture
Uterine prolapse
Obstetric fistula
Maternal Death

0.000150
0.00631
0.00227
0.0173
0.0777
0.0254
0.0245
0.00
0.00209
0.194
0.130
0.114
0.300
0.158
0.0215
0.0910

Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Beta
Dirichlet

Liu et al. 2007127
Briand et al. 2012128
Harrison et al. 2015105
Dare et al. 1998126
Harrison et al. 2015105
Son et al. 2017129
Astatikie et al. 2017130
Briand et al. 2012128
Harrison et al. 2015105
Roa et al. 202021
Harrison et al. 2016106
Roa et al. 202021
Ayenew et al. 202120
Roa et al. 202021
Dolea et al. 200012
Gaym et al. 2002131

Outcomes within each management strategy (caesarean section, instrumental delivery, and prolonged obstructed
labour) were not mutually exclusive but are assumed to be the primary cause of morbidity or mortality
experienced by individual women.
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Table 9 Probabilities of Long-Term Maternal Outcomes Following Obstructed Labour
Parameter

Mean

Distribution

Source

Rectovaginal fistula
Vesicovaginal fistula
Repaira
Surgical success
Surgical failure
Stress incontinence

0.212
0.788
0.250
0.726
0.0992
0.175

Beta
Beta
Beta
Dirichlet
Dirichlet
Dirichlet

Kelly et al. 1998100
Kelly et al. 1998100
Gebremedhin et al. 2019101
Holme et al. 2007102
Holme et al. 2007102
Holme et al. 2007102

a = Repair surgery occurred once in the woman’s lifetime, with 3 possible outcomes (success, failure, remain
with stress incontinence). There was no probability of death associated with repair surgery102

Table 10 Probabilities of Neonatal Events Following Obstructed Labour

Caesarean
Section

Instrumental
Delivery

Prolonged
Obstructed
Labour

Parameter

Mean

Distribution

Source

Stillbirths
NICU Admission
Neonatal mortality in
NICU
Stillbirths
NICU Admission
Neonatal mortality in
NICU

0.0163
0.151

Beta
Beta

Harrison et al. 2015105
Amegan-Aho et al. 2018104

0.202

Beta

Hoque et al. 2011110

0.0694
0.151

Beta
Beta

Harrison et al. 2015105
Amegan-Aho et al. 2018104

0.202

Beta

Hoque et al. 2011110

Stillbirths

0.386

Beta

Ayenew et al. 202120

Intrapartum hypoxia
Hypoxic-ischemic
encephalopathy (HIE)a

0.256

Beta

Roa et al. 202021

0.303

Beta

Graham et al. 200822

Abbreviations: NICU, Neonatal Intensive Care Unit.
a = Hypoxic-ischemic encephalopathy occurs conditionally upon experiencing intrapartum hypoxia
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Table 11 Maternal Mortality Following Sequelae due to Obstructed Labour

Hospital
(Caesarean
Section and
Instrumental
Delivery)
No Hospital
(Prolonged
Obstructed
Labour)

Parameter

Mean

Distribution Source

Sepsis
Hemorrhage
Surgical site infection
Uterine rupture
Hysterectomy
Sepsis
Hemorrhage
Surgical site infection
Uterine rupture

0.333
0.0322
0.0551
0.304
0.200
0.493
0.250
0.0500
0.450

Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta

Prual et al. 2000107
Prual et al. 2000107
Chu et al. 2015108
Prual et al. 2000107
Huque et al. 2018109
Prual et al. 2000107
Harrison et al. 2016106
Harrison et al. 2016106
Harrison et al. 2016106

In-hospital mortality due to obstructed labour sequelae following caesarean section and instrumental delivery
were assumed to be the same107

Table 12 Disability Weights for Maternal and Neonatal Outcomes
Disability
Parameter
Distribution
Weight
Caesarean Section
0.349
Beta
Instrumental Delivery* 0.375
Beta
Obstructed Labour
0.324
Beta
Short-Term
In-Hospital
and InCommunity
Maternal
Outcomes

Long-Term
Maternal
Outcomes
Long-Term
Neonatal
Outcomes

Source
GBD 1990111
Estimate
GBD 20197

Sepsis (acute)*

0.499

Beta

KBD 2015,112
Estimate

Hemorrhage
Surgical site infection
Uterine prolapse

0.324
0.051
0.404

Beta
Beta
Beta

GBD 20197
GBD 20197
KBD 2015112

Uterine rupture

0.490

Beta

Gilbert et al. 2013,114
Chung et al. 2001113

Hysterectomy*
Stress incontinence

0.324
0.0250

Beta
Beta

Rectovaginal fistula

0.501

Beta

Vesicovaginal fistula
Sepsis (long-term)
Full Health
Hypoxic-Ischemic
Encephalopathy
Full Health

0.342
0.133
0.0100

Beta
Beta
Beta

GBD 20197
GBD 20197
Estimate

0.351

Beta

GBD 20197

0.0100

Beta

Estimate

GBD 20197
GBD 1990111
GBD 20197

Abbreviations: GBD, Global Burden of Disease Study; KBD, Korean Burden of Disease Study.
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Table 13 Costs Related to Interventions and Sequelae for Obstructed Labour
Mean
Parameter
(PPP-adjusted
Distribution
Source
$USD 2020)
Caesarean Section

$303.48

Gamma

Alkire et al. 201555

Instrumental Delivery

$177.36

Gamma

Adamu et al. 2013115 *

Hemorrhage

$123.02

Gamma

Levin et al. 2003132

Hysterectomy

$584.48

Gamma

Lorenzoni et al. 2015133 *

Fistula repair

$406.30

Gamma

Epiu et al. 201836

Sepsis (acute)

$464.32

Gamma

Fenny et al. 2020134

Sepsis (long-term)

$239.11

Gamma

Farrah et al. 202099 *

Surgical site infection

$509.53

Gamma

Silverstein et al. 2016,135
Monahan et al. 2020136

Uterine rupture

$510.14

Gamma

Alsuwaidan et al. 2020137 *

Current healthcare
expenditure per capita
(SADC)

$53.03

Gamma

Taskforce on Innovative
International Financing for
Health Systems103

Neonatal Intensive Care

$363.77

Gamma

Enweronu-Laryea et al.
2018138

Current healthcare
expenditure per capita
(SADC)

$53.03

Gamma

Taskforce on Innovative
International Financing for
Health Systems103

Abbreviations: USD, United States Dollar; PPP, Purchasing Power Parity; SADC, South-African
Development Community.
* = Estimated costs using relative proportions of costs of other health states. Methodology available in
Appendix F
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Table 14 Base Case Results for Maternal Model

Strategy

Existing Care
Increased Access
to Caesarean
Sections

Cost
($USD
2020)
843.04

Incremental
Incremental
Incremental CostEffectiveness
Cost ($USD
Effectiveness Effectiveness
(DALYs)
2020)
(DALYs)
Ratio
(ICER)
—
9.42
—
—

1191.00 347.96

2.85

6.57

52.97

Table 15 Sensitivity Analysis Results for Maternal Model (Discounted 0% effect, 6%
costs)
Incremental
Cost
Incremental
Incremental CostEffectiveness
Strategy
($USD Cost ($USD
Effectiveness Effectiveness
(DALYs)
2020) 2020)
(DALYs)
Ratio
(ICER)
Existing Care
622.03 —
9.73
—
—
Increased Access to
912.93 290.91
3.20
6.53
44.57
Caesarean Sections

Table 16 Probabilistic Sensitivity Analysis Results for Maternal Model (Mean
Expected Value)
Incremental
Cost
Incremental
Incremental CostEffectiveness
Strategy
($USD
Cost ($USD
Effectiveness Effectiveness
(DALYs)
2020)
2020)
(DALYs)
Ratio
(ICER)
Existing Care
910.93
—
9.33
—
—
Increased Access
to Caesarean
1245.91 334.98
2.66
6.67
50.16
Sections
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Figure 7 Tornado Diagram. Expected value of $54.52 refers to cost per disability-adjusted life year averted.
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Figure 8 Probabilistic Sensitivity Analysis (10,000 iterations) using Monte Carlo Simulation for Maternal Model (WTP = $574)
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Figure 9 ICE Scatterplot for Maternal Model. Incremental costs presented in PPP-adjusted $USD 2020 and incremental
effectiveness presented in disability-adjusted life years averted.
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Table 17 Base Case Results for Neonatal Model
Strategy
Existing Care
Increased
Access to
Caesarean
Sections

829.69

Incremental
Incremental
Incremental
Effectiveness
CostCost ($USD
Effectiveness
(DALYs)
Effectiveness
2020)
(DALYs)
Ratio (ICER)
—
17.64
—
—

1052.56

222.87

Cost
($USD
2020)

6.37

11.27

19.77

Table 18 Sensitivity Analysis Results for Neonatal Model (Discounted at 0% effect, 6%
costs)
Incremental
Cost
Incremental
Incremental
Effectiveness
CostStrategy
($USD
Cost ($USD
Effectiveness
(DALYs)
Effectiveness
2020)
2020)
(DALYs)
Ratio (ICER)
Existing Care
534.64
—
18.70
—
—
Increased Access
to Caesarean
686.01
151.37
6.98
11.72
12.93
Sections
Table 19 Probabilistic Sensitivity Analysis for Neonatal Model (Mean Expected Value)
Incremental
Cost
Incremental
Incremental
Effectiveness
CostStrategy
($USD Cost ($USD
Effectiveness
(DALYs)
Effectiveness
2020)
2020)
(DALYs)
Ratio (ICER)
Existing Care
828.51
—
25.62
—
—
Increased Access
to Caesarean
1057.59 229.09
16.13
9.49
24.16
Sections
Table 20 Combined Cost-Utility Estimates for Mother and Baby
Strategy
Existing Care
Increased Access
to Caesarean
Sections

Incremental
Incremental
Incremental
Effectiveness
CostCost ($USD
Effectiveness
(DALYs)
Effectiveness
2020)
(DALYs)
Ratio (ICER)
1672.73 —
27.06
—
—
Cost
($USD
2020)

2243.56 570.83

9.22

17.84

32.00
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Figure 10 Tornado Diagram. Expected value of $19.77 refers to cost per disability-adjusted life year averted.
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Figure 11 Probabilistic Sensitivity Analysis (10,000 iterations) using Monte Carlo Simulation for Neonatal Model (WTP =
$574)
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Figure 12 ICE Scatterplot for Neonatal Model. Incremental costs presented in PPP-adjusted $USD 2020 and incremental
effectiveness presented in disability-adjusted life years averted.
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Chapter 4

4

Conclusion

4.1 Summary of Findings
The results from the systematic review on essential surgery in LMICs and the subsequent
economic evaluation of increasing access to caesarean section in the SADC region
demonstrated that increasing access to the Bellwether procedures in developing countries
is likely cost-effective in the context of benchmark interventions and willingness-to-pay
thresholds derived from opportunity cost and PPP-adjusted GDP per capita.60,61
The systematic review on increasing access to the Bellwether procedures in LMICs
included 13 economic evaluations that estimated the cost-effectiveness of caesarean
section, laparotomy, and treatment of open fracture. Surgery type included both elective
and emergency procedures across 49 countries between 1998 and 2020. Several studies
reported generic outcomes such as cost per DALY, cost per LY saved, and cost-benefit
ratio while others reported specific outcomes such as cost per maternal mortality avoided
and cost per newborn death avoided per 1000 procedures. Due to inadequate comparator
groups, most economic measures were classified as average cost per outcome for a
specific cohort. It was thus only possible to compare five studies that included cost per
DALY averted estimates, as recommended by the WHO and IHME.29,30,32 The most costeffective procedures were exploratory laparotomy in Uganda ($7.93 per DALY
averted),58 emergency hernia repair in Zambia ($15.55 per DALY averted),59 and
caesarean section in Zambia ($16.90 per DALY averted).59 The least cost-effective
procedures were emergency caesarean section for obstructed labour across 49 low-middle
income countries ($491.81 per DALY averted)55 and fracture dislocation fixation in
Zambia ($786.13 per DALY averted).59 These estimates remain cost-effective under
benchmark WTP thresholds and PPP-adjusted WTP thresholds for each country.60,61
Overall bias as assessed with the ECOBIAS Checklist across the included studies was
high, with main biases being inefficient comparator, reporting and dissemination bias,
limited sensitivity analyses, and cost measurement omission bias.47 Notably, most studies
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did not use formal decision-analytic modelling to estimate economic measures and were
cohort-specific analyses instead of population-based.
Following the results of the systematic review, a Markov tree cycle was constructed to
assess the cost-effectiveness of increasing access to caesarean section for obstructed
labour in the SADC region compared to existing care. The cost of the increased access
strategy was $1,191 with 2.85 DALYs compared to $843 with 9.42 DALYs for the
existing care strategy. Increasing access to caesarean section from 30% to 80% and
reducing the proportion of women remaining in neglected obstructed labour from 66.67%
to 13.3% is expected to reduce a disability burden of 6.57 DALYs for an additional $348
per woman in obstructed labour, resulting in an ICER of $52.97 per DALY averted in
2020 PPP-adjusted $USD. Model outputs were most sensitive to the average cost per
capita spent on healthcare expenditure, cost of caesarean section, and probability of
surgical site infection following caesarean section. Probabilistic sensitivity analyses
demonstrated stable results with increased access being cost-effective 100% of the time at
a willingness-to-pay threshold of $172 per DALY averted.
Accompanying results for the neonates were $1,053 with an accumulated 6.37 DALYs
for the increased access strategy compared to $830 with 17.64 DALYs for the existing
care strategy. The increased access strategy led to a reduction of 11.27 DALYs for an
additional $223 per neonate born relative to the existing care strategy, resulting in an
ICER of $19.77 per DALY averted. Probabilistic sensitivity analyses were cost-effective
100% of the time at a willingness-to-pay threshold of $32.50 per DALY averted. A
combined estimate of cost-utility for mothers and babies cost $32.00 per DALY averted
comparing increased access to existing care.
Compared to SADC-specific willingness-to-pay thresholds ranging from $574 to $2,763
per DALY averted in 2020 PPP-adjusted $USD, all results were found to be likely costeffective. However, given that our results are sensitive to health system costs, these costs
must be validated and incorporated into these cost-utility estimates before we can
definitively conclude cost-effectiveness.124 Our findings are consistent with other
published economic evaluations and epidemiological modelling studies that find
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provision of safe, timely caesarean section for obstructed labour to result in substantial
health gains and likely be cost-effective in LMICs.17–19,55,64

4.2 Strengths and Limitations
4.2.1

Systematic Review

The systematic review has several strengths. It is the first systematic review to synthesize
and appraise evidence on all cost-effectiveness estimates for increasing access to the
Bellwether procedures in LMICs, which is much needed in the context of supporting
global targets for surgical access by 2030. Importantly, gaps and limitations in the quality
in existing evidence were identified, providing opportunity to establish a standard for
future cost-effectiveness analyses conducted in LMIC settings. The findings show that
increasing access to Bellwether procedures to reduce disability and premature death is
highly cost-effective but remains limited by aspects of the economic evaluations
pertaining to lack of formal decision-analytic modelling, short time horizons, restricting
cohorts of only those who can access care, and lack of generalizability due to the limited
study settings. Limitations of this review mostly stem from the methodology and data
from the included studies which restricted the possibility of further quantitative analyses
due to high heterogeneity and incomparability across studies.

4.2.2

Economic Evaluation

Similarly, the model constructed to address the knowledge gap surrounding increasing
access to caesarean section for obstructed labour has several strengths. Primarily, it is the
first decision-analytic model to incorporate a Markov cycle decision tree to represent the
impact of increasing safe, timely caesarean section compared to existing care for women
in obstructed labour. Furthermore, the model accounts for long-term disability due to
secondary conditions following obstructed labour, such as sepsis and obstetric fistula,
across a life-time time horizon. The model employs methods recommended by the WHO
to evaluate sets of interventions to better address resource constraints by modelling the
treatment options that most accurately represent standard care.94 Most importantly, the
model addresses a largely ignored issue of unmet need in global surgery health
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economics, being that a staggering proportion of women in obstructed labour are unable
to reach the operating room or the hospital.2 These patients have been generally excluded
from economic evaluations on global surgery to date, leaving a gaping inequity in access
that the model is able to address. Finally, the model also includes an accompanying
analysis for neonates that have also been typically excluded from economic evaluations
conducted in LMICs. This is particularly impactful due to the number of stillbirths and
asphyxia-related disabilities attributed to obstructed labour that would be prevented with
access to safe, timely caesarean section.17
The model also has limitations, primarily the limited quality of data available for the
SADC region. In many cases, SADC-specific estimates were not available and estimates
from the super-region, Sub-Saharan Africa, were used to populate the model. The
proportion of those receiving caesarean section, undergoing instrumental delivery, or
unable to receive treatment were also extrapolated from pooled Demographic Health
Surveys data and WHO estimates of health facility access and deliveries in Sub-Saharan
Africa.12,25 Another limitation to the model is lack of information surrounding long-term
disability for mothers and babies after obstructed labour, besides disability due to
obstetric fistula, which remains understudied and difficult to estimate.

4.3 Health Policy Implications
Prioritizing high-value, low-cost interventions such as the Bellwether procedures is a
practical use of healthcare resources with considerable health benefits for reasonably low
cost.2,3 The goal of the systematic review and the Markov cycle model are to demonstrate
to policymakers that increasing access to safe surgery to meet the LCoGS 2030 targets
for safe surgery is likely achievable at a cost-effective capacity. Evidently, achieving the
Sustainable Development Goals in reducing maternal mortality also heavily relies on the
availability and extent of access to safe surgical management of obstructed labour. 1,9,49 53
While implementing measures to increase access to essential surgery continues to be a
global priority, there are several challenges to successful realization of these goals. High
cost, infrastructure demands, political factors, shortage of trained workers, patient
perceptions of surgery, and various demographic factors are examples of barriers that
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exist between patients and life-saving access to essential surgery.42-45 However,
meaningful efforts have been made to lessen the severity of these limitations, such as
surgical workforce training, task-shifting, alternative fee programs, and maternal care
packages for essential obstetric care.54,64,81,139
To close the gap in access by 2030, it is crucial that the unmet need in global surgery is as
accurately and comprehensively defined as possible. National Surgical, Obstetric and
Anesthesia Plans (NSOAPs) are a framework for strengthening surgical systems through
three core concepts, one of which is to define current gaps in surgical access and delivery
through the LCoGS indicators.140 Groundwork for developing NSOAPs is in various
stages globally and several countries in Sub-Saharan Africa have successfully
implemented NSOAPS to improve their national health strategic plans.140 As the amount
of country-specific data on the LCoGS core indicators expands, future economic
evaluations will be able to use higher quality data to accurately represent surgical access
in existing care and yield cost-utility estimates that are closer to reality.

4.4 Future Directions
Based on the findings of these studies, future directions for global surgery economic
evaluation should be expanded in two ways: i) to develop and implement more rigorous
standards for cost-effectiveness analyses conducted in LMICs and ii) to adapt the novel
decision-analytic model to country-specific data to provide specific estimates for
individual health systems in the SADC region. The model was created with the goal to
demonstrate to policymakers and stakeholders that death and disability due to prolonged
obstructed labour in LMICs is preventable in a cost-effective manner and worth investing
in. However, the model currently can only broadly estimate cost per DALY averted due
to the paucity of data from the SADC region. Our cost estimates for caesarean section
also solely focus on costs related to procedure and facility maintenance while excluding
health system costs of scale-up related to healthcare professional training to expand
access to obstetricians, surgeons, and anaesthesiologists. Validated estimates of these
health system costs should be developed and used for future cost-effectiveness research
in this area. Future work includes developing a clinician survey on REDCap for costs,
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event probabilities, and effectiveness to drive accompanying economic evaluations
forward and improve the current evidence base for better global health outcomes. Open
access to the model will be established to allow policy advisors, researchers, and
clinicians to input country-specific or regional data for their own assessments.
While the results of the study find increasing access to essential surgery to be costeffective, it is important to note that cost-effectiveness thresholds should not be the only
criteria for making public health decisions at a national level.141 Evidence-to-decision or
multi-criteria decision analysis frameworks, context, and further deliberation are
necessary to supplement the decision-making process.141 For this reason, significant
efforts are still required to reach the WHO targets for strengthening emergency and
essential surgical care and anaesthesia as a component of universal health coverage by
2030, as well as the UN SDG goals for reducing maternal mortality to under 70 per
100,000 live births.6,10 Despite the numerous challenges to global expansion of access to
safe and timely essential surgery, their cost-effectiveness in saving lives and potential to
reduce long-term disabilities underscores the urgent need to implement equitable,
increased access to safe surgical care.2,34 Successful achievement of these goals will
advance global development, maintain resilient health systems, and enhance human
welfare in LMICs through global commitment and partnership to guide policy and
action.10
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Appendices
Appendix A: Search Strategy for Electronic Databases and Grey Literature
Embase (Ovid)
1

developing country/ (96047)

2 ((developing or low or middle) adj3 (countr* or nation*)).mp. (180576)
3 ((third adj2 world) and (countr* or nation*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word] (2930)
4

((underdeveloped or under-developed) adj2 (countr* or nation*)).mp. (1911)

5

(least-developed adj2 (countr* or nation*)).mp. (304)

6

middle income country/ (8679)

7

low income country/ (6029)

8

LMIC.mp. (2752)

9

1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (182891)

10

bellwether.mp. (125)

11

(c?section* or c?esar?an* or c-section*).mp. (124122)

12

((abdominal* or surgical) adj2 (deliver* or birth*)).mp. (2571)

13

exp obstetric operation/ (173801)

14

exp obstetric anesthesia/ (15172)

15

(obstetric adj2 (anesthesia or operation* or surgery)).mp. (14070)

16

laparotomy/ (85823)

17

(laparotom* or minilaparotom*).mp. (111940)

18

exp open fracture/ (6508)

19

open fracture treatment.mp. (31)

20

(fracture* adj3 (open or compound)).mp. (13971)

21

fractures/su [Surgery] (8982)
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22

open fracture/ (6508)

23

open fracture reduction/ or "open reduction (procedure)"/ (3591)

24

exp laparoscopy/ (161382)

25

laparoscop*.mp. (241531)

26

minilaparoscop*.mp. (388)

27

minilaparoscop*.mp. (8)

28

celloscop*.mp. (32)

29

peritoneoscop*.mp. (1383)

30

laparoendoscop*.mp. (3240)

31

(abdom* adj3 (surgery or surgical or surgeries or surgically or operation* or operating or operativ* or operated)).ti,ab. (44405)

32

10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 (581365)

33

socioeconomics/ (146503)

34

cost benefit analysis/ (84628)

35

cost effectiveness analysis/ (151274)

36

cost of illness/ (19182)

37

cost control/ (68383)

38

economic aspect/ (118180)

39

financial management/ (117224)

40

health care cost/ (190180)

41

health care financing/ (13318)

42

hospital cost/ (21578)

43

(fiscal or financial or finance or funding).tw. (201427)

44

Cost minimization analysis/ (3507)

45

(cost adj estimate$).mp. (3454)

46

(cost adj variable$).mp. (267)

47

(unit adj cost$).mp. (4561)
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48

cost*effect*.mp. (5158)

49

cost-effect*.mp. (252753)

50

exp "cost"/ (353958)

51

cost.mp. (893345)

52

cost*analysis.mp. (20)

53

cost-analysis.mp. (13631)

54

exp quality adjusted life year/ (26575)

55

quality adjusted life year.mp. (27923)

56

QALY.mp. (16675)

57

exp "quality of life"/ (490822)

58

life year*.mp. (38423)

59

exp disability-adjusted life year/ (2027)

60

disability-adjusted life year.mp. (2617)

61

DALY.mp. (2383)

62

budget impact.mp. (4120)

63

inequity.mp. (4188)

64

exp health care disparity/ (15339)

65

inequalit*.mp. (39269)

66

equit*.mp. (30320)

67

equal*.mp. (453297)

68

health inequality aversion.mp. (6)

69

health inequality.mp. (1421)

70

exp health disparity/ (19690)

71

exp health care need/ (29929)

72

surgical need.mp. (199)

73

exp "cost utility analysis"/ (9690)
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74

cost utility analysis.mp. (10645)

75

exp "cost benefit analysis"/ (84628)

76

exp health economics/ (864297)

77

budget/ (29609)

78 budget*.ti,ab,kw. (39980)
79 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic* or pharmaco-economic* or expenditure or expenditures or
expense or expenses or financial or finance or finances or financed).ab. /freq=2 (412465)
80

(cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kw. (229933)

81

(value adj2 (money or monetary)).ti,ab,kw. (3333)

82

statistical model/ (160542)

83

economic model*.ab,kw. (4916)

84

probability/ (108625)

85

markov.ti,ab,kw. (29715)

86

monte carlo method/ (40260)

87

monte carlo.ti,ab,kw. (50440)

88

decision theory/ (1768)

89

decision tree/ (12957)

90 (decision* adj2 (tree* or analy* or model*)).ti,ab,kw. (34477)
91 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or
61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or
90 (2891764)
92

9 and 32 and 91 (1353)
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Appendix B Risk of Bias Using the ECOBIAS Tool
Part B: Model-specific aspects of bias in economic evaluation
I.

Bias related to structure

II.

Bias related to data

Study

Structural
assumption
bias

No
treatment
comparator
bias

Wrong
model bias

Limited
time
horizon
bias

Bias related
to data
identification

Bias
related
to
baseline
data

Bias
related to
treatment
effects

Bias related
to qualityof-life
weights
(utilities)

Nontransparent
data
incorporation
bias

Limited
scope
bias

III. Bias related
to
consistency
Bias related to
internal
consistency

Jha et al.
1998
Gosselin et
al. 2006
Gosselin et
al. 2008
Hounton et
al. 2009
Shilcutt et al.
2010
Gosselin et
al. 2010
Shillcutt et
al. 2013
Alkire et al.
2015
Roberts et al.
2015
Verguet et
al. 2015
Entringer et
al. 2018
Entringer et
al. 2018
Bellamkonda
et al. 2020

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Yes

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Yes

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Yes

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Partly

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

No

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Partly

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

No

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Partly

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Yes

No

N/A

N/A

N/A

N/A

Partly

N/A

No

N/A

Partly

Partly

No

No

No

Partly

Partly

Partly

No

No

Yes

No

No

No

No

No

Partly

Partly

Partly

No

No

Yes

No

No

No

N/A

N/A

N/A

N/A

No

N/A

No

N/A

No

Partly

No
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Appendix C Currency Conversions
Table C.1 Costs Conversion and Inflation for Caesarean Section
Study
Jha et al.
1998
Jha et al.
1998
Alkire 2015
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Verguet et
al. 2015
Verguet et
al. 2015
Hounton et
al. 2009
Hounton et
al. 2009
Hounton et
al. 2009
Entringer et
al. 2018a
Entringer et
al. 2018b
Entringer et
al. 2018b

Cost
41,481
18,000
38,124.00
58,291.70
107,948.00
161,184
38,124.00

Currency
Guinean
Francs
Guinean
Francs
USD
Zambian
kwacha
Zambian
kwacha
Zambian
kwacha
Zambian
kwacha

Costing
Year

PPP
Exchange
Rate

Cost ($I)

GDP Implicit
Price Deflator
(Original)

GDP Implicit
Price Deflator
(Adjusted)

Ratio

Adjusted
Cost (2020)

1994

676.887

$61.28

70.392

113.626

1.61418911

$98.92

1994

676.887

$26.59

70.392

113.626

1.61418911

$42.93

2010

1

$416.00

96.111

113.626

1.1822372

$491.81

2012

2563.23

$14.87

100

113.626

1.13626

$16.90

2012

2563.23

$22.74

100

113.626

1.13626

$25.84

2012

2563.23

$42.11

100

113.626

1.13626

$47.85

2012

2563.23

$62.88

100

113.626

1.13626

$62.88

420,000

USD

2011

--

$420,000

98.118

113.626

1.15805459

$486,382.93

140 deaths
per 100,000

USD

2011

--

--

98.118

113.626

--

122 deaths
per 100,000

2006

191.518

$182.14

90.066

113.626

1.26158595

229.7912688

2006

191.518

$195.97

90.066

113.626

1.26158595

$247.23

2006

191.518

$189.33

90.066

113.626

1.26158595

238.8553895

2016

2.133

$1,607.72

105.722

113.626

1.07476211

1727.918175

2014

1.813

$1,238.75

103.638

113.626

1.09637392

1358.136969

2014

1.813

$1,466,850.08

103.638

113.626

1.09637392

1608216.171

34884
37531
36260
3,429.27
2245.86
2659399.2

Burkina
Faso (CFA)
Burkina
Faso (CFA)
Burkina
Faso (CFA)
Brazilian
Reais
Brazilian
Reais
Brazilian
Reais
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Table C.2 Costs Conversion and Inflation for Laparotomy
Study

Cost

Jha et al. 1998

65,819

Jha et al. 1998

35,000

Jha et al. 1998

51,768

Jha et al. 1998

72,000

Shillcutt et al.
2010
Shillcutt et al.
2010
Shillcutt et al.
2013
Shillcutt et al.
2013
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Roberts et al.
2015
Bellamkonda
et al. 2020
Bellamkonda
et al. 2020

$122.328
$13.1277

Currency
Guinean
Francs
Guinean
Francs
Guinean
Francs
Guinean
Francs
Ghanian
New Cedi
Ghanian
New Cedi

Costing
Year

PPP
Exchange
Rate

Cost ($I)

GDP Implicit
Price Deflator
(Original)

GDP Implicit
Price Deflator
(Adjusted)

Ratio

Adjusted Cost
(2020)

1994

676.887

$97.24

70.392

113.626

1.61418911

156.9601916

1994

676.887

$51.71

70.392

113.626

1.61418911

83.46536266

1994

676.887

$76.48

70.392

113.626

1.61418911

123.4524255

1994

676.887

$106.37

70.392

113.626

1.61418911

171.7001746

2008

0.472

$259.17

94.285

113.626

1.20513337

312.3338033

2008

0.472

$27.81

94.285

113.626

1.20513337

33.51828256

499.33

USD

2011

0.551

$906.23

98.118

113.626

1.15805459

$1,049.46

78.18

USD

2011

0.551

$141.89

98.118

113.626

1.15805459

164.313444

2012

2563.23

$17.71

100

113.626

1.13626

20.12134564

2012

2563.23

$25.97

100

113.626

1.13626

29.50508902

2012

2563.23

$8.96

100

113.626

1.13626

10.1773695

2012

2563.23

$13.68

100

113.626

1.13626

15.54617063

2012

2563.23

$31.35

100

113.626

1.13626

35.6208376

2012

2563.23

$49.37

100

113.626

1.13626

56.09242844

2018

1,300.42

$7.69

110.296

113.626

1.03019148

7.926359755

2018

1,300.42

$142.38

110.296

113.626

1.03019148

146.6758791

45,390.70
66,559.00
22,958.60
35,069.80
80,355.20
126,536
10,005.50
185,150

Zambian
kwacha
Zambian
kwacha
Zambian
kwacha
Zambian
kwacha
Zambian
kwacha
Zambian
kwacha
Ugandan
shilling
Ugandan
shilling
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Table C.3 Costs Conversions and Inflation for Open Fracture
Study

Roberts et
al. 2015

Roberts et
al. 2015

Roberts et
al. 2015

Roberts et
al. 2015

Fracture
dislocation
reduction
(Global)
Fracture
dislocation
reduction
(Zambia)
Fracture
dislocation
fixation
(Global)
Fracture
dislocation
fixation
(Zambia)

PPP
Exchange
Rate

Cost ($I)

GDP Implicit
Price
Deflator
(Original)

GDP Implicit
Price Deflator
(Adjusted)

Ratio

Adjusted Cost
(2020)

Cost

Currency

Costing
Year

363,494

Zambian
kwacha

2012

2563.23

$141.81

100

113.626

1.13626

161.134074

519,887

Zambian
kwacha

2012

2563.23

$202.82

100

113.626

1.13626

230.4618792

1,189,480

Zambian
kwacha

2012

2563.23

$464.06

100

113.626

1.13626

527.2872683

1,773,400

Zambian
kwacha

2012

2563.23

$691.86

100

113.626

1.13626

786.1344803
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Appendix D PRISMA Checklist
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Appendix E Willingness-To-Pay Thresholds for SADC Countries
Country

Population

Weight

Low threshold

Angola

31,825,295

0.08991821

901.1466955

High
Threshold
4327.067466

Botswana
Comoros
Democratic Republic of Congo
Eswatini
Lesotho
Madagascar
Malawi
Mauritius
Mozambique
Namibia
Seychelles
South Africa
Tanzania
Zambia
Zimbabwe
Total

2,303,697
850,886
86,790,567
1,148,130
2,125,268
26,969,307
18,628,747
1,265,711
30,366,036
2,494,530
97,625
58,558,267
58,005,463
17,861,030
14,645,468
353,936,027

0.00650879
0.00240407
0.24521541
0.00324389
0.00600467
0.07619825
0.05263309
0.0035761
0.08579527
0.00704797
0.00027583
0.16544873
0.16388686
0.05046401
0.04137886

3897.152376
39.08319002
8.933300575
707.9640706
106.0829443
31.26655201
10.04996315
4692.216127
17.86660115
1487.394546
9279.465972
2480.107572
50.24981573
160.7994103
45.78316545

11634.50734
894.4467201
428.7984276
3836.852597
1484.044558
800.647064
447.7816913
12408.3545
599.6478011
5559.862945
15715.90904
9948.346853
1018.396266
1825.743305
975.9630878

Weighted low

Weighted high

81.02950035

389.0821733

25.36576543
0.093958616
2.190582939
2.296558492
0.636992761
2.382456647
0.528960622
16.77983905
1.532869819
10.48311003
2.559524311
410.3306539
8.235284359
8.114582504
1.894455024
574.4550948

75.72662177
2.150310039
105.147981
12.44633277
8.911193462
61.0079077
23.56813436
44.37352963
51.44694331
39.18573938
4.334867046
1645.941376
166.901763
92.13432218
40.38423636
2762.743431
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Appendix F Costs
Methodology for Calculating PPP-adjusted $USD and Inflation of Costs
To adjust the costs used in the model for varying currencies and inflation, the following general procedure was used:
i)

Adjust costs in original currency to account for purchasing power parity (PPP). Purchasing power parity incorporates the
prices of specific goods to compare the absolute purchasing power of a country’s currency. PPPs incorporate price
information for a representative basket of products and services across countries to allow for comparison.

𝐶𝑜𝑠𝑡 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑃𝑃𝑃 =

𝐶𝑜𝑠𝑡 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑦
𝑃𝑃𝑃 𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒 𝑟𝑎𝑡𝑒

Costs adjusted with PPP are in the units of international dollars ($I) but will be referred to as PPP-adjusted $USD to
maintain comparability. One international dollar has the same purchasing power for goods and services in a cited country
as one United States Dollar ($USD) in the United States at a given point in time.48 PPP exchange rates were taken from the
International Monetary Fund: World Economic Outlook database.142

ii)

Adjust PPP-adjusted USD for inflation and convert all costs to a single base year, 2020. Costs were inflated using Gross
Domestic Product (GDP) implicit price deflators which reflect price changes of all goods contributing to GDP and average
annual rate of inflation during the specific period.48

𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑠𝑡 (2020 𝑝𝑟𝑖𝑐𝑒) = 𝐶𝑜𝑠𝑡 (𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑐𝑜𝑠𝑡𝑖𝑛𝑔 𝑦𝑒𝑎𝑟) ×

𝐺𝐷𝑃 𝑖𝑚𝑝𝑙𝑖𝑐𝑖𝑡 𝑝𝑟𝑖𝑐𝑒 𝑑𝑒𝑓𝑙𝑎𝑡𝑜𝑟 𝑓𝑜𝑟 2020
𝐺𝐷𝑃 𝑖𝑚𝑝𝑙𝑖𝑐𝑖𝑡 𝑝𝑟𝑖𝑐𝑒 𝑑𝑒𝑓𝑙𝑎𝑡𝑜𝑟 𝑓𝑜𝑟 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑦𝑒𝑎𝑟
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US inflation rates more accurately reflect price changes of tradeable resources in comparison to local inflation rates. GDP
implicit price deflators were taken from the International Monetary Fund: World Economic Outlook database.142
A sample calculation follows below:
The cost for treatment of acute sepsis was $934.50 in 2019 Ghanaian Cedi.

𝐶𝑜𝑠𝑡 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑃𝑃𝑃 =

$934.50
= $458.76
2.037

The PPP-adjusted cost in USD for treatment of acute sepsis was then inflated to 2020 prices from the original costing year of 2019.

𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑐𝑜𝑠𝑡 (2020 𝑝𝑟𝑖𝑐𝑒) = $458.76 ×

113.626
= $464.32
112.265

The adjusted cost to account for PPP and inflation was $464.32 USD for treating acute sepsis. Additional assumptions and details for
costs used in the analyses can be found in Table 26 and 27.
Due to scarcity of information, assumptions in cost were necessary for cost of instrumental delivery, hysterectomy, treatment for longterm sepsis, and uterine rupture (details in Table 26). Costs for instrumental delivery, hysterectomy, and uterine rupture were
estimated by calculating the ratio between cost of procedure and cost of caesarean section in the source country. The ratio was then
applied to the cost of caesarean section estimated for the SADC region using Alkire and colleagues’ calculations. A sample calculation
follows below:

𝐶𝑜𝑠𝑡 𝑜𝑓 𝑖𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡𝑎𝑙 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 (𝑆𝐴𝐷𝐶) =

𝐶𝑜𝑠𝑡 𝑜𝑓 𝑖𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡𝑎𝑙 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 𝑖𝑛 𝑁𝑖𝑔𝑒𝑟𝑖𝑎
× 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑐𝑎𝑒𝑠𝑎𝑟𝑒𝑎𝑛 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 (𝑆𝐴𝐷𝐶)
𝐶𝑜𝑠𝑡 𝑜𝑓 𝑐𝑎𝑒𝑠𝑎𝑟𝑒𝑎𝑛 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑁𝑖𝑔𝑒𝑟𝑖𝑎

109

𝐶𝑜𝑠𝑡 𝑜𝑓 𝑖𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡𝑎𝑙 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 (𝑆𝐴𝐷𝐶) =

$28,800
× $303.48 = $177.36
$49,300

Cost of treating long-term sepsis was estimated by calculating a ratio of sepsis treatment costs in year 2 to treatment in year 1 and
applying it similarly to the cost of caesarean section estimated for the SADC region.
Table F.1 Details and Assumptions for Costs
Parameter

Costing Details and Assumptions

Preference Order

Source

SADC Region (1)

Alkire et al. 2015

Standardized profile including costs for caesarean section,
associated devices and medicines, operative facility time,
medical human resources time, post-operative hospital stay for
stabilization, facility maintenance, and equipment.
Caesarean Section
Estimated average cost for 9 SADC countries: Comoros, the
Democratic Republic of Congo, Lesotho, Madagascar, Malawi,
Mauritius, Mozambique, Tanzania, and Zambia.

Instrumental Delivery

Estimated with the proportion of costs of caesarean section
compared to instrumental delivery from Adamu et al. 2013,
applied to the cost of caesarean section in the SADC region.

SADC Region (1),
assumptions (7)

Adamu et al. 2013*

Hemorrhage

Cost of treating postpartum haemorrhage in a public hospital in
Malawi (from two facilities). Costs included drugs and supplies
(unit costs) and variable costs including personnel,
maintenance, and utilities.

Country-specific in the
SADC region (3)

Levin et al. 2003
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Estimated average cost using proportion of costs of caesarean
section compared to hysterectomy in South Africa, applied to
the cost of caesarean section in the SADC region.

Country-specific in the
SADC region (3),
assumptions (7)

Lorenzoni et al.
2015*

Fistula repair

Cost of providing repair surgery for obstetric fistula in Uganda
(the Centre for Fistula Care in Mulago National Referral
Hospital and the Kitovu Regional Referral Hospital). Costs
included costs of procedure, supplies, drugs, infrastructure,
equipment, personnel, and patient accommodation.

Country-specific in
Sub-Saharan Africa (4)

Epiu et al. 2018

Sepsis (acute)

Costs of treating puerperal sepsis in Ghana (Eastern Regional
Hospital and Greater Accra Regional Hospital) Costs included
costs of treatment, diagnostic tests, medical procedures,
supplies, drugs, clinical support, and staff-related costs.

Country-specific in
Sub-Saharan Africa (4)

Fenny et al. 2020

Sepsis (long-term)

Estimated average cost using proportion of costs for sepsis
treatment in year 1 compared to year 2 in Ontario, Canada,
applied to the long-term cost of sepsis. Costs included costs of
treatment, diagnostic tests, laboratory services, professional
fees, medication, and inpatient hospitalizations.

High-income countries
(6), (assumptions (7)

Farrah et al. 2020*

Surgical site infection

Costs of treating surgical site infection following abdominal
surgery in Rwanda (Rwanda Military Hospital). Costs included
costs for treatment, supplies, drugs, tests, hospitalization, and
additional ancillary fees for transportation.

Country-specific in
Sub-Saharan Africa
(4), assumptions (7)

Silverstein et al.
2016, Monahan et
al. 2020

Hysterectomy

Original cost sourced is for private hospital costs of
hysterectomy in South Africa from OECD Health Working
Paper No. 85. Costs included cost of procedure, drugs,
equipment, staff, facility maintenance, and hospital stay.

111

Estimated average cost using proportion of costs of caesarean
section compared to uterine rupture in Saudi Arabia, applied to
the cost of caesarean section in the SADC region.
Uterine rupture

Current healthcare
expenditure per capita
(SADC) for mothers

Original cost sourced is for uterine rupture treatment at King
Saud Medical City in Saudi Arabia. Costs included cost of
surgical intervention, consultations, drugs, laboratory work,
equipment, and hospitalization.
The minimum recommended per capita spending on health for
LMICs to provide essential health services. Investment would
go towards strengthening health systems and universal
coverage of interventions that reduce maternal mortality,
diagnosis, prevention and treatment of infectious diseases,
primary care, and health promotion.

Costs for in-patient neonatal services (neonatal intensive care
unit) for perinatal asphyxia in a regional hospital and largest
district hospital in the Greater Accra Region of Ghana. Costs
Neonatal Intensive Care included costs for diagnostics, treatment and therapeutics,
medicines, clinical supplies, laboratory services, and
hospitalization.

Current healthcare
expenditure per capita
(SADC) for neonates

The minimum recommended per capita spending on health for
LMICs to provide essential health services. Investment would
go towards strengthening health systems and universal
coverage of interventions that reduce maternal mortality,
diagnosis, prevention and treatment of infectious diseases,
primary care, and health promotion.

High-income countries
(6), (assumptions (7)

Alsuwaidan et al.
2020*

Sub-Saharan Africa (2)

Taskforce on
Innovative
International
Financing for
Health Systems

Country-specific in
Sub-Saharan Africa (4)

Enweronu-Laryea et
al. 2018

Sub-Saharan Africa (2)

Taskforce on
Innovative
International
Financing for
Health Systems
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Appendix C.2 Cost Conversions and Inflation
Parameter

Cost

Currency

Costing
Year

PPP
Exchange
Rate

Cost ($I)

GDP Implicit
Price Inflator
(Original)

GDP Implicit
Price Inflator
(Adjusted)

Adjusted
Cost (2020)

Source

Caesarean Section

$256.70

USD

2010

1

$256.70

96.111

113.626

$303.48

Alkire et al. 2015

Instrumental
Deliverya

$28,800

Nigerian
Naira

2011

--

--

--

--

$177.36

Adamu et al. 2013

Hemorrhage

$1,107

1998

35.2

$81.51

75.283

113.626

$123.02

Levin et al. 2003

Hysterectomyb

$34,432

2013

5.296

$6,501.51

101.755

113.626

$584.48

Lorenzoni et al. 2015

Fistula
repair

$378

2016

1

$378.04

105.722

113.626

$406.30

Epiu et al. 2018

Sepsis (acute)

$934.50

2019

2.037

$458.76

112.265

113.626

$464.32

Fenny et al. 2020

Sepsis (long-term)c

--

Ghanaian
Cedi
--

--

--

--

--

--

$239.11

Farrah et al. 2020

Surgical site
infection

$483

USD

2017

1

$483

107.71

113.626

$509.53

Silverstein et al. 2016,
Monahan et al. 2020

Uterine ruptured

$10,086.00

Saudi
Riyal

2020

--

--

--

--

$510.14

Alsuwaidan et al. 2020

Current healthcare
expenditure per
capita (SADC)

$44

USD

2008

1

$44

94.285

113.626

$53.03

Taskforce on Innovative
International Financing
for Health Systems

Malawian
Kwacha
South
African
Rand
USD

Neonatal Intensive
Ghanaian
$522.59
2016
1.544
$338.46
105.722
113.626
Care
Cedi
Current healthcare
expenditure per
$44
USD
2008
1
$44
94.285
113.626
capita (SADC)
a = Estimated, cost of caesarean section was $28,800 Nigerian Naira in Nigeria (Adamu and colleagues)
b = Estimated, cost of caesarean section was estimated to be $3,200 USD in South Africa
c = Estimated, cost of sepsis in year 1 and 2 were $65,682 and $33,824 CAD respectively (Farrah and colleagues)
d = Estimated, cost of caesarean section was estimated to be $6,000 Saudi Riyal

$363.77
$53.03

Enweronu-Laryea et al.
2018
Taskforce on Innovative
International Financing
for Health Systems
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Appendix G Probabilities
G.1 Treatment Proportions for Existing Care and Increased Access to Caesarean Section
In the existing coverage arm, the proportion of women in neglected obstructed labour is derived from Demographic Health Surveys
data for health facility deliveries in SSA and WHO estimates.12,25 The estimated incidence of obstructed labour is 6.0 per 100 live
births. The proportion of deliveries in health facilities (33 per 100 live births) was used as a proxy measure for the incidence of
neglected obstructed labour, which was estimated to be 4.0 per 100 live births (or two-thirds of women in obstructed labour).12 The
proportion of women receiving caesarean section or instrumental delivery is based on a WHO estimate of 90% undergoing caesarean
section and 10% undergoing instrumental delivery if receiving treatment for obstructed labour.12 The ‘existing care’ strategy is
therefore defined as 66.67% of women remaining in prolonged obstructed labour, 30% accessing caesarean section, and 3.33%
receiving instrumental delivery.
The target coverage level was based on the 68th WHA resolutions and Lancet Commission on Global Surgery 2030 goals to provide a
minimum of 80% coverage of essential surgical and anesthesia services per country by 2030.2,6 The ‘increased access to caesarean
section’ strategy is defined as 80% of women receiving caesarean section, a proportional two-thirds of the remainder unable to access
care and experiencing neglected obstructed labour based on previous facility access estimates (13.3%), and 6.7% undergoing
instrumental delivery.2,6,25
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G2 Details and Assumptions for Probabilities
Appendix G2.1 Details and Assumptions for Short-Term Probabilities

Caesarean
Section and
Instrumental
Delivery

Parameter

Details and Assumptions

Preference Order

Sourcea

Sepsis

Retrospective observational study examining patients with puerperal sepsis admitted to
Ife State Hospital (ISH) in Nigeria between January 1986 to December 1995. Countryspecific estimates from Nigeria were assumed to be applicable to the SADC region and
representative of caesarean section and instrumental delivery.

Country-specific in
Sub-Saharan Africa
(4)

Dare et al.
1998

Hemorrhage

Prospective population-based observational study examining maternal, fetal, and
neonatal outcomes following prolonged labour, obstructed labour, and failure to progress
in LMICs. Data was collected from Argentina, Guatemala, India, Kenya, Pakistan, and
Zambia between January 1, 2010 to December 31, 2013. Data was taken from the Eunice
Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
using the Maternal and Newborn Health Registry (MNHR). Estimates specific to Africa
stratified by delivery mode were unavailable so we elected to use LMIC-specific
estimates that differed by instrumental and caesarean section.

Low-and middleincome countries
(5)

Harrison et al.
2015

Hysterectomy

Cross-sectional survey nested in a randomized cluster trial (QUARITE) examining
maternal and perinatal outcomes by delivery mode in Senegal and Mali between January
10, 2007 and January 10, 2008. Estimates stratified by delivery mode were available and
assumed to be representative of the SADC region.

Country-specific in
Sub-Saharan Africa
(4)

Briand et al.
2012

Maternal
Death

See above assumptions for “hemorrhage”

Low-and middleincome countries
(5)

Harrison et al.
2015

Surgical site
infection

Retrospective observational study examining post-operative surgical site infection after
caesarean section in three LMIC countries. Analyses used data from four emergency
obstetric programs supported by Médecins Sans Frontières (Burundi, Democratic
Republic of Congo, and Sierra Leone) between August 1, 2010 to January 31, 2011.

Country-specific in
the SADC region
(3) and SubSaharan Africa (4)

Chu et al.
2015

Uterine
rupture

Retrospective population-basd cohort study of all women in Canada (excluding Quebec
and Manitoba) giving birth between April 1991 through March 2005, stratified by
delivery mode.

High-income
country (6)

Liu et al. 2007

Caesarean
Section
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Surgical site
infection
Instrumental
Delivery

Prolonged
Obstructed
Labour

Retrospective secondary analysis of data from the Caesarean Registry from the NICHD
on maternal and neonatal outcomes stratified by delivery mode between 2008 and 2011.
Endometritis after operative vaginal delivery was assumed to be representative of
postpartum infection (or surgical site infection). Data following caesarean section were
comparable to estimates sourced from SSA (see Chu and colleagues above).

High-income
country (6)

Son et al. 2017

Uterine
rupture

Cross-sectional study examining maternal and fetal outcomes of uterine rupture
conducted in Northwest Ethiopia in December 2015. Data was assumed to be
representative of instrumental delivery although a proportion were assisted by caesarean
sections (17.4%).

Country-specific in
Sub-Saharan Africa
(4)

Astatikie et al.
2017

Sepsis

Cross-sectional clinician survey and epidemiological modelling study of burden of
disease related to prolonged obstructed labour comorbidities in Asia and Africa in
November and December 2018. 83.1% of clinician respondents worked primarily in subSaharan Africa

Sub-Saharan Africa
(2), includes some
Asian countries (5)

Roa et al.
2020

Hemorrhage

Mathematical model (MANDATE) evaluating interventions to reduce maternal mortality
from prolonged labour, obstructed labour, and prolonged obstructed labour in SubSaharan Africa. Estimate for hemorrhage incorporated published literature and expert
opinion.

Sub-Saharan Africa
(2)

Harrison et al.
2016

Surgical site
infection

See above assumptions for “sepsis”

Sub-Saharan Africa
(2), includes some
Asian countries (5)

Roa et al.
2020

Uterine
rupture

Systematic review and meta-analysis examining incidence, causes, and maternofetal
outcomes of obstructed labour in Ethiopia. Pooled estimate from 16 primary studies with
28,591 mothers giving birth. Estimates from Ethiopia were assumed to be applicable to
the SADC region due to lack of data.

Country-specific in
Sub-Saharan Africa
(4)

Ayenew et al.
2021

Uterine
prolapse

See above assumptions for “sepsis”

Sub-Saharan Africa
(2), includes some
Asian countries (5)

Roa et al.
2020

Obstetric
fistula

WHO descriptive study on burden of disease related to obstructed labour and sequelae,
stratified by WHO region. The incidence rate of obstetric fistula is expressed as the
proportion of the neglected obstructed labour cases for SSA

Sub-Saharan Africa
(2)

Dolea et al.
2000

Maternal
Death

Retrospective observational study of all deliveries occurring at a district hospital to
assess incidence and outcomes of obstructed labour in Ethiopia from September 1990 to
May 1999. Estimates from Ethiopia were assumed to be applicable to the SADC region
due to lack of data.

Country-specific in
Sub-Saharan Africa
(4)

Gaym et al.
2002
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Appendix G2.2 Details and Assumptions for Long-Term Probabilities
Parameter

Details and Assumptions

Preference Order

Source

Rectovaginal
fistula

Retrospective review of patients (716) treated for vesicovaginal and rectovaginal fistulae in Africa
(578) at Addis Ababa Fistula Hospital and Britain (138 patients). It was assumed that patients did
not experience direct mortality due to obstetric fistula and that estimates from Ethiopia were
representative of the SADC region due to lack of data.

Country-specific
in Sub-Saharan
Africa (4)

Kelly et al.
1998

Vesicovaginal
fistula

See above assumptions for “rectovaginal fistula”

Country-specific
in Sub-Saharan
Africa (4)

Kelly et al.
1998

Repair

Retrospective secondary analysis using 16 national Demographic and Health Surveys in SSA
between 2010 and 2017 to describe health-seeking behaviour of women with obstetric fistula in
SSA. Estimates from Zambia were assumed to be applicable to the SADC region due to lack of
data.

Sub-Saharan
Africa (2)

Gebremedhin
et al. 2019

Surgical success

Retrospective review of patients receiving treatment for obstetric fistula at the Monze Mission
Hospital in Zambia between August 2003 and December 2005.

Surgical failure

See above assumptions for “surgical success”

Stress
Incontinence

See above assumptions for “surgical success”

Country-specific
in the SADC
region (3)
Country-specific
in the SADC
region (3)
Country-specific
in the SADC
region (3)

Holme et al.
2007
Holme et al.
2007
Holme et al.
2007
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Appendix G2.3 Probabilities of Neonatal Events Following Obstructed Labour

Caesarean
Section and
Instrumental
Delivery

Parameter

Details and Assumptions

Preference
Order

Source

Stillbirths

Prospective population-based observational study examining maternal, fetal, and
neonatal outcomes following prolonged labour, obstructed labour, and failure to
progress in LMICs. Data was collected from Argentina, Guatemala, India, Kenya,
Pakistan, and Zambia between January 1, 2010 to December 31, 2013. Data was taken
from the Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) using the Maternal and Newborn Health Registry (MNHR).
Estimates specific to Africa stratified by delivery mode were unavailable so we
elected to use LMIC-specific estimates that differed by instrumental and caesarean
section.

Low-and
middleincome
countries (5)

Harrison et al.
2015

Neonatal
mortality in
NICU

Retrospective descriptive review of neonatal admissions and outcomes at Empangeni
Hospital in South Africa between January and December 2005. Estimates for
mortality were stratified by mode of delivery and assumed to be applicable to the
SADC region due to lack of data.

Countryspecific in the
SADC region
(3)

Hoque et al.
2011

A descriptive review of neonatal intensive care unit admissions stratified by cause for
admission over a six-month period at the Volta Regional Hospital in Ethiopia from
September 2016 to March 2017. Estimates from Ghana were assumed to be applicable
to the SADC region due to lack of data.
Systematic review and meta-analysis examining incidence, causes, and maternofetal
outcomes of obstructed labour in Ethiopia. Pooled estimate from 16 primary studies
with 28,591 mothers giving birth. Estimates from Ethiopia were assumed to be
applicable to the SADC region due to lack of data.

Countryspecific in
Sub-Saharan
Africa (4)
Countryspecific in
Sub-Saharan
Africa (4)
Sub-Saharan
Africa (2),
includes some
Asian
countries (5)

NICU Admission

Stillbirths

Prolonged
Obstructed
Labour

Intrapartum
hypoxia

Cross-sectional clinician survey and epidemiological modelling study of burden of
disease related to prolonged obstructed labour comorbidities in Asia and Africa in
November and December 2018. 83.1% of clinician respondents worked primarily in
sub-Saharan Africa

Hypoxicischemic
encephalopathy
(HIE)

Systematic review and meta-analysis examining infants with intrapartum hypoxiaischemia and related outcomes in the USA. Pooled estimates were assumed to be
applicable to the SADC region due to lack of data.

High-income
country (6)

Amegan-Aho
et al. 2018

Ayenew et al.
2021

Roa et al,
2020

Graham et al.
2008

118

Appendix G2.4 Probabilities of Maternal Mortality Following Obstructed Labour
Parameter

Sepsis

Hospital
(Caesarean
Section and
Instrumental
Delivery)

Preference Order

Source

Sub-Saharan Africa (2),
country-specific in SubSaharan Africa (4)

Prual et al.
2000

Hemorrhage

See above assumptions for “sepsis”

Sub-Saharan Africa (2),
country-specific in SubSaharan Africa (4)

Prual et al.
2000

Surgical site
infection

Retrospective observational study examining post-operative surgical site infection after
caesarean section in three LMIC countries. Analyses used data from four emergency
obstetric programs supported by Médecins Sans Frontières (Burundi, Democratic
Republic of Congo, and Sierra Leone) between August 1, 2010 to January 31, 2011.

Country-specific in the
SADC region (3) and SubSaharan Africa (4)

Chu et al.
2015

Uterine
rupture

See above assumptions for “sepsis”

Sub-Saharan Africa (2),
country-specific in SubSaharan Africa (4)

Prual et al.
2000

Sub-Saharan Africa (2)

Huque et
al. 2018

Sub-Saharan Africa (2),
assumptions (7)

Prual et al.
2000,
Harrison et
al. 2016

Surgical site
infection

Retrospective secondary analysis using data from the WOMAN trial carried out in 21
countries. Death rate among hysterectomy cases was calculated specific to Africa and
assumed to be representative of the SADC region overall.
Mathematical model (MANDATE) evaluating interventions to reduce maternal mortality
from prolonged labour, obstructed labour, and prolonged obstructed labour in SubSaharan Africa. The mortality from uterine rupture estimated for caesarean and
instrumental delivery (in-hospital) was calculated against that of prolonged obstructed
labour (no hospital) as a proportion and applied to the in-hospital estimate of mortality
from sepsis. This was assumed to be applicable to the SADC region due to lack of data.
See above for information on the MANDATE model. Estimate was for postpartum
hemorrhage and incorporated published literature and expert opinion.
See above for information on the MANDATE model. Estimate incorporated published
literature and expert opinion.

Uterine
rupture

See above for information on the MANDATE model. Estimate incorporated published
literature and expert opinion.

Hysterectomy

Sepsis
No Hospital
(Prolonged
Obstructed
Labour)

Details and Assumptions
Multicentre, prospective population-based study to measure incidence of maternal
morbidity in West Africa (December 1994 to June 1996) mainly in Burkina Faso, Côte
d’Ivoire, Mali, Mauritania, Niger, and Senegal. Case fatality rates stratified by delivery
mode were unavailable, so it was assumed that case fatality after a woman develops the
condition (e.g. sepsis) is the same across caesarean section and instrumental delivery
since they are able to reach a hospital. It was assumed that these estimates were
applicable to the SADC region due to lack of data.

Hemorrhage

Sub-Saharan Africa (2)
Sub-Saharan Africa (2)
Sub-Saharan Africa (2)

Harrison et
al. 2016
Harrison et
al. 2016
Harrison et
al. 2016
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Appendix H Disability Weight Modifications
Methodology for Calculating Disability Weight for Acute Sepsis
To estimate utility when information was unavailable, the following methodology was used:
i)

Calculate proportions between the disability weights of various health states

𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =

𝐷𝑊 𝑜𝑓 ℎ𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒 (𝑆𝑆𝐴)
𝐷𝑊 𝑜𝑓 ℎ𝑒𝑚𝑜𝑟𝑟ℎ𝑎𝑔𝑒 (𝐾𝑜𝑟𝑒𝑎)

𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =

0.324
= 0.6304
0.514

ii)

Repeat for obstructed labour and genital prolapse and average the proportions.

iii)

Apply the proportion to the disability weight of maternal sepsis from the KBD 2015112
𝐷𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑠𝑒𝑝𝑠𝑖𝑠 = 𝐷𝑊 𝑜𝑓 𝑠𝑒𝑝𝑠𝑖𝑠 (𝐾𝑜𝑟𝑒𝑎) × 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 (𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝐺𝐵𝐷 2019 𝑎𝑛𝑑 𝐾𝐵𝐷 2015)
𝐷𝑖𝑠𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑠𝑒𝑝𝑠𝑖𝑠 = 0.749 × 0.666 = 0.499
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Table H.1 Details and Assumptions for Disability Weights

Short-Term
In-Hospital
and InCommunity
Maternal
Outcomes

Health Condition or
State

Details and Assumptions

Preference
Order

Reference

Caesarean Section

Disability weight for undergoing caesarean section.

Sub-Saharan
Africa (2)

GBD 1990

Instrumental Delivery

Disability weight estimated for instrumental delivery through expert opinion, using
disability weights for caesarean section, uterine prolapse, hysterectomy, and uterine
rupture as benchmarks for severity of condition.

Assumptions (7)

Estimate

Obstructed Labour

Disability weight for experiencing obstructed labour (acute event).

Sub-Saharan
Africa (2)

GBD 2019

Sepsis (acute)

Disability weight for experiencing acute sepsis, estimated using proportion of GBD
2019 to KBD 2015 disability weights and applied to the KBD 2015 disability weight
of experiencing sepsis (see above for sample calculation).

High-income
country (6),
assumption (7)

KBD 2015,
Estimate

Hemorrhage

Disability weight for experiencing maternal hemorrhage (> 1L blood lost).

Sub-Saharan
Africa (2)

GBD 2019

Surgical site infection

Disability weight for experiencing infectious disease (acute episode, moderate).

Sub-Saharan
Africa (2)

GBD 2019

Uterine prolapse

Disability weight for experiencing uterine prolapse, assumed to be applicable based
on comparison of other health state disability weights as benchmark comparisons to
the GBD 2019 values.

High-income
country (6)

KBD 2015

High-income
country (6)

Gilbert et al.
2013, Chung et
al. 2001

Sub-Saharan
Africa (2),
assumptions (7)

GBD 2019

Uterine rupture

Hysterectomy

Disability weight for uterine rupture taken from an economic evaluation of trial of
labour after caesarean section in the United States. The original study used disutility,
which was assumed to be efficient to estimate disability weight in our analyses.
Original disutility was calculated using the Quality of Well-Being classification
system.
Disability weight for undergoing hysterectomy following uterine rupture. Value was
estimated by associating the relevant health state lay description “severe pain in
belly, unable to carry out daily activities” from the GBD 2019 study.
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Long-Term
Maternal
Outcomes

Long-Term
Neonatal
Outcomes

Stress incontinence

Disability weight of experiencing stress incontinence (long-term)

Sub-Saharan
Africa (2)

GBD 1990

Rectovaginal fistula

Disability weight for living with rectovaginal fistula. If women experienced both
rectovaginal fistula and vesicovaginal fistula, the more severe disability weight
associated with rectovaginal fistula was applied.

Sub-Saharan
Africa (2)

GBD 2019

Vesicovaginal fistula

Disability weight for living with vesicovaginal fistula.

Sub-Saharan
Africa (2)

GBD 2019

Sepsis (long-term)

Disability weight for experiencing puerperal sepsis. It was assumed that this lower
estimate was applicable to long-term sepsis through expert opinion. See above for
acute sepsis estimates.

Sub-Saharan
Africa (2)

GBD 2019

Hypoxic-ischemic
encephalopathy
(neonatal)

Applied proportionally to the those who experience birth asphyxiation

Sub-Saharan
Africa (2)

GBD 2019

Assumptions (7)

Estimate

Disability weight of returning to full health was assumed to be 0.01 due to lack of
estimates of baseline disability weights for women living in the SADC region. It is
Full Health
likely that the baseline disability is higher but lack of accurate information exists in
current literature.
Abbreviations: GBD, Global Burden of Disease Study; KBD, Korean Burden of Disease Study.
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Appendix I Probabilistic Sensitivity Analysis for the Maternal Model
I.1 Methodology for Probabilistic Sensitivity Analyses
For the probabilistic sensitivity analysis (PSA), distributions were used in calculations depending on the type of parameter. Beta
distributions were used for parameter values bound between 0 and 1, such as utilities and probabilities.143 Dirichlet distributions were
used in the case of health states leading to multiple outcomes such as short-term outcomes following neglected obstructed labour (i.e.
sepsis, hemorrhage, surgical site infection, uterine rupture, uterine prolapse, survival, or death) or outcomes following repair surgery
for obstetric fistula (i.e. surgery success, failure, or remaining in stress incontinence). Uncertainty surrounding costs was accounted for
using gamma distributions, bound between 0 and infinity and ideal for skewed data.143 Results were calculated across 10,000 iterations
to examine stability of the base case results.
Distributions for probabilities were calculated by inputting sample size integer parameters from sourced literature on TreeAge
Healthcare Pro 2021 where possible (e.g. total number of women receiving caesarean section and those that developed hemorrhage
from that cohort). If sample size and number of events was unavailable, a lower and upper limit of ±10% was applied to calculate
alpha and beta values. See Appendix G2 for information regarding literature sources and assumptions.
Distributions for utility used upper and lower limits (95% confidence intervals) from their original source (i.e. Global Burden of
Disease 2019 study, Korean Burden of Disease 2015 study, Chung and colleagues, or Gilbert and colleagues).7,112-14 If published 95%
confidence intervals were not available, a lower and upper limit of ±10% was applied to calculate alpha and beta values.
Distributions for costs applied the assumption of a lower and upper limit of ±10% to calculate alpha, beta, and lambda values.
All alpha and beta values used in the PSA are presented in tables below.
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I.2 Tables for Values Used in Probabilistic Sensitivity Analysis
I.2.1 Probabilities for Maternal Events Following Obstructed Labour

Caesarean
Section

Instrumental
Delivery

Prolonged
Obstructed
Labour

Beta
Beta
Beta
Beta
Beta

Number
of Events
146
161
93
7
71

Total
Sample Size
8428
15459
1276
46766
11255

0.00227
0.0173

Beta
Beta

35
146

Hemorrhage
Surgical site infection

0.0777
0.0254

Beta
Beta

Uterine rupture

0.0245

Hysterectomy
Maternal Death
Sepsis
Hemorrhage
Surgical site infection
Uterine rupture
Uterine prolapse

Alpha

Beta

Sourcea

------

------

Dare et al. 1998
Harrison et al. 2015
Chu et al. 2015
Liu et al. 2007
Briand et al. 2012

15414
8428

---

---

Harrison et al. 2015
Dare et al. 1998

150
24

1931
945

---

---

Harrison et al. 2015
Son et al. 2017

Beta

254

10379

--

--

Astatikie et al. 2017

0.00
0.00209
0.194
0.130
0.114
0.300
0.158

Beta
Beta
Dirichlet
Dirichlet
Dirichlet
Dirichlet
Dirichlet

0
4
------

0
1916
------

--73
334
59
30
68

--304
2236
454
69
366

Briand et al. 2012
Harrison et al. 2015
Roa et al. 2020
Harrison et al. 2016
Roa et al. 2020
Ayenew et al. 2021
Roa et al. 2020

Obstetric fistula
Maternal Death
Rectovaginal fistula
Vesicovaginal fistula

0.0215
0.0910
0.212
0.788

Beta
Dirichlet
Beta
Beta

-86
152
564

-945
716
716

376
----

17107
----

Repair

0.250

Beta

329

1317

--

--

Surgical success
Surgical failure

0.726
0.0992

Dirichlet
Dirichlet

183
25

252
252

---

---

Dolea et al. 2000
Gaym et al. 2002
Kelly et al. 1998
Kelly et al. 1998
Gebremedhin et al.
2019
Holme et al. 2007
Holme et al. 2007

Stress incontinence

0.175

Dirichlet

44

252

--

--

Holme et al. 2007

Parameter

Mean

Distribution

Sepsis
Hemorrhage
Surgical site infection
Uterine rupture
Hysterectomy

0.0173
0.0104
0.0729
0.000150
0.00631

Maternal Death
Sepsis

Italicized parameters used the assumption of +/- 10% of the mean as upper and lower confidence limits
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I.2.2 Probabilities of Neonatal Events Following Obstructed Labour

Caesarean
Section

Instrumental
Delivery

Prolonged
Obstructed
Labour

Parameter

Mean

Distribution

Number
of Events

Total Sample
Size

Alpha

Beta

Source

Stillbirths

0.0163

Beta

252

15488

--

--

Harrison et al. 2015

Neonatal mortality in NICU

0.202

Beta

317

1573

--

--

Hoque et al. 2011

NICU Admission

0.151

Beta

136

900

--

--

Amegan-Aho et al. 2018

Stillbirths

0.0694

Beta

134

1931

--

--

Harrison et al. 2015

Neonatal mortality in NICU

0.202

Beta

317

1573

--

--

Hoque et al. 2011

NICU Admission

0.151

Beta

136

900

--

--

Amegan-Aho et al. 2018

Stillbirths

0.386

Beta

--

--

20

32

Ayenew et al. 2021

Intrapartum hypoxia

0.256

Beta

--

--

77

222

Roa et al. 2020

Hypoxic-ischemic
encephalopathy (HIE)

0.303

Beta

33

109

--

--

Graham et al. 2008

Italicized parameters used the assumption of +/- 10% of the mean as upper and lower confidence limits

I.2.3 Mortality Following Sequelae due to Obstructed Labour and Distributions for PSA

Hospital
(Caesarean
Section and
Instrumental
Delivery)
No Hospital
(Prolonged
Obstructed
Labour)

Parameter

Mean

Distribution

Number of
Events

Total
Sample Size

Alpha

Beta

Source

Sepsis

0.333

Beta

6

18

--

--

Prual et al. 2000

Hemorrhage

0.0322

Beta

11

342

--

--

Prual et al. 2000

Surgical site infection

0.0551

Beta

22

399

--

--

Chu et al. 2015

Uterine rupture

0.304

Beta

7

23

--

--

Prual et al. 2000

Hysterectomy
Sepsis
Hemorrhage
Surgical site infection
Uterine rupture

0.200
0.493
0.250
0.0500
0.450

Beta
Beta
Beta
Beta
Beta

204
-----

1020
-----

-194
288
365
211

-200
864
6933
258

Huque et al. 2018
Prual et al. 2000
Harrison et al. 2016
Harrison et al. 2016
Harrison et al. 2016

Italicized parameters used the assumption of +/- 10% of the mean as upper and lower confidence limits
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I.2.4 Disability Weights for Maternal Model and Distributions for PSA

Short-Term InHospital and InCommunity
Maternal
Outcomes

Long-Term
Maternal
Outcomes

Long-Term
Neonatal
Outcomes

Parameter

Disability Weight

Distribution

Alpha

Beta

Source

Caesarean Section

0.349

Beta

250

466

GBD 1990

Instrumental Delivery*

0.375

Beta

240

400

Estimate

Obstructed Labour

0.324

Beta

22

45

GBD 2019

Sepsis (acute)*

0.499

Beta

192

193

KBD 2015, Estimate

Hemorrhage

0.324

Beta

22

45

GBD 2019

Surgical site infection

0.051

Beta

21

399

GBD 2019

Uterine prolapse

0.404

Beta

84

124

KBD 2015

Uterine rupture

0.490

Beta

11

12

Gilbert et al. 2013, Chung et al.
2001

Hysterectomy*

0.324

Beta

22

45

GBD 2019

Stress incontinence

0.0250

Beta

375

14607

GBD 1990

Rectovaginal fistula

0.501

Beta

19

18

GBD 2019

Vesicovaginal fistula

0.342

Beta

18

35

GBD 2019

Sepsis (long-term)

0.133

Beta

23

147

GBD 2019

Full Health

0.0100

Beta

38032

3765151

Estimate

Hypoxic-Ischemic
Encephalopathy

0.351

Beta

25

56

GBD 2019

3765151

Estimate

Full Health
0.0100
Beta
38032
* = Estimated disability weights (see Appendix F for calculation methods and assumptions)
Italicized parameters use the assumption of +/- 10% of the mean as upper and lower confidence limits
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I.2.5 Costs Related to Interventions and Sequelae for Obstructed Labour
Parameter

Mean

Distribution

Alpha

Beta

Caesarean Section

$303.48

Gamma

384

0.79

Alkire et al. 2015

Instrumental Delivery

$177.36

Gamma

384

0.46

Adamu et al. 2013

Hemorrhage

$123.02

Gamma

384

0.32

Levin et al. 2003

Hysterectomy

$584.48

Gamma

384

1.52

Lorenzoni et al. 2015

Fistula repair

$406.30

Gamma

384

1.06

Epiu et al. 2018

Sepsis (acute)

$464.32

Gamma

384

1.21

Fenny et al. 2020

Sepsis (long-term)

$239.11

Gamma

384

0.62

Farrah et al. 2020

Surgical site infection

$509.53

Gamma

384

1.33

Silverstein et al. 2016, Monahan et al.
2020

Uterine rupture

$510.14

Gamma

384

1.33

Alsuwaidan et al. 2020

Current healthcare expenditure per capita (SADC)

$53.03

Gamma

384

0.14

Taskforce on Innovative International
Financing for Health Systems

Neonatal Intensive Care

$363.77

Gamma

384

0.95

Enweronu-Laryea et al. 2018

Current healthcare expenditure per capita (SADC)

$53.03

Gamma

384

0.14

Taskforce on Innovative International
Financing for Health Systems

All cost parameters used the assumption of +/- 10% of the mean as upper and lower confidence limits

Source
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I.3 Acceptability values at willingness-to-pay from the PSA
I.3.1 Maternal Model Acceptability at WTP
Willingness-to-pay ($)

Acceptability

0
0
28.7
0
57.4
0.6938
86.1
0.8809
114.8
0.946
143.5
0.999
172.2
1
Acceptability is defined as the probability of the ‘increased
access to caesarean section’ strategy being cost-effective

I.3.2 Neonatal Model Acceptability at WTP
Willingness-to-pay ($)

Acceptability

16.25
0
19.5
0.0001
22.75
0.1095
26
0.9316
29.25
0.9997
32.5
1
Acceptability is defined as the probability of the ‘increased
access to caesarean section’ strategy being cost-effective
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Appendix J One-Way Sensitivity Analyses
J.1 Methodology for One-Way Sensitivity Analyses
One-way sensitivity analyses were calculated across model parameters to assess how changes in a parameter affect the cost-utility
estimates. Results were presented in tornado diagrams that show the impact (increase or decrease) as well as the range in ICER
values.143 The range in parameters were taken from published 95% confidence intervals from the source literature. When published
values were not available, a lower and upper limit of ±10% was applied. Supplementary tornado diagrams and outputs for the
maternal model (all parameters, costs, disability weights, and mortality) and outputs for the neonatal model (all parameters) are
presented below.
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J.2 Tornado Diagrams and Outputs for Maternal Outcomes
J.2.1 Tornado Diagram (All Variables)
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J.2.2 Tornado Diagram Outputs (All Variables)
c_health_woman

Variable
Low
47.73

Variable
Base
53.03

Variable
High
58.33

32.07843

Risk
%
0.494

Cumulative
Risk %
0.494

c_csection

273.13

303.48

4.49058

20.16528

0.31

0.804

p_infectionCS

0.01724

55.78007

3.27189

10.70525

0.165

0.969

d_hemorrhageOL

54.00231

55.04327

1.04096

1.0836

0.017

0.986

Decrease

54.22099

54.78844

0.56745

0.322

0.005

0.991

560.48

Increase

54.27443

54.76784

0.49341

0.24346

0.004

0.994

0.01732

0.01906

Increase

54.35708

54.64274

0.28566

0.0816

0.001

0.996

0.3141

0.349

0.3839

Increase

54.38241

54.66058

0.27817

0.07738

0.001

0.997

d_sepsisOL

0.44357

0.49286

0.54214

Decrease

54.4314

54.60977

0.17838

0.03182

0

0.997

p_fistula

0.01935

0.0215

0.02365

Decrease

54.34717

54.52114

0.17397

0.03026

0

0.998

u_hemorrhage

0.22

0.324

0.442

Decrease

54.43158

54.60031

0.16874

0.02847

0

0.998

c_ID

159.62

177.36

195.09

Increase

54.4424

54.59983

0.15744

0.02479

0

0.998

c_sepsis

417.89

464.32

510.76

Increase

54.44897

54.59332

0.14434

0.02084

0

0.999

d_UR_OL

0.405

0.45

0.495

Decrease

54.45263

54.5878

0.13517

0.01827

0

0.999

u_vfistula

0.227

0.342

0.478

Decrease

54.4559

54.57643

0.12053

0.01453

0

0.999

p_hemorrhageID

0.06991

0.07768

0.08545

Decrease

54.43239

54.52114

0.08875

0.00788

0

0.999

c_sepsis_longterm

215.2

239.11

263.02

Decrease

54.48015

54.56212

0.08197

0.00672

0

1

p_sepsisID

0.01559

0.01732

0.01906

Decrease

54.44568

54.52427

0.07859

0.00618

0

1

d_sepsis

0.3

0.33333

0.36667

Increase

54.49282

54.56899

0.07617

0.0058

0

1

p_infectionID

0.02286

0.0254

0.02794

Increase

54.45911

54.52114

0.06202

0.00385

0

1

u_rfistula

0.339

0.501

0.657

Decrease

54.49105

54.55242

0.06137

0.00377

0

1

d_infection

0.04962

0.05

0.06065

Increase

54.52114

54.57456

0.05342

0.00285

0

1

p_UR_ID

0.02203

0.02447

0.02692

Increase

54.48712

54.52831

0.04118

0.0017

0

1

p_hemorrhageCS

0.00937

0.01041

0.01146

Decrease

54.48095

54.52114

0.04019

0.00162

0

1

d_infectionOL

0.045

0.05514

0.055

Decrease

54.52114

54.55231

0.03117

0.00097

0

1

c_hemorrhage

110.72

123.02

135.33

Increase

54.50698

54.5353

0.02832

0.0008

0

1

Variable Name

Impact

Low

High

Spread

Spread2

Increase

51.68925

57.35303

5.66378

333.82

Increase

52.27548

56.76605

0.07288

0.10423

Increase

52.50818

0.225

0.25

0.275

Decrease

u_OL

0.22

0.324

0.442

c_SSI

458.58

509.53

p_sepsisCS

0.01559

u_csection
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u_uterineprolapse

0.338

0.404

0.471

Decrease

54.50782

54.53426

0.02644

0.0007

0

1

p_vfistula

0.70894

0.7877

0.86648

Increase

54.50981

54.53364

0.02383

0.00057

0

1

c_UR

459.13

510.14

561.15

Increase

54.5097

54.53257

0.02287

0.00052

0

1

u_uterinerupture

0.29

0.49

0.69

Decrease

54.51152

54.53075

0.01923

0.00037

0

1

d_UR

0.27391

0.30435

0.33478

Increase

54.51915

54.53792

0.01877

0.00035

0

1

c_repairfistula

365.67

406.3

446.93

Decrease

54.51203

54.53024

0.01822

0.00033

0

1

u_ID

0.3375

0.375

0.4125

Increase

54.51231

54.52997

0.01766

0.00031

0

1

u_sepsis

0.088

0.133

0.19

Decrease

54.51581

54.52534

0.00953

0.00009

0

1

d_csection

0.00204

0.00227

0.0025

Increase

54.51274

54.52114

0.0084

0.00007

0

1

u_sepsis_acute

0.44883

0.4987

0.54857

Decrease

54.51793

54.52435

0.00642

0.00004

0

1

u_nodisability

0.0099

0.01

0.0101

Increase

54.51815

54.52413

0.00598

0.00004

0

1

p_repair

0.22483

0.24981

0.27479

Increase

54.51632

54.52114

0.00482

0.00002

0

1

p_surgsuccess

0.65357

0.72619

0.79881

Increase

54.52114

54.52531

0.00417

0.00002

0

1

u_infection

0.032

0.051

0.074

Increase

54.51993

54.5226

0.00267

0.00001

0

1

d_hemorrhage

0.02895

0.03216

0.03538

Decrease

54.52114

54.52204

0.0009

0

0

1

u_incontinence

0.0225

0.025

0.0275

Decrease

54.52111

54.52117

0.00006

0

0

1

p_UR_CS

0.00013

0.00015

0.00016

Increase

54.52114

54.52114

0

0

0

1

p_hysterectomyCS

0.00568

0.00631

0.00694

Increase

54.52114

54.52114

0

0

0

1

p_sepsisOL

0.17442

0.1938

0.21318

Increase

54.52114

54.52114

0

0

0

1

p_hemorrhageOL

0.117

0.13

0.143

Increase

54.52114

54.52114

0

0

0

1

p_infectionOL

0.10287

0.1143

0.12573

Increase

54.52114

54.52114

0

0

0

1

p_UP_OL

0.14184

0.1576

0.17336

Increase

54.52114

54.52114

0

0

0

1

p_UR_OL

0.21

0.3

0.39

Increase

54.52114

54.52114

0

0

0

1

d_ID

0.00188

0.00209

0.0023

Increase

54.52114

54.52114

0

0

0

1

d_OL

0.0819

0.09101

0.10011

Increase

54.52114

54.52114

0

0

0

1

d_hysterectomy

0.18

0.2

0.22

Increase

54.52114

54.52114

0

0

0

1

c_hysterectomy

526.03

584.47795

642.93

Increase

54.52114

54.52114

0

0

0

1

u_hysterectomy

0.22

0.324

0.442

Increase

54.52114

54.52114

0

0

0

1

p_stressincontinence

0.15714

0.1746

0.19206

Increase

54.52114

54.52114

0

0

0

1
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J.2.3 Tornado Diagram for Costs Related to Maternal Outcomes

J.2.4 Tornado Diagram Outputs for Costs Related to Maternal Outcomes
Variable Name
c_health_woman
c_csection
c_SSI
c_ID
c_sepsis
c_sepsis_longterm
c_hemorrhage
c_UR
c_repairfistula
c_hysterectomy

Variable
Low
47.73
273.13
458.58
159.62
417.89
215.2
110.72
459.13
365.67
526.03

Variable
Base
53.03
303.48
509.53
177.36
464.32
239.11
123.02
510.14
406.3
584.47795

Variable
High
58.33
333.82
560.48
195.09
510.76
263.02
135.33
561.15
446.93
642.93

Impact

Low

High

Spread

Spread2

Risk %

Increase
Increase
Increase
Increase
Increase
Decrease
Increase
Increase
Decrease
Increase

51.68925
52.27548
54.27443
54.4424
54.44897
54.48015
54.50698
54.5097
54.51203
54.52114

57.35303
56.76605
54.76784
54.59983
54.59332
54.56212
54.5353
54.53257
54.53024
54.52114

5.66378
4.49058
0.49341
0.15744
0.14434
0.08197
0.02832
0.02287
0.01822
0

32.07843
20.16528
0.24346
0.02479
0.02084
0.00672
0.0008
0.00052
0.00033
0

0.611
0.384
0.005
0
0
0
0
0
0
0

Cumulative
Risk %
0.611
0.994
0.999
0.999
1
1
1
1
1
1
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J.2.5 Tornado Diagram for Maternal Mortality due to Obstructed Labour Sequelae

J.2.6 Tornado Diagram Outputs for Maternal Mortality due to Obstructed Labour Sequelae
Variable Name
d_hemorrhageOL
d_UR_OL
d_sepsisOL
d_sepsis
d_infection
d_infectionOL
d_UR
d_csection
d_hemorrhage
d_ID
d_OL
d_hysterectomy

Variable
Low
0.225
0.405
0.44357
0.3
0.04962
0.045
0.27391
0.00204
0.02895
0.00188
0.0819
0.18

Variable
Base
0.25
0.45
0.49286
0.33333
0.05
0.05514
0.30435
0.00227
0.03216
0.00209
0.09101
0.2

Variable
High
0.275
0.495
0.54214
0.36667
0.06065
0.055
0.33478
0.0025
0.03538
0.0023
0.10011
0.22

Impact

Low

High

Spread

Spread2

Risk %

Decrease
Decrease
Decrease
Increase
Increase
Decrease
Increase
Increase
Decrease
Increase
Increase
Increase

53.88624
54.33458
54.33652
54.3793
54.40286
54.40286
54.40088
54.39451
54.40286
54.40286
54.40286
54.40286

54.92288
54.46922
54.46825
54.44598
54.45599
54.43386
54.41957
54.40286
54.4038
54.40286
54.40286
54.40286

1.03665
0.13464
0.13173
0.06668
0.05314
0.031
0.01869
0.00835
0.00094
0
0
0

1.07464
0.01813
0.01735
0.00445
0.00282
0.00096
0.00035
0.00007
0
0
0
0

0.961
0.016
0.016
0.004
0.003
0.001
0
0
0
0
0
0

Cumulative
Risk %
0.961
0.977
0.992
0.996
0.999
1
1
1
1
1
1
1
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J.2.6 Tornado Diagram for Disability Weights Related to Obstructed Labour

J.2.7 Tornado Diagram Outputs for Disability Weights Related to Obstructed Labour
Variable Name
u_OL
u_csection
u_hemorrhage
u_vfistula
u_rfistula
u_uterineprolapse
u_uterinerupture
u_ID
u_sepsis
u_sepsis_acute
u_nodisability
u_infection
u_incontinence
u_hysterectomy

Variable
Low
0.22
0.3141
0.22
0.227
0.339
0.338
0.29
0.3375
0.088
0.44883
0.0099
0.032
0.0225
0.22

Variable
Base
0.324
0.349
0.324
0.342
0.501
0.404
0.49
0.375
0.133
0.4987
0.01
0.051
0.025
0.324

Variable
High
0.442
0.3839
0.442
0.478
0.657
0.471
0.69
0.4125
0.19
0.54857
0.0101
0.074
0.0275
0.442

Impact

Low

High

Spread

Spread2

Risk %

Decrease
Increase
Decrease
Decrease
Decrease
Decrease
Decrease
Increase
Decrease
Decrease
Increase
Increase
Decrease
Increase

54.10336
54.26443
54.31349
54.33776
54.37284
54.38957
54.39327
54.39405
54.39754
54.39966
54.39987
54.40165
54.40283
54.40286

54.66958
54.542
54.48186
54.45803
54.43407
54.41595
54.41245
54.41167
54.40706
54.40606
54.40584
54.40432
54.40289
54.40286

0.56622
0.27757
0.16837
0.12027
0.06123
0.02638
0.01919
0.01762
0.00951
0.00641
0.00597
0.00266
0.00006
0

0.3206
0.07704
0.02835
0.01446
0.00375
0.0007
0.00037
0.00031
0.00009
0.00004
0.00004
0.00001
0
0

0.719
0.173
0.064
0.032
0.008
0.002
0.001
0.001
0
0
0
0
0
0

Cumulative
Risk %
0.719
0.892
0.956
0.988
0.997
0.998
0.999
1
1
1
1
1
1
1
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J.3 Tornado Diagram Outputs for Neonatal Outcomes
c_health_baby

Variable
Low
47.73

Variable
Base
53.03

Variabl
e High
58.33

Impact

Low

High

Spread

Spread2

Risk %

Increase

18.0409

21.50559

3.46469

12.00407

0.865

Cumulative
Risk %
0.865

d_OL

0.2549

0.3859

0.5168

Decrease

19.61213

20.51514

0.903

0.81541

0.059

0.923

u_hypoxia

0.245

0.351

0.467

Decrease

19.41185

20.11546

0.70361

0.49507

0.036

0.959

p_NICU_CS

0.136

0.15111

0.16622

Increase

19.59296

20.11548

0.52252

0.27303

0.02

0.979

c_NICU

327.39

363.77

400.14

Increase

19.52922

20.0172

0.48797

0.23812

0.017

0.996

p_HIE

0.27248

0.3028

0.33303

Decrease

19.66267

19.88542

0.22276

0.04962

0.004

1

p_NICU_ID

0.136

0.15111

0.16622

Increase

19.75519

19.82033

0.06514

0.00424

0

1

d_NICU

0.18137

0.20153

0.22168

Increase

19.77324

19.80667

0.03342

0.00112

0

1

p_hypoxia

0.23076

0.2564

0.28204

Decrease

19.76094

19.78955

0.02861

0.00082

0

1

d_stillbirthCS

0.01464

0.01627

0.0179

Increase

19.75532

19.77544

0.02012

0.0004

0

1

d_stillbirthID

0.06245

0.06939

0.07633

Increase

19.76143

19.77511

0.01368

0.00019

0

1

u_nodisability

0.0099

0.01

0.0101

Increase

19.77152

19.77497

0.00345

0.00001

0

1

Variable Name
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Appendix K Calculation and Assumptions for Combined Cost-Utility Estimate for Mother and Baby
To provide an estimate of the combined benefits of increasing access to caesarean section for mothers and babies, a combined costutility estimate was calculated under the assumption that the costs and effects were additive. The follow methodology was used:
i)

Costs and effectiveness estimates were combined for mother and baby for the existing care strategy
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐶𝑜𝑠𝑡 𝑓𝑜𝑟 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 𝐶𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑚𝑜𝑡ℎ𝑒𝑟 + 𝐶𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑏𝑎𝑏𝑦
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐶𝑜𝑠𝑡 𝑓𝑜𝑟 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = $843.04 + $829.69

𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑓𝑜𝑟 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 𝐷𝐴𝐿𝑌𝑠 𝑓𝑜𝑟 𝑚𝑜𝑡ℎ𝑒𝑟 + 𝐷𝐴𝐿𝑌𝑠 𝑓𝑜𝑟 𝑏𝑎𝑏𝑦
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑓𝑜𝑟 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 9.42 𝐷𝐴𝐿𝑌𝑠 + 17.64 𝐷𝐴𝐿𝑌𝑠
ii)

Procedure was repeated for the increased access strategy
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐶𝑜𝑠𝑡 𝑓𝑜𝑟 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 𝐶𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑚𝑜𝑡ℎ𝑒𝑟 + 𝐶𝑜𝑠𝑡𝑠 𝑓𝑜𝑟 𝑏𝑎𝑏𝑦
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐶𝑜𝑠𝑡 𝑓𝑜𝑟 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = $1191.00 + $1052.56

𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑓𝑜𝑟 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 𝐷𝐴𝐿𝑌𝑠 𝑓𝑜𝑟 𝑚𝑜𝑡ℎ𝑒𝑟 + 𝐷𝐴𝐿𝑌𝑠 𝑓𝑜𝑟 𝑏𝑎𝑏𝑦
𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑓𝑜𝑟 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠 𝑆𝑡𝑟𝑎𝑡𝑒𝑔𝑦 = 2.85 𝐷𝐴𝐿𝑌𝑠 + 6.37 𝐷𝐴𝐿𝑌𝑠
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iii)

Incremental costs and effectiveness were calculated
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 = 𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠 − 𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 = $2243.56 − $1679.51

𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 = 𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐷𝐴𝐿𝑌𝑠 𝑜𝑓 𝐸𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝐶𝑎𝑟𝑒 − 𝐶𝑜𝑚𝑏𝑖𝑛𝑒𝑑 𝐷𝐴𝐿𝑌𝑠 𝑓𝑜𝑟 𝐼𝑛𝑐𝑟𝑒𝑎𝑠𝑒𝑑 𝐴𝑐𝑐𝑒𝑠𝑠
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 = 27.06 𝐷𝐴𝐿𝑌𝑠 − 9.22 𝐷𝐴𝐿𝑌𝑠
iv)

Incremental cost-effectiveness ratio was calculated for cost per DALY averted

𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 − 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑅𝑎𝑡𝑖𝑜 =

𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 − 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠 𝑅𝑎𝑡𝑖𝑜 =

𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐶𝑜𝑠𝑡
𝐼𝑛𝑐𝑟𝑒𝑚𝑒𝑛𝑡𝑎𝑙 𝐸𝑓𝑓𝑒𝑐𝑡

$570.83
= $32.00 𝑝𝑒𝑟 𝐷𝐴𝐿𝑌 𝑎𝑣𝑒𝑟𝑡𝑒𝑑
17.84 𝐷𝐴𝐿𝑌𝑠
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Appendix L Age and Mortality Tables for Mothers and Babies
L.1 Age Table Calculation for Start Age in Model
To account for the age distribution among women aged 15 to 49 in the SADC region, the population proportions for each age group
were calculated using the total population and applied to women entering the decision tree to determine their starting age. The
following table used data from the GBD 2019 study for population estimates in Sub-Saharan Africa. The GBD 2019 study used census
and population registry location-years.7
L.1.1 Age Table for Women Age 15 – 49 in SSA
Metric
Age
Measure
Group
Number
Population
15 to 19
Number
Population
20 to 24
Number
Population
25 to 29
Number
Population
30 to 34
Number
Population
35 to 39
Number
Population
40 to 44
Number
Population
45 to 49

Value

Lower Limit

Upper Limit

118045517.7
99335866.48
83646132.09
70920863.67
59437282.44
48429447.2
38565376.13

113300465.4
95388169.81
80388969.94
68221072.58
57192430.73
46610500.17
37089622

122545528
103145714.9
86864450.69
73587350.53
61661005.61
50219735.77
40015277.47
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L.2 Background Mortality for Mothers and Babies
Background mortality was estimated using GBD 2019 Life Tables that give probability of death for each age group in SSA, presented
in the table below. The GBD 2019 study used vital registration systems, household surveys, sample registration systems, census,
disease surveillance, and demographic surveillance systems to estimate probability of death.7
L.2.1 Age-Specific Background Mortality for Women in SSA
Age Group

Measure

Value

Lower Limit

Upper Limit

10 to 14

Probability of death

0.00322702

0.00283939

0.00369285

15 to 19

Probability of death

0.00522938

0.00449112

0.00613231

20 to 24
25 to 29
30 to 34
35 to 39
40 to 44
45 to 49
50 to 54

Probability of death
Probability of death
Probability of death
Probability of death
Probability of death
Probability of death
Probability of death

0.007505
0.01080307
0.01511975
0.0200597
0.02606931
0.03347585
0.04476215

0.00642428
0.00909925
0.01307455
0.01743614
0.0231992
0.029844
0.03967667

0.00880502
0.01301689
0.01764319
0.02304425
0.0294146
0.03801584
0.05072255

55 to 59

Probability of death

0.06019755

0.05328658

0.06861861

60 to 64

Probability of death

0.08781039

0.07886011

0.09841783

65 to 69

Probability of death

0.12624893

0.11596635

0.13862625

70 to 74

Probability of death

0.19336296

0.18119522

0.20781046

75 to 79

Probability of death

0.28124691

0.26845174

0.29713757

80 to 84

Probability of death

0.41340369

0.40045789

0.4296512

85 to 89

Probability of death

0.53083965

0.51393211

0.5546191

90 to 94
95 to 99
100 plus

Probability of death
Probability of death
Probability of death

0.67053432
0.7958159
0.88536033

0.65194081
0.7789731
0.87287437

0.69011415
0.80978189
0.89425456
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L.2.2 Age-Specific Background Mortality for Neonates in SSA
Age
Group
<1 year

Measure

Value

Lower Limit

Upper Limit

Probability of death

0.04852258

0.04279735

0.05557117

1 to 4

Probability of death

0.02679061

0.0233071

0.03127402

5 to 9

Probability of death

0.00502385

0.00430445

0.00590262

10 to 14

Probability of death

0.00374959

0.00331268

0.00427001

15 to 19

Probability of death

0.00635538

0.00555295

0.00725204

20 to 24

Probability of death

0.00895272

0.00784897

0.01017167

25 to 29

Probability of death

0.01198776

0.01046481

0.01379842

30 to 34

Probability of death

0.01658756

0.01457848

0.01906661

35 to 39

Probability of death

0.02253893

0.01980338

0.02576687

40 to 44

Probability of death

0.03060471

0.02733187

0.03426385

45 to 49

Probability of death

0.04019339

0.03618192

0.04517133

50 to 54

Probability of death

0.0548082

0.04932792

0.06116604

55 to 59

Probability of death

0.07395989

0.06675291

0.08286859

60 to 64

Probability of death

0.10698647

0.09761727

0.1177657

65 to 69

Probability of death

0.15021095

0.13953834

0.16245587

70 to 74

Probability of death

0.21952617

0.20799598

0.23310687

75 to 79

Probability of death

0.30739389

0.29647574

0.32135717

80 to 84

Probability of death

0.4344075

0.42251731

0.44925169

85 to 89

Probability of death

0.55606159

0.54284982

0.57369999

90 to 94

Probability of death

0.69127857

0.67658325

0.70657172

95 to 99

Probability of death

0.8079571

0.79487548

0.81969626

100 plus

Probability of death

0.89263383

0.8830638

0.90030513
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Appendix M Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Checklist
Item
Section/Item
Recommendation
No.
Title and abstract
Identify the study as an economic evaluation or use more specific terms such as
Title
1
“cost-effectiveness analysis”, and describe the interventions compared

Abstract

2

Provide a structured summary of objectives, perspective, setting, methods
(including study design and inputs), results (including base case and uncertainty
analyses), and conclusions

Reported on
Page No.

31

N/A

Introduction
Background and objectives
Methods
Target population and
subgroups
Setting and location
Study perspective

3

4
5
6

Comparators

7

Time horizon

8

Discount rate

9

Choice of health outcomes

10

Measure of effectiveness

11a

Provide an explicit statement of the broader context for the study. Present the
study question and its relevance for health policy or practice decisions

Describe characteristics of the base case population and subgroups analyzed,
including why they were chosen
State relevant aspects of the system(s) in which the decision(s) need(s) to be made
Describe the perspective of the study and relate this to the costs being evaluated
Describe the interventions or strategies being compared and state why they were
chosen
State the time horizon(s) over which costs and consequences are being evaluated
and say why appropriate
Report the choice of discount rate(s) used for costs and outcomes and say why
appropriate
Describe what outcomes were used as the measure(s) of benefit in the evaluation
and their relevance for the type of analysis performed.
Single study-based estimates: Describe fully the design features of the single
effectiveness study and why the single study was a sufficient source of clinical
effectiveness data.

31-33

34
34-35
34
34-35
35
35
34
N/A
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11b
Measurement and valuation of
preference- based outcomes

12

13a
Estimating resources and costs
13b

Currency, price date, and
conversion

14

Choice of model

15

Assumptions

16

Analytical methods

17

Synthesis-based estimates: Describe fully the methods used for identification of
included studies and synthesis of clinical effectiveness data
If applicable, describe the population and methods used to elicit preferences for
outcomes
Single study-based economic evaluation: Describe approaches used to estimate
resource use associated with the alternative interventions. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs
Model-based economic evaluation: Describe approaches and data sources used to
estimate resource use associated with model health states. Describe primary or
secondary research methods for valuing each resource item in terms of its unit
cost. Describe any adjustments made to approximate to opportunity costs
Report the dates of the estimated resource quantities and unit costs. Describe
methods for adjusting estimated unit costs to the year of reported costs if
necessary. Describe methods for converting costs into a common currency base
and the exchange rate.
Describe and give reasons for the specific type of decision-analytical model used.
Providing a figure to show model structure is strongly recommended.
Describe all structural or other assumptions underpinning the decision-analytical
model.
Describe all analytical methods supporting the evaluation. This could include
methods for dealing with skewed, missing, or censored data; extrapolation
methods; methods for pooling data; approaches to validate or make adjustments
(such as half cycle corrections) to a model; and methods for handling population
heterogeneity and uncertainty.

38-39,
Appendix
G1 and G2
N/A

N/A

42-43
Appendix F

42-43
43, Figures
2-6
35-38,
Appendix FK
43 - 45
Appendix E,
G, I-K

Results
Study parameters

18

Report the values, ranges, references, and, if used, probability distributions for all
parameters. Report reasons or sources for distributions used to represent
uncertainty where appropriate. Providing a table to show the input values is
strongly recommended.

60-63,
Appendix FJ
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Incremental costs and outcomes

19

20a
Characterising uncertainty
20b

Characterising heterogeneity
Discussion
Study findings, limitations,
generalizability, and current
knowledge
Other

21

22

Sources of funding

23

Conflicts of interest

24

For each intervention, report mean values for the main categories of estimated
costs and outcomes of interest, as well as mean differences between the
comparator groups. If applicable, report incremental cost-effectiveness ratios.
Single study-based economic evaluation: Describe the effects of sampling
uncertainty for the estimated incremental cost and incremental effectiveness
parameters, together with the impact of methodological assumptions (such as
discount rate, study
perspective).
Model-based economic evaluation: Describe the effects on the results of
uncertainty for all input parameters, and uncertainty related to the structure of the
model and assumptions.
If applicable, report differences in costs, outcomes, or costeffectiveness that can be explained by variations between subgroups of patients
with different baseline characteristics or other observed variability in effects that
are not reducible by more information.
Summarise key study findings and describe how they support the conclusions
reached. Discuss limitations and the generalisability of the findings and how the
findings fit with current knowledge.
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